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ABSTRACT CYP19A1	   or	   aromatase,	   is	   a	   human	   steroidogenic	   P450	   important	   for	   estrogen	   biosynthesis	   in	  humans.	  Over	  activation	  of	  aromatase	  results	  in	  malignancies	  of	  the	  breast	  tissue,	  especially	  in	  post	  menopausal	   women.	   In	   fact,	   aromatase	   inhibitors	   constitute	   the	   front	   line	   therapy	   for	   estrogen	  receptor	  positive	  (ER+)	  breast	  cancer	  in	  post-­‐menopausal	  women	  which	  accounts	  for	  over	  70%	  of	  all	  breast	  cancer	  cases	  in	  the	  United	  States.	  	  Starting	   with	   its	   androgenic	   substrates,	   testosterone	   and	   androstenedione,	   CYP19A1	   forms	  estradiol	  and	  estrone	  utilizing	  one	  molecule	  of	  atmospheric	  oxygen	  and	  two	  reducing	  equivalents	  in	  the	   form	  of	  NADPH.	  This	   is	  accomplished	   in	  a	   three-­‐step	  process	  one	  of	  which	   involves	  a	  carbon-­‐carbon	  bond	  scission	  and	  aromatization.	  The	  catalytic	  mechanism	  of	  P450s	  has	  been	  long	  studied	  and	  it	  is	  well	  known	  that	  an	  oxo-­‐ferryl	  π-­‐cation	  radical,	  known	  as	  “Compound	  1”	  in	  P450	  chemistry	  is	   the	   reactive	   intermediate	   that	   catalyzes	   most	   of	   the	   reactions	   of	   P450s.	   The	   identity	   of	   the	  reaction	   intermediate	  that	  catalyzes	  the	  terminal	  step	  estrogen	  biosynthesis	  by	  CYP19A1	  is	  still	  a	  mystery.	   There	   is	   evidence	   in	   the	   literature	   suggesting	   the	   involvement	   of	   Compound	   1	   via	   a	  hydrogen	   abstraction	   that	   initiates	   deformylation	   and	   subsequent	   aromatization.	   There	   is	   also	  suggestion	  of	  the	  peroxo-­‐anion	  or	  “Compound	  0”	  acting	  as	  a	  nucleophile,	  attacking	  the	  electrophilic	  carbonyl	   carbon	   of	   19-­‐oxo-­‐androstenedione	   forming	   a	   peroxide	   adduct	   that	   then	   fragments	   to	  produce	  acyl-­‐carbon	  cleavage.	  Owing	   to	   the	   interesting	  chemistry	  CYP19A1	  catalyzes	  and	   its	   role	   in	  human	  health	   I	   focused	  my	  attention	  towards	  elucidating	  the	  mechanism	  of	  this	  critical	  enzyme	  with	  the	  hope	  that	  a	  detailed	  picture	   of	   the	  workings	   of	   CYP19A1	  will	   help	   guide	   efforts	   to	  make	  more	   specific	   inhibitors	   and	  improve	  breast	  cancer	  prognosis.	  	  CYP19A1	  is	  a	  membrane-­‐bound	  hemeprotein	  with	  a	  rich	  spectroscopic	  landscape	  thus	  affording	  an	  opportunity	   to	   apply	   a	   repertoire	   of	   biophysical	   approaches	   to	   help	   piece	   together	   a	   reaction	  mechanism.	   	   I	   used	   the	   Nanodisc	   technology	   to	   stabilize	   CYP19A1	   in	   its	   native	   membrane-­‐like	  environment	   to	   obtain	   a	   mono-­‐disperse,	   stable	   and	   homogenous	   enzyme	   preparation	   that	   is	  amicable	   to	   the	   optical,	   resonance	   Raman	   (rR)	   and	   electron	   paramagnetic	   resonance	   (EPR)	  spectroscopy	   and	   also,	   cryoradiolysis	   and	   cryospectroscopy.	   The	   approach	   I	   have	   applied	   in	   this	  project	  has	  been	   that	  of	   characterizing	   the	   individual	   fate	  of	   reaction	   intermediates	  on	   their	  way	  from	  substrates	  to	  products	  thereby	  catching	  them	  ‘in	  action’.	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My	   cryospectroscopy,	  EPR,	   rR	  and	   steady	   state	  kinetics	   efforts	  outlined	   in	   this	  doctoral	   thesis	   all	  implicate	   “Compound	   1”	   as	   the	   reactive	   intermediate	   that	   is	   responsible	   for	   the	   carbon-­‐carbon	  scission	  reactivity	  of	  CYP19A1.	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Chapter 1: Introduction 
OBJECTIVE, APPROACH AND OVERVIEW CYP19A1,	   or	   aromatase	   is	   a	   human	   steroidogenic	   P450	   important	   for	   estrogen	   biosynthesis	   in	  humans.	   Starting	   with	   its	   androgenic	   substrates,	   testosterone	   and	   androstenedione,	   it	   forms	  estradiol	  and	  estrone	  utilizing	  one	  molecule	  of	  oxygen	  and	  two	  reducing	  equivalents	  in	  the	  form	  of	  NADPH.	  This	  is	  accomplished	  in	  a	  three-­‐step	  process	  one	  of	  which	  involves	  a	  carbon-­‐carbon	  bond	  scission	  and	  aromatization.	  Over	  activation	  of	  aromatase	  results	  in	  malignancies	  of	  the	  breast	  tissue,	  especially	   in	   post-­‐menopausal	   women.	   In	   fact,	   aromatase	   inhibitors	   constitute	   the	   front	   line	  therapy	   for	   ER+	   breast	   cancer	   in	   post-­‐menopausal	   women,	   which	   accounts	   for	   over	   70%	   of	   all	  breast	  cancer	  cases	  in	  the	  United	  States.	  Owing	  to	  the	  interesting	  chemistry	  CYP19A1	  catalyzes	  and	  its	   role	   in	   human	   health	  we’ve	   focused	   our	   attention	   towards	   elucidating	   the	  mechanism	   of	   this	  critical	   enzyme.	   Our	   hope	   is	   that	   a	   detailed	   picture	   of	   the	  workings	   of	   CYP19A1	  will	   help	   guide	  efforts	  to	  make	  more	  specific	  inhibitors	  and	  improve	  breast	  cancer	  prognosis.	  	  CYP19A1	  is	  a	  membrane-­‐bound	  hemeprotein	  with	  a	  rich	  spectroscopic	  landscape	  thus	  affording	  an	  opportunity	   to	   apply	   a	   repertoire	   of	   biophysical	   approaches	   to	   help	   piece	   together	   a	   reaction	  mechanism.	   I	   used	   the	   Nanodisc	   technology	   to	   stabilize	   CYP19A1	   in	   its	   native	   membrane-­‐like	  environment	   to	   obtain	   a	   mono-­‐disperse,	   stable	   and	   homogenous	   enzyme	   preparation	   that	   is	  amicable	   to	   the	   optical,	   RR	   and	  EPR	   spectroscopy	   and	   also,	   cryoradiolysis	   and	   cryospectroscopy.	  The	   approach	   I	   have	   applied	   in	   this	   project	   has	  been	   that	   of	   characterizing	   the	   individual	   fate	   of	  reaction	  intermediates	  on	  their	  way	  from	  substrates	  to	  products	  thereby	  catching	  them	  ‘in	  action’.	  Chapter	   1	   provides	   a	   background	   about	   CY19A1;	   cytochrome	   P450s,	   the	   enzyme	   superfamily	  CYP19A1	   belongs	   to	   and	   the	   Nanodisc	   technology.	   Chapter	   2	   details	   temperature	   derivative	  spectroscopy	  (TDS),	  a	  technique	  that	  was	  developed	  to	  monitor	  autoxidation	  in	  P450s,	  behavior	  of	  the	   first	  quasi-­‐stable	   iron-­‐oxygen	   intermediate	   in	  P450	  called	  the	  oxy-­‐ferrous	  complex.	  Chapter	  3	  provides	  an	  account	  of	  how	  TDS	  can	  be	  extended	  to	  monitor	  other	  process	  important	  in	  P450s	  such	  as	  spin-­‐state	  equilibrium,	  diatomic	  ligand	  binding	  and	  behavior	  of	  the	  peroxo-­‐anion	  upon	  thermal	  annealing.	   Chapter	   4	   and	   5	   contain	   information	   obtained	   about	   the	   nature	   of	   oxy-­‐ferrous	   and	  reduced	   oxy-­‐ferrous	   complexes	   of	   CYP19A1	   in	   various	   substrate-­‐bound	   states	   using	   electron	  paramagnetic	   resonance	   (EPR)	   and	   resonance	   Raman	   (rR)	   spectroscopies.	   Chapter	   6	   details	   the	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steady	   state	   turnover	   behavior	   of	   CYP19A1	   and	   the	   effect	   of	   solvent	   substitution	   on	   NADPH	  consumption	  and	  product	  formation.	  
CYTOCHROMES P450 
Introduction Cytochromes	   P450	   are	   an	   extremely	   diverse	   group	   of	   enzymes	   found	   across	   the	   tree	   of	   life	   that	  catalyze	  a	  variety	  of	  chemical	  modifications	  on	  an	  equally	  diverse	  set	  of	  substrate	  molecules.	  They	  are	   found	  animals,	  plants,	   insects,	  bacteria,	   fungi	  and	  even	  viruses!	  Over	  21,000	  P450s	  have	  been	  discovered	   till	   date	   (Nelson	  2009).	  D.	  Nelson	   in	  his	   recent	   article	  presents	   a	   beautiful	   account	   of	  how	  P450s	  have	  helped	  shape	  our	  planet’s	  history	  and	  our	  present	  biosphere	  over	  millions	  of	  years	  of	  evolution	  that	  it	  really	  makes	  one	  wonder	  how	  life	  on	  earth	  would	  be	  like	  without	  these	  magical	  enzymes	  (Nelson	  2013).	  57	  of	  these	  21,000+	  P450s	  belong	  to	  humans	  where	  they	  catalyze	  critical	  functions	  of	  xenobiotic	  metabolism	  such	  as	  CYP3A4	  and	  CYP2C9	  and	  steroid	  hormone	  biosynthesis	  such	   as	   CYP19A1,	   CYP17A1	   and	   CYP11A1	   (Figure	   1).	   CYP19A1,	   the	   subject	   of	   this	   thesis,	   takes	  androgens,	   androstenedione	   and	   testosterone	   and	   converts	   them	   to	   estrogens,	   estrone	   and	  estradiol	  respectively.	  	  
Catalytic mechanism of P450s Cytochrome	   P450s,	   using	   two	   reducing	   equivalents	   in	   the	   form	   of	   NADPH	   and	   one	   molecule	   of	  molecular	   oxygen	   catalyze	   a	   variety	   of	   chemical	   transformations	   including,	   but	   not	   limited	   to,	  hydroxylation	  of	  unactivated	  alkanes,	  epoxidation,	  N-­‐oxidation,	  dearylation	  and	  aromatization.	  The	  unique	  ability	  of	  these	  enzymes	  to	  catalyze	  such	  a	  broad	  variety	  of	  reactions	  using	  the	  same	  active	  site	   geometry	   has	   piqued	   the	   interest	   of	  many	   a	   researchers	  worldwide	   since	   their	   discovery	   by	  Omura	  and	  Sato	  fifty	  years	  ago	  (Omura	  &	  Sato	  1962).	  The	  reaction	  mechanism	  of	  P450s	  is	  depicted	  in	  the	  form	  of	  a	  wheel	  (Figure	  2)	  with	  seven	  different	  iron-­‐oxygen	  intermediates,	  each	  representing	  a	  different	  stage	  of	  the	  reaction	  in	  terms	  of	  state	  of	  the	  bound	  substrate,	  bound	  oxygen,	  electronic	  state	  of	  heme	  iron	  and	  protonation.	  The	  wheel	  also	  contains	  three	  unproductive	  pathways	  whereby	  the	  enzyme	  undergoes	  futile	  cycles,	  consuming	  NADPH	  and	  O2	  but	  not	  yielding	  any	  product.	  These	  are	  referred	   to	  as	   the	  autoxidation	  shunt,	   the	  peroxide	  shunt	  and	   the	  oxidase	  shunt.	  They	  will	  be	  discussed	  in	  more	  detail	  later	  in	  the	  text.	  The	  enzyme	  in	  its	  resting	  state	  exists	  as	  a	  water-­‐ligated,	  hexa-­‐coordinated,	  low-­‐spin	  ferric	  heme	  [1].	  Water	   is	   a	  weak	   ligand	   and	   is	   easily	   knocked	   off	   by	   an	   incoming	   substrate.	   Displacement	   of	   the	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water	  molecule	   converts	   the	   enzyme	   to	   a	   penta-­‐coordinated,	   high-­‐spin	   ferric	   heme	   [2].	   The	   spin	  state	   change	   is	   accompanied	   by	   a	   large	   positive	   shift	   in	   the	   heme-­‐iron	   reduction	   potential.	   The	  heme-­‐iron	  can	  now	  be	  easily	  reduced	  by	  electrons	  from	  NADPH	  supplied	   in	  turn	  by	  P450’s	  redox	  partner,	   cytochrome	  P450	   reductase	   or	   CPR.	   The	   resulting	   ferrous	   heme	   [3]	   binds	   a	  molecule	   of	  oxygen	  to	  yield	  the	  oxy-­‐ferrous	  complex	  [4],	  the	  first	  quasi-­‐stable	  intermediate	  in	  P450s.	  The	  oxy-­‐ferrous	  complex	  lies	  at	  the	  cusp	  of	  the	  autoxidation	  shunt,	  whereby	  a	  spontaneous	  loss	  of	  the	  bound	  oxygen	   and	   reducing	   equivalents	   in	   the	   form	   a	   superoxide	   anion	   returns	   the	   enzyme	   back	   to	   its	  ferric	   resting	   state.	   On	   the	   productive	   arm	   of	   the	   catalytic	   wheel,	   the	   oxy-­‐ferrous	   complex	   is	  reduced	   by	   another	   electron	   from	   CPR	   to	   form	   the	   peroxo-­‐anion	   [5a].	   Protonation	   at	   the	   distal	  oxygen	  converts	  the	  peroxo	  anion	  into	  the	  hydroperoxo	  anion	  [5b].	  Peroxo	  anion	  and	  hydroperoxo	  anion	  are	  interchangeably	  referred	  to	  as	  ‘Compound	  0’	  in	  P450	  chemistry.	  Another	  protonation	  at	  the	  distal	  oxygen	  causes	  a	  heterolytic	  O-­‐O	  bond	  cleavage	  releasing	  a	  water	  molecule	  and	  yielding	  an	  oxo-­‐ferryl	  π-­‐cation	  radical,	  also	  referred	  to	  as	  ‘Compound	  1’	  [6].	  	  Protons	  required	  for	  the	  first	  and	  second	   protonation	   events	   are	   provided	   by	   an	   intricately	   laid	   out	   hydrogen	   bonding	   network	  formed	  by	  a	  conserved	  acid-­‐alcohol	  pair,	  usually	  aspartic	  acid	  and	  threonine	  and	  water	  molecules	  present	   in	   the	   active	   site.	   	   Substrate	   hydroxylation	   occurs	   via	   the	   hydrogen	   abstraction/	   oxygen	  rebound	  mechanism	  mediated	  Compound	  1	  (Groves	  1985).	  The	  hydroxylated	  product	   is	   released	  and	  the	  enzyme	  returns	  back	  to	  its	  resting	  state.	   In	  addition	  to	  the	  autoxidation	  shunt,	  two	  more	  uncoupling	  pathways	  exist.	   Incorrect	  protonation	  i.e.	   that	   at	   the	   proximal	   oxygen	   atom	   of	   the	   peroxo	   anion	   results	   in	   futile	   cycling	   releasing	   the	  bound	  -­‐OOH	  moiety	  as	  hydrogen	  peroxide.	  This	  uncoupling	  pathway	  is	  referred	  to	  as	  the	  peroxide	  shunt.	  The	  highly	  reactive	  ferryl-­‐oxo	  intermediate	  [6]	  instead	  of	  oxygenating	  the	  substrate	  can	  itself	  be	  oxidized	   to	  water,	   in	   a	  process	   referred	   to	  as	   the	  oxidase	   shunt.	  The	  oxidase	   shunt	  effectively	  results	  in	  four-­‐electron	  reduction	  of	  dioxygen	  molecule	  with	  the	  net	  formation	  of	  two	  molecules	  of	  water.	  
HUMAN AROMATASE  
Role, gene organization of CYP19 and tissue specific expression Human	  aromatase	  is	  the	  product	  of	  the	  123	  kb	  long	  CYP19A1	  gene	  on	  chromosome	  15q.21.1.	  93	  kb	  of	  the	  123	  kb	  form	  the	  regulatory	  region,	  housing	  at	  least	  10	  different	  promoters.	  The	  30	  kb	  coding	  region	   contains	   nine	   different	   coding	   exons	   and	   a	   number	   of	   non-­‐coding	   alternative	   first	   exons.	  Together,	  these	  features	  allow	  for	  a	  high	  degree	  of	  tissue	  specific	  regulation	  of	  expression	  (Bulun	  et	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al.	  2004).	  Aromatase	  is	  primarily	  expressed	  in	  ovaries,	  testes	  and	  brain	  where	  it	  is	  responsible	  for	  reproductive	  development,	   fertility	   and	   sexual	  behavior,	   respectively	   through	  estrogen	   synthesis.	  In	  addition	  to	  the	  gonads	  and	  brain,	  humans	  and	  other	  primates	  express	  aromatase	  in	  extragonadal	  sites	   such	   as	   bone,	   adipose	   tissue,	   placenta	   and	   vascular	   tissue	   (Simpson	   et	   al.	   1994).	   In	   these	  tissues	   estrogens	   are	   responsible	   for	   bone	  mineralization,	   closure	   of	   the	   epiphyseal	   plates,	   lipid	  homeostasis	  and	  prevention	  of	  atherosclerosis	  (Simpson	  et	  al.	  2002;	  Harada	  et	  al.	  1999).	  	  Mutations	   in	   CYP19A1	   leading	   to	   human	   aromatase	   deficiency	   have	   been	   known	   to	   cause	  virilization	  of	  females,	  pseudohemaphrodism	  in	  female	  newborns	  and	  tall	  stature	  due	  to	  failure	  in	  epiphyseal	  closure	  and	  bone	  undermineralization	  in	  their	  male	  counterparts	  (Simpson	  2000;	  Jones	  et	   al.	   2007).	   These	   abnormalities	   occur	   due	   to	   the	   inability	   of	   affected	   individuals	   to	   produce	  endogenous	  estrogens	  are	  often	  treatable	  by	  hormonal	  therapy	  if	  detected	  early.	  Overexpression	  of	  aromatase	   causes	   aromatase	   excess	   syndrome	   (AEXS)	   characterized	   by	   gynecomastia,	   infertility	  and	   Leydig	   cell	   tumors	   in	   males	   and	   thelarche	   in	   females.	   Both	   sexes	   experience	   an	   premature	  growth	   spurt	   and	  early	   closure	  of	   epiphyseal	  plates	   (Shozu	  et	   al.	   2003).	  These	   conditions	  arising	  from	   mutations	   of	   the	   CYP19A1	   gene	   are	   rare.	   A	   more	   severe	   impact	   of	   abnormal	   aromatase	  expression	  on	  human	  health	   is	   seen	   in	  post-­‐menopausal	  women	   in	   the	   form	  of	  estrogen	  receptor	  positive,	  or	  ER+	  breast	  cancer.	  ER+	  breast	  cancer	  has	  the	  poorest	   long-­‐term	  survival	  rates	  among	  various	  breast	  cancer	  subtypes	  and	  claims	  upwards	  of	  39,000	  lives	  each	  year	  in	  the	  United	  States	  alone.1	  	  
Aromatase and breast cancer The	   ovarian	   granulosa	   cells	   are	   the	   primary	   source	   of	   aromatase	   in	   premenopausal	   women.	   In	  postmenopausal	   women	   however,	   estrogen	   is	   no	   longer	   synthesized	   in	   the	   ovary	   but	   in	   other	  tissues	   such	   as	   vascular	   endothelium,	   smooth	  muscle	   cells,	   skin	   and	   adipose	   tissue	   including	   the	  adipose	  tissue	  present	  in	  the	  breast	  itself.	  Estrogens	  synthesized	  within	  these	  extragonadal	  sites	  act	  predominantly	   at	   the	   local	   tissue	   level	   in	   a	   paracrine	   or	   intracrine	   manner	   (Labrie	   2003).	   As	   a	  consequence,	   despite	   low	   circulating	   estrogen	   levels,	   the	   concentration	   of	   estrogen	   in	   the	   breast	  tissue	   of	   postmenopausal	   patients	   is	   several	   fold-­‐higher	   than	   that	   in	   premenopausal	   women.	  Abnormal	   levels	   of	   estrogen	   in	   the	   breast	   tissue	   lead	   to	   an	   over	   activation	   of	   estrogen	   receptor	  which	  in	  turn	  leads	  to	  uncontrolled	  cell	  growth	  and	  development	  of	  a	  tumor.	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Breast	  Cancer	  Facts	  &	  Figures	  2013-­‐2014:	  http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-­‐042725.pdf	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Approximately	  75%	  of	  breast	  cancers	  test	  positive	  for	  the	  estrogen	  receptor	  (ER),	  the	  progesterone	  receptor	  (PgR),	  or	  both.	  Estrogen	  stimulation	  of	  these	  receptors	  is	  an	  important	  factor	  for	  growth	  and	  development	  of	  a	  tumor.	  Competitive	  antagonists	  for	  the	  estrogen	  receptor	  such	  as	  Tamoxifen	  have	  been	  used	  to	  treat	  patients	  with	  ER+	  breast	  cancer	  since	  its	  FDA	  approval	  in	  1977.	  Tamoxifen	  along	   with	   reducing	   estrogen	   receptor	   activation	   prevents	   bone	   demineralization	   and	   improves	  their	  lipid	  profiles	  (Love	  1994).	  However,	  Tamoxifen	  treatment	  increases	  the	  risk	  for	  endometrial	  cancer	  and	  thromboembolic	  disease	  (Cuzick	  et	  al.	  2003)	  in	  these	  patients.	  There	  are	  also	  instances	  of	  relapse	  occurring	  15	  years	  after	  a	  5-­‐year	  course	  of	  Tamoxifen	  treatment	  (Fisher	  et	  al.	  2001).	  	  Aromatase	  inhibitors	  (AIs)	  such	  as	  exemestane,	  anastrozole,	  letrozole	  constitute	  the	  state	  of	  art	  for	  ER+	  breast	  cancer	  treatment.	  AIs	  reduce	  estrogen	  levels	  by	  inhibiting	  the	  production	  of	  aromatase	  itself.	  AIs	  do	  not	   inhibit	   the	  ovarian	  production	  of	  aromatase	  so	  only	  women	  without	   functioning	  ovaries	  benefit	  from	  this	  kind	  of	  therapy.	  The	  benefit	  of	  using	  AIs	  is	  fewer	  serious	  side	  effects	  ,	  such	  as	   endometrial	   cancer	   and	   stroke,	   than	   Tamoxifen.	   However,	   the	   use	   of	   AIs	   has	   been	   associated	  with	   heart	   problems	   and	   osteoporosis.	   There	   is	   a	   dire	   need	   for	  more	   specific,	  mechanism-­‐based	  inhibitors	  to	  aromatase	  to	  provide	  better	  disease	  prognosis	  for	  breast	  cancer	  patients	  and	  therefore,	  it	  is	  paramount	  that	  we	  direct	  our	  efforts	  towards	  gaining	  a	  molecular	  understanding	  of	  this	  unique	  enzyme.	  
Structural organization CYP19A1	   consists	   of	   a	   thiolate-­‐ligated	   heme	   prosthetic	   group	   enclosed	   in	   a	   polypeptide	   chain	   of	  503	  amino	  acids.	  A	  hydrophobic	  tail	  of	  about	  40	  amino	  acids	  on	  its	  N-­‐terminal	  helps	  it	  attach	  to	  the	  endoplasmic	   reticulum	  where	   it	   is	   localized.	   In	   2009,	   Ghosh	   and	   colleagues	   (Ghosh	   et	   al.	   2009)	  solved	   the	   X-­‐ray	   crystal	   structure	   of	   full-­‐length	   human	   placental	   aromatase	   in	   complex	   with	   its	  substrate,	  androstenedione	  (pdb	  id:	  3eqm).	  	  CYP19A1	  retains	  the	  characteristic	  P450	  fold	  with	  some	  unique	  features.	  Most	  notable	  is	  the	  I-­‐helix	  distortion	  caused	  by	  a	  proline	  residue	  at	  position	  308,	  a	  residue	  unique	  to	  CYP19A1	  among	  other	  P450s.	   I-­‐helix	   distortion	   in	   P450s	   is	   not	   uncommon	   (Podust	   et	   al.	   2001;	   Rowland	   et	   al.	   2006;	  Nagano	  et	  al.	  2005;	  Williams	  et	  al.	  2004)	  however,	  in	  this	  case	  it	  seems	  to	  be	  specifically	  designed	  to	  create	   room	   for	   the	   3-­‐keto	   group	   of	   the	   substrate	   in	   CYP19A1's	   active	   site.	   Superposition	   of	   the	  aromatase	   backbone	  with	   bacterial	   P450cam	   and	   P450eryF	   as	  well	   as	  with	   human	   CYP3A4	   and	  CYP2D6	  has	  shown	  that	  without	  this	  shift,	   the	  3-­‐keto	  end	  of	  the	  substrate	  would	  clash	  with	  the	  I-­‐helices	  of	  respective	  P450s	  (Ghosh	  et	  al.	  2009)	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The	  active	  site	  of	  aromatase	   is	  made	  up	  of	  hydrophobic	  and	  polar	  residues	  arranged	   in	  a	  manner	  that	   complement	   the	   steroid	   backbone	   and	   confer	   the	   enzyme	   its	   high	   specificity	   towards	   its	  substrates.	   Additional	   H-­‐bonding	   interactions	   between	   the	   3-­‐keto	   and	   17-­‐keto	   oxygen	   atom	   of	  androstenedione	  and	  Met-­‐374/	  Arg	  115	  and	  Asp	  309	  respectively	  stabilize	  the	  substrate	  molecule	  in	  a	  specific	  orientation	  with	  respect	  to	  the	  heme	  iron.	  	  There	  exists	  an	  elaborate	  network	  of	  H-­‐bonding	  and	  salt-­‐bridge	  interactions	  involving	  among	  other	  residues,	  Asp-­‐309,	  3-­‐keto	  group	  of	  the	  substrate	  and	  water	  molecules	  present	  in	  the	  active	  site	  that	  presumably	  provide	  protons	   for	   the	   first	  and	  second	  protonation	  of	   the	  oxy-­‐ferrous	  complex	  and	  keeps	  the	  Asp-­‐309	  protonated	  so	  it	  may	  participate	  in	  substrate	  binding	  interaction	  as	  well.	  	  The	   2.9	   °A	   resolution	   structure	   is	   informative	   but	   does	   not	   offer	   insights	   into	   the	   reaction	  mechanism	   for	   the	   aromatization	   step	  of	  CYP19A1.	  Moreover,	   the	   crystal	   structure	  was	  obtained	  with	  AD,	  substrate	  for	  the	  hydroxylation	  step,	  bound	  at	  the	  active	  site.	  
REACTION CATALYZED CYP19A1	   catalyzes	   the	   conversion	   of	   androgens	   (androstenedione,	   testosterone,	   and	   16α-­‐hydroxytestosterone)	   to	   estrogens	   (estrone,	   17β-­‐estradiol,	   and	   estriol,	   respectively)	   via	   a	   three-­‐step	  reaction	  (Figure	  3).	  The	  first	  two	  steps	  involve	  consecutive	  hydroxylation	  reactions	  that	  result	  in	  the	  formation	  of	  a	  C19	  hydroxyl,	  followed	  by	  a	  gem-­‐diol	  intermediate	  that	  dehydrates	  to	  yield	  a	  C19	  aldehyde.	   In	   the	   third	  and	   final	   step	  of	   estrogen	   synthesis,	   the	   carbon-­‐carbon	  bond	  between	  C19	   and	   C10	   undergoes	   scission	   resulting	   in	   release	   of	   the	   C19	   carboxyl	   as	   formic	   acid	   and	   a	  concomitant	  aromatization	  of	  A-­‐ring	  of	  the	  steroid	  molecule	  (Akhtar	  et	  al.	  2011).	  
Proposed mechanisms of C-C lyase and aromatization by human aromatase The	   first	   two	   steps	   of	   CYP19A1	   catalysis	   are	   generally	   accepted	   as	   being	   classic	   Cpd1	  mediated	  hydroxylations.	  During	  these	  steps,	  the	  acid-­‐alcohol	  pair,	  T310	  and	  D309	  conserved	  in	  the	  I-­‐helix	  of	  CYP19A1	  along	  with	   active	   site	  water	  molecules	  play	   an	   important	   role	   in	  protonating	   the	  distal	  oxygen	  atom	  of	  the	  peroxo	  anion	  to	  facilitate	  O-­‐O	  bond	  cleavage	  and	  generate	  Cpd	  1,	  as	  described	  in	  CYP101	   and	   CYP17A1	   (Poulos	   et	   al.	   1985;	   Raag	   et	   al.	   1991;	   Imai	   &	   Nakamura	   1989;	   Nagano	   &	  Poulos	  2005;	  Vidakovic	  et	  al.	  1998;	  Khatri	  et	  al.	  2014).	  However,	  the	  mechanism	  of	  the	  third	  step	  is	  still	  a	  matter	  of	  considerable	  debate.	  Two	  competing	  hypotheses	  exist.	  They	  are	  referred	  to	  as	  the	  ‘Compound	  0’,	   or	  peroxo-­‐anion	  mechanism	  and	   the	   ‘Compound	  1’	  mechanism	  on	   the	  basis	  of	   the	  reactive	  intermediate	  that	  is	  proposed	  to	  carry	  out	  catalysis.	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In	   the	   ‘Compound	   0	   mechanism’	   (Panel	   A,	   Figure	   4)	   C-­‐C	   bond	   cleavage	   occurs	   through	   the	  participation	  of	  FeIII-­‐[O-­‐O]-­‐2	  species,	  or	  peroxo	  anion	  that	  is	  stabilized	  by	  the	  electrophilic	  property	  of	  the	  carbonyl	  group	  of	  19-­‐oxo-­‐AD.	  It	  has	  been	  proposed	  that	  19-­‐oxo-­‐AD	  causes	  a	  displacement	  of	  Thr-­‐310	  of	  the	  acid-­‐alcohol	  pair	  of	  CYP19A1.	  This	  disturbs	  the	  H-­‐bonding	  network	  at	  the	  active	  site	  and	   as	   a	   result	   proton	   delivery	   to	   the	   distal	   oxygen	   of	   the	   heme-­‐O-­‐O	   moiety	   is	   stalled,	   thus	  stabilizing	  the	  peroxo	  anion	  (Graham-­‐Lorence	  et	  al.	  1995).	  The	  peroxo	  anion	  acting	  as	  a	  nucleophile	  attacks	   the	   C19	   carbonyl	   of	   its	   19-­‐oxo	   substrate	   generating	   a	   peroxide	   adduct	   that	   subsequently	  fragments	  resulting	  in	  acyl-­‐carbon	  cleavage,	  release	  of	  C19	  as	  formic	  acid	  and	  aromatization	  of	  the	  A-­‐ring.	  The	   ‘Compound	  1	  mechanism’	  (Panel	  B,	  Figure	  4)	  represents	  a	  more	  traditional	  route	  of	  catalysis	  wherein	  protonation	  of	  the	  peroxoanion	  generates	  a	  ferryl-­‐oxo	  π-­‐cation	  radical	  via	  an	  intermediate	  hydroperoxo	   anion.	   The	  high	   valent	   heme-­‐oxygen	   radical,	   Cpd	  1	   abstracts	   the	   1β-­‐hydrogen	   from	  the	   A-­‐ring	   of	   its	   steroid	   substrate	   thus	   initiating	   aromatization	   and	   the	   deformylation	   cascade	  which	  results	  in	  a	  C10-­‐C19	  bond	  cleavage.	  A	   clear	   answer	   as	   to	   the	   mechanism	   used	   in	   the	   third	   step	   of	   the	   aromatase	   reaction	   has	   been	  missing	  due	  to	  conflicting	  evidence	  in	  the	  field.	  Non-­‐enzymatic	  deformylation	  of	  19-­‐oxo-­‐AD	  mimic	  by	  a	  peroxo-­‐ferric	  model	  complex	  (Wertz	  et	  al.	  1998)	  and	  the	  use	  of	  peroxo-­‐ferric	  species	  directly	  as	  a	  reactive	  intermediate	  by	  CYP2B4,	  CYP17	  and	  CYP51	  for	  C-­‐C	  cleaving	  reactions	  with	  aldehyde-­‐	  or	   ketone-­‐containing	   substrates,	   and	   by	   nitric	   oxide	   synthase	   (Vaz	   et	   al.	   1996;	  Woodward	   et	   al.	  2009;	  Shyadehi	  et	  al.	  1996;	  Lee-­‐Robichaud	  et	  al.	  1995)	  support	   the	   ‘Cpd	  0	  mechanism’.	  However,	  application	  of	  density	   functional	   theory	   	   (DFT)	  on	   	  a	  minimal	  CYP19	  active	  site	  model	  showed	  an	  strong	  energetic	  preference	  for	  Cpd	  1	  mediated	  hydrogen	  abstraction	  from	  C1	  of	  19-­‐oxo	  AD	  rather	  than	   direct	   reaction	   of	   the	   peroxo-­‐ferric	   species,	   or	   Cpd	   0	   with	   19-­‐oxo	   AD	   to	   produce	   estrone	  (Hackett	  et	  al.	  2005).	  Owing	   to	   its	   role	   in	   human	   health,	   the	   interesting	   chemistry	   it	   catalyzes	   and	   the	   controversy	  surrounding	   the	  mechanism	   for	   the	   terminal	  C-­‐C	   lyase	   step	  of	   aromatase	   I	  undertook	   the	   task	  of	  doing	   a	   systematic	   characterization	   of	   the	   reactive	   intermediates	   in	   CYP19A1	   on	   its	   path	   from	  reactants	  to	  products.	  
 EXPRESSION AND PURIFICATION OF CYP19A1 A	  modified	  version	  of	  human	  CYP19	  having	  a	  hexahistidine	  tag	  on	  the	  C-­‐terminal	  was	  expressed	  in	  DH5α	  cells	  co-­‐expressing	  the	  GroES/EL	  chaperone	  system.	  Cells	  were	  grown	  for	  ~40	  hours	  at	  29	  °C	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in	  the	  presence	  of	  1	  mM	  δ-­‐aminolevulinic	  acid,	  1	  mM	  isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG)	  and	   4	   mg/ml	   L-­‐arabinose	   (for	   induction	   of	   GroES/GroEL	   chaperones).	   Resuspension	   of	   the	   cell	  pellet	  in	  100	  mM	  potassium	  phosphate	  (KPi)	  pH	  7.4,	  50	  mM	  NaCl,	  	  20%	  glycerol,	  10	  µM	  AD,	  10	  mM	  
β-­‐mercaptoethanol	   (β-­‐Me)	   and	   0.1	   mM	   phenylmethylsulfonyl	   fluoride	   (PMSF)	   followed	   by	  sonication	   and	   ultracentrifugation	   yielded	   a	   membrane	   pellet.	   Supernatant	   obtained	   after	  solubilization	  of	   the	  membrane	  pellet	   in	  100	  mM	  KPi	  pH	  7.4,	   500	  mM	  NaCl,	   20%	  glycerol,	   3	  mM	  Androstenedione,	  10	  mM	  β-­‐Me,	  0.1	  mM	  PMSF,	  and	  0.1	  %	  cholate	  and	  1	  %	  Tween-­‐20	  (Buffer	  A)	  and	  ultracentrifugation	   was	   loaded	   on	   a	   Ni-­‐NDA	   column.	   The	   column	   was	   washed	   with	   buffer	   A	  containing	   16	  mM	   imidazole	   and	   buffer	   A	   containing	   50	  mM	   imidazole	   and	   eluted	  with	   buffer	   A	  containing	   250	  mM	   imidazole.	   Fractions	   having	  RZ	   of	   greater	   than	   0.8	  were	   pooled	   and	   dialyzed	  against	  100	  mM	  KPi	  pH	  7.4,	  0.1	  mM	  EDTA,	  20%	  glycerol,	  0.1%	  Tween-­‐20,	  10	  µM	  AD	  and	  10	  mM	  β-­‐Me	  at	  4	   °C.	  The	  protein	  was	   then	  concentrated	  using	  Amicon	  centrifugal	   concentrators	  of	  10,000	  MWCO,	  flash-­‐frozen	  with	  liquid	  nitrogen	  and	  stored	  at	  -­‐80	  °C	  until	  further	  use.	  
NANODISC TECHNOLOGY TO STABILIZE HUMAN AROMATASE CYP19A1	   is	   a	   membrane	   bound	   enzyme	  making	   the	   biophysical	   characterization	   of	   this	   protein	  outside	  the	  membrane	  environment	  challenging.	  The	  Nanodisc	  system	  developed	  by	  the	  Sligar	  lab	  provides	   a	   solution	   to	   this	   problem	   through	   self-­‐assembly	   of	  membrane	   proteins	   into	   nanoscale	  lipid	  bilayers	   that	  maintain	   full	   functionality	  of	   the	  protein	  (Bayburt	  et	  al.	  2002;	  Bayburt	  &	  Sligar	  2003).	   This	   provides	   a	   soluble,	  monodisperse,	   homogenous	   and	   stable	   preparation	  of	  membrane	  proteins	  to	  which	  biophysical	  and	  chemical	  methods	  can	  be	  applied.	  
Overview of the Nanodisc technology Nanodiscs	   are	   nanometer-­‐sized	   circular	   patches	   of	   lipid	   bilayer	   held	   together	   by	   two	   strings	   of	  amphipathic	  helices	  acting	  as	  an	  encircling	  belt.	  The	  amphipathic	  helices	  are	  part	  of	  a	  genetically	  engineered	   version	   of	   human	   apolipoprotein	   A1	   referred	   to	   as	   the	   membrane	   scaffold	   protein	  (MSP).	  Different	  versions	  of	  MSP	  (MSP1D1,	  MSP1E3D1)	  have	  been	  developed	  with	  varying	  number	  of	   helices	   thereby	   providing	   control	   over	   disc	   size	   and	   therefore,	   ability	   to	   incorporate	   different	  sized	  proteins	  into	  Nanodiscs.	  The	  amphipathic	  nature	  of	  surrounding	  belt	  protein	  allows	  the	  entire	  assembly	  to	  be	  soluble	  in	  aqueous	  buffer	  systems.	  This	  is	  truly	  enabling	  in	  the	  study	  of	  membrane	  proteins	  since	  not	  only	  do	  Nanodiscs	  help	  stabilize	  membrane	  proteins	  in	  their	  native	  membrane-­‐like	   environments,	   they	   render	   them	   soluble	   in	   aqueous	   solutions	   thus	   allowing	   application	   of	   a	  whole	  slew	  of	  biophysical	  and	  biochemical	  tools	  that	  would	  otherwise	  have	  been	  unusable.	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Traditional	  methods	  of	  studying	  membrane	  proteins	   include	  using	  reconstitution	  systems	  such	  as	  mixed	  detergents,	  lipid	  micelles	  and	  liposomes.	  Micelles	  do	  not	  contain	  a	  lipid	  bilayer	  and	  therefore,	  do	   not	   represent	   the	   membrane	   protein’s	   native	   environment	   very	   well.	   Lipid	   vesicles	   and	  liposomes	  are	  better	  in	  this	  regard	  but	  offer	  no	  control	  over	  stoichiometry,	  oligomerization	  state	  or	  local	   lipid	   environment	   of	   the	  membrane	   protein	   target.	   Nanodiscs	   surmount	   all	   these	   problems	  and	  have	  been	  successfully	  applied	  to	  mechanistic	   investigations	  of	  variety	  of	  membrane	  proteins	  such	  as	  cytochrome	  P450s	  (Denisov	  &	  Sligar	  2011),	  ion	  channels	  (Shenkarev	  et	  al.	  2010),	  G-­‐protein	  coupled	   receptors	   (Leitz	   et	   al.	   2006)	   and	   transporters	   (Ritchie	   et	   al.	   2009).	   Some	   examples	  highlighting	   the	   advances	   that	   the	   use	   of	   Nanodisc	   technology	   has	   enabled	   in	   these	   systems	   are	  listed	  below:	  
! By	   providing	   precise	   control	   over	   the	   oligomerization	   state	   of	   incorporated	   protein	   target,	  Nanodiscs	  have	  helped	   identify	   the	   functional	  unit	  of	   chemotactic	   receptors	   (Li	  &	  Hazelbauer	  2011;	  Boldog	  et	  al.	  2006)	  
! By	  providing	  stable	  and	  homogenous	  enzyme	  preparations,	  Nanodiscs	  have	  facilitated:	  
! The	   characterization	   of	   microscopic	   rate	   constants	   and	   binding	   intermediates	   of	  CYP3A4,	   a	   critical	   xenobiotic	   metabolizing	   human	   hepatic	   P450,	   that	   can	   bind	   up	   to	  three	  different	  substrate	  molecules.	  This	  has	  implications	  in	  drug-­‐drug	  interactions	  for	  eliminating	  undesirable	  side-­‐effects	  of	  drugs,	  especially	  in	  patients	  following	  a	  regimen	  of	   multiple	   lifestyle	   and/or	   disease	   management	   drugs	   (Denisov	   et	   al.	   Unpublished	  
work)	  
! Stabilization	  of	  transient	   intermediates	  of	  membrane-­‐bound	  P450s	  such	  as	  CYP17	  and	  CYP19	  (the	  subject	  of	  this	  thesis)	  for	  spectroscopic	  analysis	  (Gantt	  et	  al.	  2009;	  Luthra	  et	  al.	  2011b).	  
! By	  providing	   a	  means	   to	   precisely	   control	   the	   local	   lipid	   environment	   of	  membrane	   proteins	  Nanodiscs	   have	   helped	   unravel	   the	  minutiae	   of	   recruitment	   and	   assembly	   of	   protein-­‐protein	  complexes	   central	   to	   the	   blood	   coagulation	   cascade	   in	   humans.	   (Morrissey	   et	   al.	   2008;	  Morrissey	  et	  al.	  2011)	  Marriage	   of	   Nanodisc	   technology	   with	   detection	  modalities	   such	   as	   nuclear	   magnetic	   resonance	  spectroscopy	  (NMR)	  (Kijac	  et	  al.	  2007;	  Glück	  et	  al.	  2009),	  surface	  plasmon	  resonance	  spectroscopy	  (SPR)	  (Borch	  et	  al.	  2008;	  Glück	  et	  al.	  2011),	  mass	  spectrometry	  (Marty	  et	  al.	  2012),	  ring	  resonators	  (Sloan	  et	  al.	  2013)	  and	  microscale	  thermophoresis	  (Singh	  et	  al.	  2013)	  widens	  the	  scope	  of	  analytical	  tools	   that	  may	   be	   applied	   to	   study	   various	   aspects	   of	   a	  membrane	   protein	   biochemistry	   such	   as	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ligand	   binding,	   protein	   structure,	   protein-­‐protein	   and	   protein-­‐lipid	   interaction	   with	   exceptional	  fidelity.	  The	  experiments	  described	  in	  this	  thesis	  rely	  on	  the	  ability	  to	  produce	  stable,	  fully	  functional	  ligand	  (substrate,	   oxygen)–iron	   complexes	   that	   would	   be	  amicable	   to	   various	   spectroscopic	   methods.	  Nanodiscs	  by	  providing	  a	  native-­‐like	  membrane	  bilayer	  environment	  and	  eliminating	  the	  need	  for	  detergents,	  liposomes	  etc.	  satisfy	  both	  these	  requirements.	  
Incorporation of CYP19A1 into Nanodiscs Nanodiscs	   are	   formed	   by	   the	   process	   of	   self-­‐assembly	   upon	   removal	   of	   detergent	   from	   a	  reconstitution	   mixture	   comprising	   of	   MSP,	   lipids	   and	   membrane	   protein	   target	   solubilized	   in	   a	  detergent	  of	  choice	  using	  dialysis	  or	  hydrophobic	  beads.	  The	  relative	  amounts	  and	  concentration	  of	  lipids,	   detergent,	   target	   protein	   are	   critical	   in	   ensuring	   a	   successful	   incorporation	   of	   the	   protein	  target	   in	  Nanodiscs.	  A	  detailed	  description	  of	   the	  protocol	   followed	   for	   incorporating	  CYP19	   into	  Nanodiscs	  follows:	  	  A	   stable	  preparation	  of	  CYP19A1	  was	  obtained	  by	   incorporating	   it	   into	  MSP1D1-­‐POPC	  Nanodiscs	  using	   the	   protocol	   described	   in	   (Luthra	   et	   al.	   2013).	   Briefly,	   1-­‐palmitoyl-­‐2-­‐oleoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	   (POPC)	   was	   dried	   in	   18-­‐ml	   glass	   culture	   tube	   from	   a	   chloroform	   stock	   under	  stream	  of	  nitrogen	  so	  as	  to	  deposit	  a	  thin	  layer	  of	  dried	  lipids	  on	  the	  sides	  of	  the	  glass	  culture	  tubes.	  Remaining	  chloroform	  was	  removed	  by	  placing	  the	  tubes	  inside	  a	  vacuum	  desiccator	  for	  4-­‐6	  hours.	  Once	  completely	  dried,	  the	  lipids	  were	  dissolved	  in	  100	  mM	  sodium	  cholate	  to	  achieve	  a	  final	  lipid	  concentration	   of	   50	   mM.	   Disc	   reconstitution	   mixture	   was	   prepared,	   targeting	   a	  POPC:MSP1D1:CYP19A1	   ratio	   of	   1300:20:1	   and	   final	   POPC	   concentration	   of	   6-­‐7	   mM.	   It	   was	  incubated	  on	  ice	  for	  15	  minutes	  after	  which	  1-­‐ml	  equivalent	  of	  hydrophobic	  beads	  (Amberlite	  XAD-­‐2)	   was	   added	   per	   ml	   of	   solution	   with	   the	   help	   of	   a	   10-­‐ml	   plastic	   syringe	   with	   its	   luer-­‐lock	  connection	   cut	   off.	   The	   tube	   was	   then	   placed	   on	   a	   shaker	   platform	   for	   6	   hours	   at	   4	   °C.	   Protein	  solution	  containing	  empty	  and	  membrane	  protein	  containing	  discs	  was	  separated	   from	  the	  slurry	  by	  passing	  it	  through	  a	  filter	  column.	  The	  spent	  beads	  were	  rinsed	  with	  one	  volume	  of	  100	  mM	  KPi	  pH	  7.4	  thrice	  and	  the	  wash	  solution	  added	  to	  the	  pool.	  Discs	  with	  CYP19	  incorporated	  in	  them	  were	  then	  separated	  from	  empty	  discs	  by	  nickel	  affinity	  chromatography	  taking	  advantage	  of	  the	  His-­‐tag	  on	   CYP19.	   The	   eluent	   from	   the	  Ni-­‐NTA	   column	  was	   concentrated	   using	   4-­‐ml	   Amicon	   centrifugal	  concentrators	   of	   10,000	   MWCO	   and	   purified	   using	   size-­‐exclusion	   chromatography.	   The	   desired	  fractions	   from	  SEC	  were	  pooled	  and	  concentrated.	  15%	  (v/v)	  ultra-­‐pure	  glycerol	   (Sigma-­‐Aldrich)	  was	  added	  to	  CYP19A1	  discs,	  the	  entire	  solution	  flash-­‐frozen	  and	  stored	  at	  -­‐80	  °C	  until	  further	  use.	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Figure	   5	   contains	   a	   schematic	   representation	   of	   the	   disc	   assembly	   process	   of	   CYP19A1	   into	  Nanodiscs.	   	  































































































































































































































































































Figure	  1.	  Human	  steroidogenic	  pathway	  showing	  the	  role	  of	  various	  P450s,	  especially	  CYP19A1.	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  Figure	   3:	   Conversion	   of	   Androstenedione	   to	   Estrone	   by	   CYP19A1.	   Red	   marks	   the	   modifications	  introduced	  into	  the	  steroid	  molecule	  by	  the	  action	  of	  CYP19A1	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  Figure	  4:	  Proposed	  hypothesis	  for	  the	  lyase	  chemistry	  of	  CYP19A1.	  A.	  ‘Compound	  0’	  mechanism	  and	  B.	  ‘Compound	  1’	  mechanism’.	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  Figure	  5:	  Schematic	  representation	  of	  the	  disc	  assembly	  process.	   	  
Ni-NTA!
Removal of empty discs!
SEC!
Detergent 
removal!Reconstitution mixture: Lipids, Membrane Scaffold protein (MSP) and 
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Reproduced	  (or	   'Reproduced	  in	  part')	  with	  permission	  from	  [Luthra,	  A.;	  Denisov,	  I.	  G.;	  Sligar,	  S.	  G.	  
Anal.	  Chem.	  2011,	  83,	  5394.]	  Copyright	  [2011]	  American	  Chemical	  Society."	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Chapter 2: Temperature Derivative Spectroscopy (TDS) To 
Monitor Autoxidation In Cytochromes P450 
INTRODUCTION Temperature	  derivative	  spectroscopy	  (TDS)	  (Berendzen	  &	  Braunstein	  1990)	  is	  a	  type	  of	  relaxation	  spectroscopy	   that	   involves	   a	   temperature-­‐dependent	   “perturbation”	   and	   a	   corresponding	  “observable”.	  The	  perturbation	  may	  be	  the	  formation	  or	  decay	  of	  a	  molecular	  species	  by	  photolysis,	  ligand	  binding,	  or	  a	  mere	  change	  in	  temperature.	  The	  list	  of	  observables	  that	  may	  be	  used	  with	  TDS	  includes	   Raman	   scattering,	   circular	   dichroism,	   fluorescence	   anisotropy,	   and	   UV-­‐Vis	   absorption	  spectroscopy.	  Previously,	  TDS	  has	  been	  used	  extensively	  to	  study	  various	  aspects	  of	  ligand	  binding	  and	  dynamics	  in	  myoglobin	  (Nienhaus	  et	  al.	  1994)	  and	  neuroglobin	  (Kriegl	  et	  al.	  2002).	  	  Here	  TDS	  has	   been	   adapted	   to	   characterize	   the	   energetics	   of	   autoxidation	   in	   cytochromes	   P450s.	  Autoxidation	  is	  the	  first	  major	  uncoupling	  pathway	  in	  P450s	  wherein	  the	  oxy-­‐ferrous	  complex	  loses	  the	  bound	  oxygen	  as	  superoxide	  anion	  and	  oxidizes	  back	  to	  the	  ferric	  state.	  This	  results	  in	  the	  net	  wasteful	  expenditure	  of	  one	  reducing	  equivalent.	  	  The	  autoxidation	  shunt	  constitutes	   the	  major	  unproductive	  pathway	   for	  many	  P450s	  and	  thus	   its	  quantitation	   and	   mechanism	   of	   action	   are	   of	   interest	   to	   pharmacologists,	   toxicologists,	   and	  biochemists.	  Autoxidation	  is	  intimately	  coupled	  to	  the	  redox	  potential	  of	  heme	  iron	  in	  these	  enzyme	  systems	   (Clark	   et	   al.	   2006),	   and	   different	   substrates	   exercise	   their	   control	   on	   the	   rates	   of	  autoxidation	  primarily	  by	  modulating	  the	  midpoint	  reduction	  potential	  of	  the	  heme	  iron.	  The	  rates	  of	  autoxidation	  in	  P450s	  range	  from	  0.005	  s-­‐1	  in	  camphor-­‐bound	  CYP101	  (Lipscomb	  et	  al.	  1976)	  to	  20	  s-­‐1	  in	  substrate-­‐free	  CYP3A4	  at	  5	  °C	  (Denisov	  et	  al.	  2006).	  It	  is	  known	  that	  the	  autoxidation	  shunt	  accounts	  for	  a	  major	  fraction	  of	  reactive	  oxygen	  species	  (ROS)	  in	  mammalian	  P450	  CYP11A1,	  both	  in	  vivo	  and	  in	  vitro	  (Derouet-­‐Hümbert	  et	  al.	  2005),	  and	  this	  can	  lead	  to	  the	  induction	  of	  apoptosis	  in	  cells.	   The	   oxy-­‐ferrous	   complexes	   of	   various	   cytochromes	   P450	   have	   been	   characterized	  spectroscopically	  (Luthra	  et	  al.	  2011a).	  However,	  the	  more	  physiologically	  relevant	  information	  is	  the	  autoxidation	  rates	  and	  the	  energy	  of	  activation	   for	   the	  conversion	  of	   the	  oxy-­‐ferrous	  complex	  into	   the	   ferric	   resting	   state	   of	   the	   enzyme.	   The	  most	   commonly	   used	  method	   to	   investigate	   the	  autoxidation	   of	   cytochromes	   P450	   in	   the	   0.01-­‐10	   s	   time	   range	   is	   stopped-­‐flow	   spectroscopy.	  However,	   this	   requires	   special	   equipment	   and	   substantial	   amounts	   of	   enzyme	   which	   normally	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cannot	   be	   recovered	   after	   experiments.	   Alternatively,	   TDS	   provides	   a	   relatively	   easy	   and	   quick	  method	   to	  obtain	   the	  same	   information	  using	  a	   regular	   slow	  scanning	  spectrophotometer	  and	  an	  easily	   assembled	   optical	   cryostat.	   Because	   the	   measurements	   are	   done	   at	   lower	   temperatures,	  where	   all	   reaction	   rates	   are	   dramatically	   slowed,	   TDS	   makes	   possible	   studies	   of	   fast	   reactions	  without	  the	  need	  of	  expensive	  instrumentation.	  The	  Nanodisc	  technology	  allows	  the	  same	  method	  to	  be	  used	  with	  the	  membrane	  proteins	  solubilized	   in	   the	  native	  bilayer	  environment	  at	  a	  known	  oligomerization	   state	   (Bayburt	   &	   Sligar	   2010).	   In	   monitoring	   autoxidation	   using	   TDS,	   the	  perturbation	  and	  the	  observable	  are	  the	  decay	  of	  oxy-­‐P450	  and	  the	  spectral	  changes	  in	  the	  UV-­‐vis	  region	  induced	  by	  conversion	  of	  the	  oxy-­‐ferrous	  complex	  to	  the	  ferric	  form.	  
MATERIALS AND METHODS 
Expression and purification of CYP101 Expression	   of	   CYP101	   in	   Escherichia	   coli	   (E.	   coli)	   and	   protein	   purification	   were	   performed	   as	  described	  in	  (Makris	  et	  al.	  2007).	  Mutagenesis	  of	  the	  CYP101	  gene	  (pCamT7)	  was	  performed	  using	  Stratagene	  Quikchange	  kit	  following	  the	  manufacturer’s	  directions.	  The	  CYP101	  gene	  with	  a	  hexa-­‐histidine	   tag	   added	   at	   the	   C-­‐terminal	   (pT7-­‐P450	   His)	   was	   expressed	   in	   BL21	   (DE3)	   cells	  (Stratagene)	   and	   grown	   overnight	   in	   the	   presence	   of	   0.5	   mM	   δ-­‐aminolevulinic	   acid.	   After	   cell	  sonication,	   resuspension	   in	   50	   mM	   KPi,	   pH	   7.4,	   containing	   150mM	   KCl	   (buffer	   A),	   and	  ultracentrifugation,	  the	  protein	  extract	  was	  loaded	  on	  a	  Ni-­‐NTA	  column	  (Amersham),	  washed	  with	  buffer	  A	  in	  the	  presence	  of	  50	  mM	  imidazole,	  and	  eluted	  with	  the	  same	  buffer	  supplemented	  with	  20	   mM	   ethylenediaminetetraacetic	   acid	   (EDTA).	   The	   red	   fractions	   in	   the	   eluent	   were	   dialyzed	  against	  50	  mM	  KPi,	  400	  μM	  D-­‐camphor,	  and	  20	  mM	  β-­‐mercaptoethanol,	  pH	  7.4,	  overnight	  at	  4	  °C.	  Solid	   ammonium	   sulfate	   was	   added	   to	   30%	   saturation	   over	   30	   min,	   and	   the	   protein	   was	  subsequently	   loaded	   onto	   a	   phenyl–sepharose	   CL6B	   column	   equilibrated	   in	   the	   same	   buffer	   and	  eluted	  in	  a	   linear	  gradient	  from	  30	  to	  0%	  ammonium	  sulfate.	  Resulting	  fractions	  with	  an	  Rz-­‐value	  (A392/	  A280)	  greater	  than	  1.45	  were	  judged	  as	  pure	  and	  concentrated	  using	  an	  Amicon	  cell.	  
Expression, purification and Nanodisc incorporation of CYP19A1 The	  expression,	  purification	  and	  incorporation	  of	  CYP19A1	  into	  POPC	  Nanodiscs	  was	  performed	  as	  previously	  described	  	  on	  pages	  7	  and	  10.	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Preparing oxy-samples for optical spectroscopy A	  60	  µl	  aliquot	  of	  a	  mixture	  of	  100	  µM	  CYP19A1	  in	  1-­‐palmitoyl-­‐2-­‐oleoylphosphatidylcholine	  (POPC)	  Nanodiscs,	   125	  µM	  4-­‐androstenedione	   (obtained	   from	  Sigma)	   and	  2.5	  µM	  methylviologen	   in	   100	  mM	   phosphate	   buffer,	   pH	   7.4,	   was	   taken	   in	   a	   small	   glass	   vial	   with	   a	   poly(tetrafluoroethylene)	  (PTFE)/Red	   rubber	   septa	   (SUPELCO)	   and	   deoxygenated	   by	   argon,	   under	   rotation,	   for	   3–4	   min.	  Separately,	  540	  µl	  of	  a	  solution	  containing	  75%	  glycerol,	  125	  µM	  substrate,	  and	  100	  mM	  phosphate	  buffer,	   pH	   7.4,	  was	   prepared	   in	   a	  methacrylate	   cuvette	   (4.3	  mm	   path	   length	   UV-­‐enhanced	   semi-­‐microcells,	  Fisher)	  and	  saturated	  using	  pure	  oxygen	  by	  bubbling	  and	  occasional	  stirring	  for	  15	  min.	  Concentrated	  CYP19A1	  with	  125	  µM	  AD,	  methylviologen	   (MV:CYP19A1	  molar	   ratio	  of	  1:50),	   100	  mM	  KPi,	   pH	  7.4,	   and	  15%	  glycerol	  was	  deoxygenated	   and	   reduced	  with	  2.5	  Molar	   equivalents	   of	  dithionite	   in	   a	   Coy	   Laboratories	   anaerobic	   glovebox.	   Dithionite	   concentration	   was	   determined	  using	  its	  molar	  absorption	  coefficient	  of	  8.05	  mM-­‐1cm-­‐1	  at	  315	  nm	  (McKenna	  et	  al.	  1991).	  To	  form	  the	  oxy–ferrous	  complex,	  the	  reduced	  AD–bound	  CYP19	  sample	  in	  glycerol	  was	  manually	  injected	  into	   a	   solution	   of	   aerobic	   glycerol	   containing	   buffer	   precooled	   to	   243	   K,	   mixed	   for	   45	   seconds,	  transferred	  to	  a	  200	  K	  dry	   ice/ethanol	  bath,	  and	  stored	   in	   liquid	  nitrogen	  before	   further	  use.	  The	  same	  procedure	  was	  used	   to	   form	   the	  oxy	   complex	  of	   soluble	  CYP101,	   except	  no	  methylviologen	  was	  used.	  
Thermal annealing instrumentation The	  experiments	  were	  performed	  in	  a	  home-­‐built	  cryostat	  setup	  previously	  described	  in	  (Denisov	  et	   al.	   2002).	   The	   cyrostat	   comprises	   an	   unsilvered	   Pyrex	   glass	   dewar	   that	   is	   transparent	   to	  wavelengths	   above	   300	   nm.	   A	   holder	   attached	   to	   the	   top	   cover	   of	   the	   dewar	   houses	   the	   cuvette	  during	   the	  experiment.	  Prior	   to	  beginning	   the	  experiment,	   the	  dewar	   is	  precooled	   to	  200	  K	  using	  liquid	  nitrogen	  at	  the	  bottomof	  the	  dewar,	  added	  through	  a	  plastic	  funnel	  attached	  to	  the	  top	  cover	  of	   the	   dewar.	   The	   sample	   is	   never	   in	   direct	   contact	   with	   liquid	   nitrogen	   to	   prevent	   cracks	   and	  maintain	  the	  optical	  transparency.	  A	  thermocouple	  in	  contact	  with	  the	  sample	  solution	  was	  used	  to	  monitor	   the	   temperature	   of	   the	   sample	   during	  measurement.	   Figure	   6	   shows	   the	   cryostat	   setup	  with	  its	  various	  components	  labeled.	  
Choosing an optimal temperature ramping rate For	  a	  first-­‐order	  reaction	  involving	  conversion	  of	  a	  species	  S	  to	  product	  P	  the	  rate	  of	  disappearance	  of	  S	  can	  be	  calculated	  using	  the	  Arrhenius	  equation	  and	  represented	  mathematically	  as,	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𝑑𝑆𝑑𝑡 =   − 𝐴. 𝑒𝑥𝑝 −𝐸! 𝑅𝑇 . 𝑆   [1]  Rearranging,	  we	  get	  𝑑𝑆𝑆 =   −𝐴. 𝑒𝑥𝑝 −𝐸! 𝑅𝑇 . 𝑑𝑡   [2]  For	  a	  linear	  temperature-­‐time	  dependence,	  dT	  =	  mdt.	  Here,	  m	  is	  the	  slope	  of	  the	  temperature-­‐time	  profile.	  Substituting	  for	  dt	  and	  integrating	  within	  proper	  limits,	  we	  get	  𝑑𝑆𝑆!! =   − 1𝑚 . 𝐴. 𝑒𝑥𝑝 −𝐸! 𝑅𝑇 .𝑑𝑇!!!!    [3]  Figure	   7	   contains	   a	   series	   of	   calculated	   curves	   depicting	   the	   decay	   of	   the	   oxy-­‐ferrous	   complex,	  generated	  using	   [3]	  with	   an	  Arrhenius	   activation	   energy	   of	   18	   kcal/mol	   and	   varying	   ramp	   rates.	  This	   graph	   illustrates	   how	   the	   ramping	   rate	   influences	   the	   time	   span	   of	   an	   experiment	   and,	  therefore,	  the	  number	  of	  data	  points	  available	  for	  analysis.	  The	  number	  of	  available	  data	  points	  is	  determined	  by	  the	  ability	  of	  the	  instrumentation	  to	  record	  high	  quality	  spectra	  at	  the	  rate	  of	  data	  acquisition	   which	   defines	   the	   level	   of	   accuracy	   in	   extracting	   parameters	   such	   as	   Ea	   (activation	  energy)	  and	  kT	  (rate	  of	  autoxidation	  at	  a	  particular	  temperature).	  For	  instance,	  at	  the	  scanning	  rate	  600	  nm/min,	  one	   can	  measure	   the	   full	   spectrum	   in	   the	   range	  of	  750	   to	  300	  min	   in	  1	  min,	  which	  corresponds	  to	  one	  spectrum	  per	  kelvin	  at	  a	  temperature	  ramping	  rate	  of	  1	  K/min.	  
Data acquisition All	   UV-­‐vis	   absorption	   spectra	  were	   acquired	  with	   a	   Cary	   300	   Bio	   UV-­‐visible	   spectrophotometer.	  (Varian	  Instruments),	  in	  a	  continuous	  scan	  mode,	  at	  a	  scan	  rate	  of	  600	  nm/min	  and	  a	  45-­‐second	  gap	  between	  scans.	  A	  thermocouple	  inserted	  into	  the	  sample	  cuvette	  was	  used	  to	  monitor	  temperature.	  Temperature	   readings	   were	   noted	   at	   the	   start	   and	   end	   of	   each	   UV-­‐vis	   scan	   and	   averaged	   for	  analysis.	  
Data analysis The	  raw	  spectral	  data	  from	  the	  spectrophotometer	  were	  first	  corrected	  for	  baseline	  shifts	  between	  scans	   by	   subtracting	   the	   average	   absorbance	   at	   595-­‐600	   nm	   of	   each	   spectrum.	   The	   baseline-­‐corrected	  and	  time-­‐dependent	  data	  were	  analyzed	  by	  a	  singular	  value	  decomposition	  (SVD)	  routine	  in	  MATLAB	   to	   identify	   the	   eigenvectors	   and	   eigenvalues	   of	   the	   reaction.	   SVD	   is	   a	   linear-­‐algebra	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technique	  that	  allows	  one	  to	  determine	  the	  number	  of	  spectrally	  distinguishable	  components	  that	  are	  involved	  in	  a	  reaction	  and	  to	  extract	  maximum	  information	  about	  the	  transition	  between	  these	  species	   from	   experimental	   data	   set.	   Figure	   8(a)	   shows	   the	   TDS	   data	   for	   AD-­‐bound	   CYP19	  reconstructed	  using	  the	  first	  two	  eigenvectors.	  Isosbestic	  points	  show	  a	  single	  transition,	  which	  is	  the	   decomposition	   of	   the	   oxy-­‐ferrous	   complex	   into	   the	   ferric	   resting	   state.	   The	   small	   drift	   at	   the	  isosbestic	  point	  at	  408	  nm	  is	  due	  to	  the	  temperature-­‐dependent	  changes	  of	  the	  band	  shape	  of	  both	  components,	  i.e.,	  substantial	  narrowing	  and	  sharpening	  of	  Soret	  bands	  at	  low	  temperatures.	  Figure	  8(b)	   shows	   the	   first	   four	   abstract	   absorption	   spectra	  multiplied	   by	   their	   corresponding	   singular	  values	   for	   the	   autoxidation	  of	   P450.	  Only	   the	   first	   two	  main	   spectral	   components	   are	   significant,	  with	  others	  being	  close	  to	  zero.	  This	  clearly	  indicates,	  along	  with	  isosbestic	  points	  in	  the	  raw	  data,	  the	  presence	  of	  only	  two	  major	  absorbing	  species	  in	  the	  data	  set.	  Hence,	  the	  second	  concentration	  vector	   from	  SVD	   is	   a	  measure	  of	   disappearance	  of	   the	  oxy-­‐ferrous	   complex	  or	   appearance	  of	   the	  ferric	   complex.	   These	   difference	   spectra	  were	   normalized	   and	   fitted	   to	   a	  modified	   rate	   equation	  derived	  on	  the	  basis	  of	  the	  Kramers’	  theory	  to	  account	  for	  variable	  temperature	  (equation	  [4]).	  The	  time	  and	  temperature	  increments	  were	  used	  directly	  as	  time	  steps	  for	  integration.	  
Fitting the concentration profile to the TDS equation The	  autoxidation	  of	  oxy-­‐CYP101	  and	  oxy-­‐CYP19A1	  in	  their	  substrate	  bound	  states	  can	  be	  modeled	  as	   a	   first-­‐order	   reaction.	   For	   reactions	   occurring	   in	   the	   high-­‐friction/	   high-­‐viscosity	   regime,	   a	  modified	  Kramers’	  theory	  (Yedgar	  et	  al.	  1995)	  provides	  a	  good	  description	  of	  the	  reaction	  kinetics	  where	  the	  rate	  constant	  for	  a	  biochemical	  reaction	  can	  be	  expressed	  as:	  
𝑘 =    𝐴𝜂! 𝑒𝑥𝑝 −𝐸! 𝑅𝑇    [4]  Here,	   A	   is	   a	   frequency	   (or	   pre-­‐exponential)	   factor,	   η,	   the	   solvent	   viscosity	   and	   Ea,	   R	   and	   T,	   the	  Arrhenius	   activation	   energy,	   gas	   constant	   and	   temperature	   (in	   Kelvin)	   respectively.	   p	   is	   an	  empirical	  exponent	  smaller	  than	  unity,	  which	  has	  been	  shown	  to	  be	  related	  to	  the	  molecular	  weight	  of	  the	  cosolvent	  in	  question	  and	  estimated	  as	  0.54	  for	  glycerol	  (Yedgar	  et	  al.	  1995).	  Samples	  prepared	  for	  TDS	  contain	  70%	  glycerol	  and	  are	  hence,	  highly	  viscous.	  Since	  autoxidation	  involves	   a	   dynamic	   process	   of	   opening	   of	   the	   active	   site	   to	   release	   the	   superoxide	   anion,	   the	  phenomenon	   is	   affected	   by	   the	   viscosity	   of	   the	   solution.	   It	   is	   well	   known	   that	   viscosity	   of	   pure	  liquids	   and	   their	   mixtures	   depend	   on	   temperature	   and	   pressure.	   Very	   recently,	   González	   et	   al.	  (Gonzalez	   et	   al.	   2011)	  proposed	  an	   equation	   for	   calculation	  of	   the	  dynamic	   viscosity	  of	   aqueous-­‐
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glycerol	  mixtures	  over	  a	  wide	   range	  of	   temperatures	  and	  compositions.	   In	   fitting	   the	  TDS	  data,	   a	  value	  of	  0.65	  was	  used	  as	  the	  weight	  fraction	  of	  glycerol.	  Using	  p	  as	  0.54,	  and	  the	  model	  for	  temperature	  dependence	  of	  viscosity	  proposed	  by	  González	  et	  al.	  (Gonzalez	  et	  al.	  2011)the	  TDS	  data	  for	  autoxidation	  decay	  of	  the	  oxy-­‐ferrous	  complex	  for	  camphor-­‐bound	  CYP101	  and	  AD-­‐bound-­‐CYP19A1	  was	  fitted	  to	  the	  equation	  [6]	  in	  the	  form	  given	  below.	  	  For	  a	  first-­‐order	  reaction	  involving	  decay	  of	  species	  S	  (representing	  the	  oxy-­‐complex	  of	  cytochrome	  P450),	  
𝑘 =    𝐴𝜂! 𝑒𝑥𝑝 −𝐸! 𝑅𝑇    [5]  
𝑑𝑆𝑑𝑡 =   −𝑘. 𝑆	     
𝑘 =    𝐶𝜂! 𝑒𝑥𝑝 −𝐸! 𝑅𝑇 	     𝑑𝑆𝑑𝑡 =   − 𝐶𝜂! 𝑒𝑥𝑝 −𝐸! 𝑅𝑇 . 𝑆	   (a)  The	  rate	  constant	  ‘k’	  can	  be	  alternatively	  expressed	  as,	  
𝑘 =    𝐶𝜂! 𝑒𝑥𝑝 −𝐸! 𝑅𝑇 =    𝑘!"#!.𝜂!"#!!𝜂! . 𝑒𝑥𝑝 −𝐸!𝑅𝑇 298 − 𝑇298 	   (b)  From	  (a)	  and	  (b),	  𝑑𝑆𝑆 =   − 𝑘!"#!.𝜂!"#!!𝜂! . 𝑒𝑥𝑝 −𝐸!𝑅𝑇 298 − 𝑇298 𝑑𝑡	     Integrating	  within	  proper	  limits	  for	  S	  and	  T	  we	  get,	  𝑑𝑆𝑆!! =   − 𝑘!"#!.𝜂!"#!!𝜂! . 𝑒𝑥𝑝 −𝐸!𝑅𝑇 298 − 𝑇298!!!! 𝑑𝑇 . 𝑑𝑡𝑑𝑇	   [6]  Fitting	  was	  accomplished	  with	  a	  program	  written	  in	  MATLAB,	  using	  the	  subroutine	  ‘fminsearch.m’	  that	   implements	   the	   Nelder-­‐Mead	   Simplex	   algorithm	   to	   find	   the	  minimum	   of	   a	  multiparametric,	  non-­‐linear	  function.	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RESULTS AND DISCUSSION As	  shown	   in	  Figure	  8(a),	   the	  starting	  spectra	  of	  oxygenated	  CYP19A1	   in	  70%	  glycerol	  are	  almost	  identical	   to	   those	   previously	   measured	   using	   either	   stopped	   flow	   (Grinkova	   et	   al.	   2008)	   or	  cryospectroscopy	  (Gantt	  et	  al.	  2009).	   	  At	  220	  -­‐	  230	  K	  the	  rate	  of	  autoxidation	  is	  very	  low,	  and	  the	  oxy-­‐complex	  remains	  stable.	  As	  the	  temperature	  increases,	  the	  rate	  of	  autoxidation	  also	  increases,	  and	  the	  oxy-­‐ferrous	  complex	  starts	  to	  decompose,	  as	  shown	  in	  Figure	  8(c).	  When	  the	  temperature	  reaches	  260	  K,	  the	  rate	  of	  autoxidation	  becomes	  high	  enough	  to	  change	  significantly	  the	  fraction	  of	  oxy-­‐complex	  during	  the	  time	  of	  single	  scan	  (45	  s).	  The	  curve	  shown	  in	  Figure	  8(c)	  reaches	  zero	  at	  285	  K,	  where	  all	  of	  the	  oxy-­‐CYP19A1	  returns	  to	  the	  high-­‐spin	  ferric	  form,	  as	  seen	  from	  Figure	  8(a).	  	  	  	  The	   energy	   of	   activation	   for	   the	   conversion	   of	   oxy-­‐ferrous	   CYP19A1,	   saturated	   with	  androstenedione,	  to	  ferric	  CYP19A1	  was	  calculated	  to	  be	  17.5	  kcal/mol	  with	  a	  rate	  constant	  of	  0.02	  s-­‐1	   at	   298	   K	   (Figure	   8(c)).	   	   In	   the	   case	   of	   CYP101,	   saturated	   with	   camphor,	   this	   value	   was	  determined	  to	  be	  18.0	  kcal/mole	  with	  a	  rate	  constant	  of	  0.015	  s-­‐1	  at	  298	  K	  (Figure	  9(d)).	  	  The	  values	  of	  Ea	  obtained,	   in	  both	  cases,	  correspond	  well	  with	  those	  published	  earlier	  (Lipscomb	  et	  al.	  1976;	  Grinkova	  et	  al.	  2008).	  The	  results	  obtained	  using	  TDS	  approach	  with	  a	  single	  sample	  match	  almost	  exactly	  the	  parameters	  derived	  in	  earlier	  stopped-­‐flow	  studies,	  which	  confirms	  the	  validity	  of	  TDS	  approach	  to	  the	  autoxidation	  processes	  in	  heme	  enzymes.	  Cytochromes	  P450s	  do	  not	  possess	  a	  static	  channel	  for	  the	  access	  of	  O2	  to	  the	  active	  site.	  Therefore,	  the	   protein	   has	   to	   undergo	   a	   conformational	   change	   to	   form	   a	   dynamic	   path	   for	   the	   entry	   and	  egress	  of	  ligands	  such	  as	  O2	  and	  CO.	  	  The	  high	  activation	  energy	  barrier	  for	  autoxidation	  (17	  kcal/	  mol	   for	   camphor-­‐bound-­‐CYP101(Lipscomb	   et	   al.	   1976)	   and	   18	   kcal/mol	   in	   AD-­‐bound-­‐CYP19A1	  (Grinkova	   et	   al.	   2008))	   reinforce	   this	   idea.	   	   An	   even	   higher	   activation	   energy,	   22	   kcal/mol	   was	  reported	  for	  the	  autoxidation	  of	  CYP11A1,	  another	  P450	  involved	  in	  steroid	  hormone	  biosynthesis	  (Tuckey	  &	  Kamin	  1982),	   although	   this	  measurement	  was	  made	   in	   the	  presence	   of	   38%	  ethylene	  glycol	  at	  subzero	  temperatures	  and	  was	  not	  corrected	  for	  high	  viscosity.	  As	  described	  in	  Materials	   in	  Methods,	  absolute	  rates	  of	  enzymatic	  catalysis	  usually	  depend	  on	  the	  solvent	   viscosity.	   	   The	   first	   attempts	   to	   include	   viscosity	   into	   the	  Kramers’	   approach	   to	   describe	  biochemical	  reactions	  yielded	  an	  inverse	  dependence	  of	  the	  rate	  of	  a	  reaction	  on	  viscosity	  (i.e.	  p	  =	  1)	  (Gavish	  1978)	  .	  	  This	  approach	  was	  tested	  for	  hydrolysis	  catalyzed	  by	  carboxypeptidase	  (Gavish	  &	  Werber	   1979),	   and	   later	   for	   the	   variety	   of	   processes	   such	   as	   oxygen	   escape	   from	   myoglobin	  (Beece	   et	   al.	   1980)	   and	   hemerythin	   (Lavalette	   et	   al.	   1979),	   ester	   hydrolysis	   by	   subtilisin	   (Ng	   &	  Rosenberg	   1991),	   photocycle	   of	   bacteriorhodopsin	   (Beece	   et	   al.	   1981)	   and	   hydrogen	   isotope	  
	   25	  
exchange	   in	   lysozyme	   and	   in	   other	   proteins	   (Rosenberg	   et	   al.	   1989;	   Somogyi	   et	   al.	   1988).	   In	   all	  these	   experiments	   it	   was	   observed	   that	   biochemical	   reactions	   that	   take	   place	   within	   a	   protein	  matrix	  are	  sensitive	   to	   the	  viscosity	  of	   the	  solvent,	  especially	  at	  high	  viscosities,	  and	   that	   in	  most	  cases	   a	   fractional	   power	   (p	   <	   1)	   describes	   the	   process.	   In	   a	   systematic	   study	   of	   many	   solvents,	  Yedgar	  et	  al.	   (Yedgar	  et	  al.	  1995)	  have	  shown	  that	   the	  effect	  of	  solvent	  viscosity	  on	   the	  escape	  of	  oxygen	  from	  hemerythrin	  follows	  the	  power-­‐law	  with	  p	  dependent	  on	  the	  molecular	  weight	  of	  the	  cosolvent.	  This	  relation	  can	  be	  expressed	  as:	  𝑝 𝑀 =   1.52𝑀!!.!"   [7]  where,	  M	  is	  the	  molecular	  weight	  (in	  Daltons)	  of	  the	  cosolvent.	  For	  glycerol,	  M	  =	  92	  and	  therefore,	  p	  =	  0.54.	  This	  empirical	  value	  is	  also	  the	  value	  that	  the	  authors	  determined	  experimentally.	  	  
Temperature dependence of viscosity Our	   TDS	   experiment	   samples	   temperatures	   from	   230K	   to	   290	   K.	   In	   this	   range,	   the	   viscosity	   of	  water-­‐glycerol	  mixtures	  strongly	  depends	  on	  temperature	  (Gonzalez	  et	  al.	  2011).	  There	  are	  various	  models	   that	   attempt	   to	   correlate	   viscosity-­‐temperature	   data	   of	   pure	   liquids	   and	   liquid-­‐solutions	  starting	   from	   the	   simple	  Arrhenius	   type	  models	   (Andrade	  1934)	   to	  more	   elaborate	   and	   complex	  empirical	  fits	  (Cheng	  2008;	  Chen	  &	  Pearlstein	  1987).	  Most	  of	  these	  models	  have	  been	  derived	  from	  fitting	  experimental	  data	   for	   the	  viscosity	  of	  aqueous	  glycerol	   solutions	  at	   temperatures	  between	  253	  K	  and	  above.	  These	  models	  often	  fail	  when	  used	  to	  make	  predictions	  outside	  their	  validity	  limit.	  We	  used	  the	  equation	  derived	  by	  Trejo	  González	  et	  al.	  (Gonzalez	  et	  al.	  2011),	  which	  uses	  the	  general	  Aramov-­‐Michev	  equation	  (Avramov	  2005)	  to	  model	  viscosity	  data	  of	  glycerol	  aqueous	  solutions	  in	  the	  entire	  range	  of	  compositions,	  0	  ≤	  w2	  ≤	  1	  and	  which	  also	  provides	  equations	  for	  the	  composition	  dependence	  of	  the	  parameters	  in	  this	  equation.	  This	  approach	  was	  also	  shown	  to	  be	  applicable	  over	  a	  wide	  range	  of	  temperatures	  including	  the	  supercooled	  region	  of	  water	  and	  glycerol	  where	  other	  methods	   of	   predicting	   the	   viscosity-­‐temperature	   relationship	   fail.	   The	   equations	   used	   for	  calculating	  viscosity	  of	  the	  glycerol-­‐water	  mixture	  used	  are:	  
𝜂 =   𝜂!𝑒𝑥𝑝 28.75 − ln 𝜂! 𝑇!𝑇 !    [8]  Where,	  Tg	  is	  the	  glass	  transition	  temperature	  of	  the	  liquid	  solution.	  η0,	  Tg	  and	  α	  were	  expressed	  as	  a	  functions	  of	  the	  weight	  fraction	  of	  glycerol	  (w2)	  in	  the	  solution	  as:	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𝑇! 𝐾 =   140.3 + 35.272  𝑤! − 3.879  𝑤!! + 23.467  𝑤!!   [9]  
−ln 𝜂!  /𝑚𝑃𝑎. 𝑠 = 2.1686 − 2.7096  𝑤! + 1.4449  𝑤!!	   [10]  𝛼 = 3.6344 + 1.2198  𝑤! − 1.6142  𝑤!!	   [11]  If	  not	  corrected	  for,	  temperature	  dependence	  of	  η	  contributes	  ~5	  kcal/mol	  to	  the	  observed	  energy	  barrier	  as	   seen	  by	  Gavish	  and	  Werber	  while	   studying	   the	  rate	  of	   catalysis	  of	   carboxypeptidase	   in	  different	  cosolvent	  mixture	  (Gavish	  &	  Werber	  1979).	  	  Fitting	  the	  TDS	  data	  reported	  in	  this	  paper	  to	  the	   simple	   Arrhenius	   equation,	   not	   accounting	   for	   viscosity	   of	   solution	   or	   its	   temperature	  dependence,	  yields	  the	  same	  result.	  A	  value	  of	  0.65	  was	  used	  as	  the	  weight	  fraction	  of	  glycerol	  instead	  of	  0.75	  that	  would	  result	  if	  one	  calculated	   the	  weight	   fraction	  of	  glycerol	   in	  a	  70%	  (v/v)	  glycerol-­‐water	  mixture.	  The	  presence	  of	  glycerol	  preferentially	  hydrates	  protein	  molecules	  and	  results	   in	  a	  higher	  than	  average	  content	  of	  water	   in	   the	   hydration	   shell	   of	   the	   protein	   (Sinibaldi	   et	   al.	   2007).	   Preferential	   hydration	   in	   the	  presence	  of	  glycerol	  and	  ethylene	  glycol	  is	  known	  to	  stabilize	  the	  activity	  of	  enzymes	  and	  retain	  the	  native	  structure	  of	  proteins	  (Gekko	  &	  Timasheff	  1981).	  For	  a	  75%	  w/w	  glycerol-­‐water	  mixture	  the	  amount	   of	   glycerol	   present	   in	   the	   local	   domain	   of	   the	   protein	   molecule	   is	   approximately	   65%	  (Sinibaldi	  et	  al.	  2007).	  Intracellular	  microviscosity	  is	  an	  important	  regulator	  of	  cellular	  functions	  and	  membrane	  enzyme	  activity	  (Kuimova	  et	  al.	  2009).	  	  The	  analysis	  developed	  in	  this	  work,	  integrating	  the	  two	  important	  parameters	   of	   temperature	   and	   viscosity,	   not	   only	   gives	   a	   full	   Arrhenius	   dependence	   of	   the	   also	  provides	   a	   way	   to	   calculate	   rates	   of	   autoxidation	   of	   oxy-­‐P450s	   in	   different	   cellular	   milieu.	  Importantly,	  high	  viscosity	  has	  a	  profound	  effect	  on	  the	  rates	  of	  autoxidation,	  and	  in	  some	  cases	  this	  can	   affect	   the	   stability	   of	   oxy-­‐ferrous	   intermediate	   in	   membrane	   bound	   cytochromes	   P450	   and	  overall	  uncoupling	  of	  P450	  catalysis.	  Apart	   from	   being	   quick,	   this	   technique	   offers	   high	   precision,	   in	   terms	   of	   agreement	   between	  experimental	   data	   and	   the	   theoretical	   model	   of	   autoxidation	   decay,	   as	   well	   as	   high	   accuracy,	   as	  evident	   from	   the	   comparison	   of	   Ea	   values	   obtained	  with	   this	  methodology	   and	   that	   obtained	   by	  other	   approaches.	   TDS	   gives	   spectral	   data	   corresponding	   to	   a	   finely	   spaced,	   wide	   range	   of	  temperatures,	  the	  eigenvalues	  and	  eigenvectors	  obtained	  from	  SVD	  analysis	  are	  more	  robust	  than	  that	   obtained	   from	   the	   SVD	   analysis	   of	   spectral	   data	   sets	   at	   five	   to	   six	   temperature	   points	   in	   a	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typical	   stopped-­‐flow	   experiment.	   TDS	   also	   gives	   the	   complete	   Arrhenius	   dependence	   of	   the	  autoxidation	  process	  in	  a	  single	  experiment,	  using	  very	  little	  sample.	  
CONCLUSION TDS	  provides	   a	   rapid,	   robust	   and	   a	   convenient	  method	   to	  measure	   decay	   kinetics	   of	   oxy-­‐ferrous	  complexes	   in	   cytochromes	   P450.	   Using	   this	   method,	   the	   full	   Arrhenius	   dependence	   of	   the	  autoxidation	   process	   can	   be	   measured	   in	   a	   single	   experiment,	   with	   relatively	   little	   sample.	  Furthermore,	   the	   sample	   is	   completely	   recoverable	   unlike	   in	   stopped-­‐flow.	   By	   integrating	   data	  analysis	  with	  data	  acquisition	  the	  method	  described	  has	  the	  potential	  to	  be	  developed	  into	  a	  semi-­‐automatic	  way	  to	  characterize	  the	  oxy-­‐ferrous	  complex	  in	  heme	  proteins.	  The	  concept,	   in	  general,	  can	   be	   applied	   to	   any	   temperature-­‐dependent	   process,	   the	   ‘observable’	   varying	   from	   absorption	  spectra,	  as	  illustrated	  here,	  to	  other	  parameters	  such	  as	  mid-­‐point	  reduction	  potential	  and	  pH.	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  Figure	   7:	   Theoretical	   curves	   depicting	   the	   effect	   of	   temperature	   ramp	   rate	   on	   the	   shape	   of	   the	  concentration	   profile.	   All	   curves	   were	   generated	   assuming	   an	   18	   kcal/mol	   Arrhenius	   activation	  energy	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  Figure	   8:	   (a)	   SVD	   reconstructed	   TDS	   data	   for	   AD-­‐bound	   CYP19.	   Inset:	   Difference	   spectra	  corresponding	  to	  the	  same	  data	  set.	  Both	  sets	  of	  spectra	  show	  clear	  transition	  from	  the	  oxy-­‐ferrous	  complex	  to	  the	  ferric	  resting	  state.	  	  
	  (b)	   Eigenvectors	   from	   singular	   value	   decomposition	   (SVD)	   of	   TDS	   data	   for	   AD-­‐bound	   CYP19,	  normalized	  with	  respect	  to	  the	  corresponding	  eigenvalues.	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  (c)	  Decomposition	  of	  the	  oxy-­‐ferrous	  complex	  of	  AD-­‐bound	  CYP19	  via	  autoxidation	  fitted	  to	  a	  rate	  equation	   based	   on	   Kramers’	   theory	  with	   viscosity	   corrections.	   The	   uptick	   toward	   the	   end	   of	   the	  experiment,	  as	  seen	  in	  the	  figure,	  could	  be	  due	  to	  light	  scattering.	  Condensation	  of	  water	  molecules	  on	  the	  walls	  of	  the	  cuvette	  and	  changes	  in	  turbidity	  of	  the	  sample	  solution	  with	  rise	  in	  temperature	  contribute	  to	  this	  effect	  
	  Figure	  9:	  (a)	  SVD	  reconstructed	  TDS	  data	  for	  camphor-­‐bound	  CYP101.	  !
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  (b)	   Difference	   spectra	   corresponding	   to	   the	   same	   data	   set.	   Both	   sets	   of	   spectra	   show	   clear	  transition	  from	  the	  oxy-­‐ferrous	  complex	  to	  the	  ferric	  resting	  state.	  	  
	  (c)	  Eigenvectors	  from	  singular	  value	  decomposition	  (SVD)	  of	  TDS	  data	  for	  camphor-­‐bound	  CYP101,	  normalized	  with	  respect	  to	  the	  corresponding	  eigenvalues.	  	  
!
!
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  (d)	  Decomposition	  of	  the	  oxy-­‐ferrous	  complex	  of	  camphor-­‐bound	  CYP101	  via	  autoxidation	  fitted	  to	  a	  rate	  equation	  based	  on	  Kramers’	  theory	  with	  viscosity	  corrections.	  The	  systematic	  deviations	  for	  the	   P450cam	  data	   in	   Figure	   S4	  may	   be	   due	   to	   a	   small	   fraction	   of	   substrate-­‐free	   P450cam	   in	   the	  experiment	  which	  autoxidizes	  at	  a	  higher	  rate.	  This	  can	  be	  estimated	  as	  being	  less	  than	  5%	  from	  the	  slight	   deviation	   of	   the	   fit	   from	   experimental	   data	   at	   low	   temperatures.	   For	   this	   particular	  experiment	  we	  did	  not	  gather	  data	  above	  16	  °C.	  More	  data	  points	  obtained	  at	  higher	  temperatures	  i.e.	  the	  flat	  region	  of	  the	  curve,	  would	  remove	  this	  systematic	  deviation	  as	  shown	  in	  Figure	  3c.	  
!
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Chapter 3: TDS to study protein dynamics in P450s 
INTRODUCTION The	  previous	  chapter	  presented	  the	  application	  of	  temperature	  derivative	  spectroscopy	  to	  monitor	  autoxidation	   in	   cytochromes	   P450	   (Luthra	   et	   al.	   2011b).	   TDS	   was	   used	   to	   characterize	   the	  energetics	   of	   conversion	   of	   oxy-­‐ferrous	   states	   of	   substrate	   bound	   CYP19	   and	   CYP101	   into	   the	  corresponding	   ferric	   states.	   This	   chapter	   outlines	   the	   implementation	   of	   TDS	   to	   study	   other	   key	  processes	  in	  the	  P450	  catalytic	  cycle,	  namely,	  high-­‐spin	  low-­‐spin	  relaxation,	  binding	  of	  a	  diatomic	  ligand	  and	  decay	  of	  the	  reduced	  oxy-­‐ferrous	  complex.	  	  These	   three	  processes	  have	  been	   studied	   at	   temperatures	  below	   the	   glass	   transition	  of	   aqueous-­‐glycerol	  solutions	  used	  to	  prepare	  the	  samples.	  In	  this	  temperature	  range	  protein	  motion	  is	  frozen	  and	   the	   heterogeneity	   of	   the	   protein’s	   energy	   landscape	   becomes	   consequential.	   One	   way	   to	  describe	   this	   mathematically	   is	   by	   using	   a	   normal	   distribution,	   where	   the	   activation	   energy	   is	  described	  as	  a	  Gaussian	  distribution	  described	  by	  a	  peak	  enthalpy,	  HP	  and	  a	  standard	  variance	   in	  distribution,	  σ.	  These	  concepts	  are	  discussed	  in	  more	  detail	  below:	  
Protein flexibility and rigidity For	  a	  long	  time	  after	  X-­‐ray	  crystallography	  enabled	  the	  determination	  of	  3-­‐dimensional	  structures	  of	   protein	   molecules	   it	   was	   thought	   that	   each	   protein	   molecule	   assumed	   a	   unique	   molecular	  structure	   that	   gave	   it	   its	   functional	   characteristics.	   This	   view	   held	   its	   ground	   until	   1959,	   when	  Linderstrøm-­‐Lang	   &	   Schellman	   based	   on	   studies	   of	   hydrogen/deuterium	   exchange	   in	   proteins	  concluded	  that	  proteins	  exist	  as	  a	  group	  of	  similar	  structures	  having	  comparable	  free	  energies	  and	  that	   a	   protein	   molecule	   must	   be	   thought	   of	   as	   trying	   out	   every	   possible	   structure	   rather	   than	  possessing	  a	  unique	  structure	  (Linderstrøm–Lang	  &	  Schellman	  1959).	  Both	  these	  points	  of	  view	  are	  valid	  in	  their	  own	  right.	  We	  now	  know	  that	  proteins	  reside	  the	  space	  between	  these	  two	  extremes	  of	   flexibility	   and	   rigidity	   favored	   by	   deuterium	   exchange	   experiments	   and	   X-­‐ray	   crystallography	  respectively	  and	  that	  both	  these	  aspects	  are	  absolutely	  important	  for	  proper	  function.	  
Origin of conformational substates Proteins	  are	  polypeptides	  held	  together	  by	  strong	  covalent	  bonds	  that	  are	  organized	  into	  secondary	  structure	   elements	   such	   as	   helices,	   sheets	   and	   coils,	   which	   in	   turn	   are	   assembled	   into	   unique	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tertiary	   and	   quaternary	   structures.	   The	   biological	   function	   of	   a	   protein	   molecule	   is	   intimately	  related	   to	   its	   structure	   and	   therefore,	   proper	   folding	   is	   critical	   for	   biological	   activity.	   Secondary	  structure	  formation	  and	  its	  higher	  order	  organization	  is	  governed	  by	  weak	  forces	  such	  as	  H-­‐bonds,	  van	   der	   Waals	   forces	   and	   other	   non-­‐covalent	   interactions.	   Although	   the	   overall	   3-­‐dimensional	  structure	   of	   a	   protein	   is	   unique	   and	   depends	   on	   its	   primary	   sequence,	   slight	   differences	   in	   the	  position	  and	  orientation	  of	   such	  weak	   interactions	   result	   in	  minor	  differences	   in	   the	   structure	  of	  individual	   protein	   molecules	   thus	   transforming	   the	   unique	   structure	   of	   protein	   molecule	   into	   a	  structure	  ensemble.	  Individual	  members	  of	  a	  structure	  ensemble	  are	  referred	  to	  as	  conformational	  substates.	  	  Evidence	  for	  conformational	  substates	   in	  proteins	  comes	  from	  non-­‐exponential	  rebinding	  kinetics	  of	   carbon-­‐monoxide	   (CO)	   to	   myoglobin	   (Austin	   et	   al.	   1975)	   and	   nitrous	   oxide	   (NO)	   to	   azurin	  (Ehrenstein	   &	   Nienhaus	   1992),	   temperature	   dependence	   of	   B-­‐factor	   in	   X-­‐ray	   crystallography	   of	  myoglobin	   and	   ribonuclease	   (Frauenfelder	   et	   al.	   1979;	   Tilton	   et	   al.	   1992),	   non-­‐exponential	   spin	  echo	  decays	  and	  non-­‐homogenous	  broadening	  of	  EPR	   line	  shapes	   in	  spin	   labeled	  Na+/K+	   -­‐ATPase	  (Guzzi	   et	   al.	   2014)	   and	  much	   recently	   from	  picosecond	  X-­‐ray	   solution	   scattering	   in	   sperm	  whale	  myoglobin	  (Oang	  et	  al.	  2014).	  	  
Conformational sampling A	  protein	  molecule	  is	  constantly	  shifting	  among	  its	  various	  conformational	  substates	  in	  the	  general	  neighborhood	   of	   the	   native	   structure	   via	   thermally	   driven	  motions.	   Such	  motions,	   referred	   to	   as	  ‘conformational	  motions’	  span	  time	  scales	  of	  femtoseconds	  (bond	  vibrations)	  to	  picoseconds	  (small	  group	  fluctuations)	  to	  nano-­‐	  and	  microseconds	  or	  longer	  (collective	  motion	  of	  groups	  of	  bonded	  or	  non-­‐bonded	  atoms)	  and	  corresponding	  distance	  scales	  of	   fractions	  of	  an	  Angstrom	  to	  nanometers	  (McCammon	  1984).	  Conformational	  motions	  allow	  enzymes	   to	  bind	  substrate	  molecules,	   catalyze	  reactions	  by	  breaking	  old	  and	  forming	  new	  bonds,	  and	  release	  product	  molecules	  at	  the	  end	  of	  the	  catalytic	   cycle.	   A	   rigid	  molecule	  would	   not	   be	   able	   to	   do	   any	   of	   these	   functions	   in	   a	   catalytically	  competent	  manner	  and	  therefore,	  conformational	  motion	  is	  essential	  for	  protein	  function	  (Daniel	  et	  al.	   2003). It	   has	   been	   shown	   in	   prolyl	   cis-­‐trans	   isomerase	   cyclophilin	   A	   (CypA)	   that	   the	  characteristic	  enzyme	  motions	  necessary	  for	  catalysis	  are	  already	  present	  in	  the	  free	  enzymes	  with	  frequencies	   corresponding	   to	   catalytic	   turnover	   rates	   and	   that	   protein	   motion	   important	   for	  catalysis	  is	  an	  intrinsic	  property	  of	  the	  enzyme	  (Eisenmesser	  et	  al.	  2005).	  Since	  conformational	  motions	  are	  thermally	  driven	  the	  picture	  of	  a	  protein	  molecule	  that	  emerges	  from	   an	   experiment	   depends	   on	   the	   temperature	   and	   time	   scale	   of	   measurement.	   At	   low	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temperatures,	  much	  of	   conformational	  motion	   is	   frozen	   and	   individual	   protein	  molecules	   remain	  trapped	   in	   different	   conformational	   substates	   giving	   rise	   to	   a	   distribution	   in	   reaction	   rates.	   At	  intermediate	   temperatures,	   only	   conformational	   fluctuations	   that	   occur	   on	   the	   timescale	   of	   the	  reaction	   are	   visible.	   In	   the	   high	   temperature	   regime,	   individual	   protein	   molecules	   undergo	  conformational	   relaxation	   on	   time	   scales	   much	   shorter	   than	   that	   of	   the	   reaction	   studied	   and	  therefore	  only	  a	  single,	  average	  rate	  of	  reaction	  is	  observed.	  
Modeling conformational substates In	  terms	  of	  free	  energy,	  conformational	  substates	  sit	  at	  points	  of	  local	  minima	  in	  the	  rugged	  energy	  landscape	  of	  proteins.	  The	  energy	  landscape	  itself	   is	  organized	  in	  a	  hierarchy.	  Top	  tiers	  consist	  of	  functionally	  relevant	  states	  of	  a	  protein	  and	  are	  separated	  by	  moderate	  differences	  in	  free	  energy.	  The	  lower	  tiers	  are	  much	  less	  separated	  in	  free	  energies	  and	  make	  themselves	  recognized	  only	  at	  low	   temperatures	   (Frauenfelder	   et	   al.	   2009).	   The	   top	   tier	   substates	   can	   be	   characterized	  experimentally	  and	  a	  taxonomic	  approach	  for	  classifying	  them	  is	  feasible.	  However,	  as	  we	  go	  down	  in	   the	   hierarchy	   of	   states,	   the	   number	   of	   possible	   substates	   explodes	   exponentially	   making	   a	  taxonomic	  approach	  absolutely	  unemployable	  (Frauenfelder	  et	  al.	  1991).	  	  A	  solution	  may	  be	  obtained	  by	  treating	  the	  energy	  barrier	  of	  a	  physicochemical	  process	  A	  "	  B	  as	  not	  being	  sharp	  but	  defined	  by	  a	  spectral	  function	  g(HAB),	  such	  that	  d{g(HAB)}	  or	  g(HAB)dHAB	  represents	  the	  probability	  of	  having	  the	  energy	  barrier	  between	  HAB	  and	  HAB	  +	  dHAB	  and	   𝑔 𝐻!" 𝑑𝐻!" = 1!! .	  The	  number	  of	  molecules	  going	  from	  A	  to	  B	  at	  any	  given	  time	  can	  then	  be	  given	  by,	  
𝑁! =   𝑁! 𝑔 𝐻!" 𝑑𝐻!"!! . 𝑒!!!"!	   	   [12]	  where,	  kAB	  denotes	  the	  rate	  of	  reaction	  and	  bears	  an	  Arrhenius	  dependence	  on	  HAB.	  
Nature of g(H) g(H)	  is	  temperature	  independent	  (Austin	  et	  al.	  1975;	  Frauenfelder	  et	  al.	  1988)	  and	  can	  be	  obtained	  by	  taking	  a	  Laplace	  transform	  of	  equation	  [12]	  if	  Nt	  can	  be	  measured	  over	  a	  wide	  temperature	  and	  time	  range.	  However,	  a	  more	  efficient	  way	  to	  obtain	  the	  distribution	  is	  to	  assume	  an	  analytical	  form	  of	   g(H)	   and	   then	   solve	   equation	   [12]	   numerically.	   In	   the	   literature,	   mainly	   two	   forms	   of	   g(H),	  namely	   the	   Gamma	   function	   (Ansari	   et	   al.	   1987;	   Young	   &	   Bowne	   1984;	   Austin	   et	   al.	   1975)	   and	  normal	  distribution	  (Ehrenstein	  &	  Nienhaus	  1992;	  Nienhaus	  &	  Nienhaus	  2011)	  have	  been	  used	  to	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fit	  experimental	  data	  corresponding	  to	  processes	  exhibiting	  non-­‐exponential	  decay	  kinetics	  arising	  from	  conformational	  substates	  in	  proteins.	  For	   quantification	   of	   barrier	   distributions	   corresponding	   to	   the	   experimental	   cases	   presented	   in	  this	   chapter,	   the	   activation	   energy	   barriers	  were	   assumed	   to	   follow	   a	  Gaussian	  distribution	   such	  that,	  
𝑔 𝐻 =    12𝜋𝜎! 𝑒𝑥𝑝 − 𝐻 − 𝐻! !/2𝜎! 	   	   	  [13]	  Where,	  HP	   and	  σ	   are	   the	   peak	   enthalpy	   and	   standard	   variance	   of	   the	   distribution	   respectively.	   A	  good	  agreement	  of	  the	  least-­‐squares	  fit	  to	  experimental	  data	  using	  a	  Gaussian/normal	  distribution	  to	   represent	   g(H)	   suggests	   that	   the	   model	   chosen	   represents	   the	   enthalpy	   barrier	   distribution	  observed	  in	  the	  experimental	  data	  sufficiently.	  	  For	  the	  purpose	  of	  fitting,	  the	  pre-­‐exponential	  factor	  ‘A’	  was	  fixed	  at	  109	  s-­‐1.	  One	  can	  derive	  A	  as	  one	  of	  the	  fit	  parameters	  performing	  TDS	  experiments	  at	  different	  ramping	  rates	  (‘m’).	  However,	  this	  is	  not	   feasible	   in	   practice.	   The	   model	   used	   here	   may	   be	   a	   simplification	   of	   the	   energetics	   of	   the	  processes	   studied	   but	   still	  manages	   to	   capture	   the	  main	   features	   activation	   barrier	   involved	   and	  allows	  us	  to	  make	  faithful	  and	  meaningful	  comparison	  between	  test	  cases.	  
MATERIALS AND METHODS 
Expression and purification of CYP119 Cytochrome	  P450	  CYP119	  was	  cloned	   from	  the	  genomic	  DNA	   library	  of	  Sulfolobus	  solfataricus	  P1	  and	  expressed	  and	  purified	  from	  E.	  coli	  as	  previously	  described	  (McLean	  et	  al.	  1998;	  Maves	  &	  Sligar	  2001).	  
Expression and purification of CYP101 CYP101	  was	  expressed	  and	  purified	  as	  previously	  described	  in	  Chapter	  2.	  
Preparing ferrous-CO complexes of CYP101 for studying CO-rebinding upon flash 
photolysis via TDS Approximately	  25	  nmoles	  of	  CYP101	  (from	  a	  stock	  solution	  of	  >	  500	  µM)	  was	  diluted	  in	  650	  µl	  of	  80%	   ultra-­‐pure	   glycerol	   (Sigma-­‐Aldrich)	   in	   a	   clear	   Fisherbrand	   10-­‐425	   glass-­‐vial	   with	   a	   screw	  thread	  top.	  The	  protein	  was	  deoxygenated	  by	  passing	  a	  gentle	  stream	  of	  compressed	  Argon	  over	  it	  under	   rotation	   for	   2	  minutes.	   The	   protein	   solution	  was	   then	   taken	   inside	   an	   anaerobic	   chamber	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where	  it	  was	  reduced	  with	  ~5	  mM	  sodium	  dithionite	  solution,	  prepared	  fresh	  in	  anaerobic	  buffer.	  Reduction	   was	   confirmed	   spectrophotometrically	   with	   the	   help	   of	   an	   Oriel	   spectrophotometer.	  Additional	   dithionite	   was	   added	   so	   as	   to	   maintain	   a	   similar	   height	   of	   the	   absorption	   peak	   for	  sodium	  dithionite	  and	  reduced	  P450	  (314	  nm	  for	  sodium	  dithionite	  and	  408	  nm	  for	  reduced	  P450).	  This	  approximately	   translates	   to	  a	   fifteen-­‐fold	  molar	  excess	  of	  dithionite	   in	  solution.	  The	  reduced	  protein	   solution	  was	   then	   transferred	   to	   a	  methacrylate	   cuvette	   and	   the	   volume	   of	   solution	  was	  adjusted	   to	   800	   µl	   with	   anaerobic	   buffer.	   The	   cuvette	   was	   sealed	   with	   parafilm,	   placed	   in	   a	  secondary	   container	   (glass	   cylinder	  with	   ends	   sealed	  with	   rubber	   septa)	   and	   brought	   out	   of	   the	  anaerobic	   chamber	   where	   pure,	   compressed	   carbon	   monoxide	   was	   bubbled	   through	   it	   at	   room	  temperature	  for	  45	  seconds	  at	  a	  rate	  of	  1-­‐2	  bubbles	  per	  second.	  The	  samples	  were	  then	  gradually	  cooled	   down	   to	   77K	   in	   the	   cryostat	   setup	   to	   avoid	   formation	   of	   cracks	   that	  might	   affect	   optical	  quality	  of	  the	  sample.	  
Preparing ferric samples of CYP119 for studying spin-state equilibrium kinetics Recombinant	  CYP119	  from	  Sulfolobus	  solfataricus	  P1	  was	  expressed	  and	  purified	  E.coli	  as	  described	  in	  (McLean	  et	  al.	  1998;	  Maves	  &	  Sligar	  2001).	  In	  order	  to	  obtain	  CYP119	  in	  its	  low-­‐spin	  ferrous	  state	  31.25	  µM	  of	  CYP119	   in	  100	  mM	  KPi	  pH	  7.4	  containing	  65%	  glycerol	  was	   taken	   in	  a	  methacrylate	  cuvette	   and	   cryoreduced	   with	   an	   approximately,	   3.5	   MRad	   dose	   of	   reducing	   X-­‐rays	   from	   a	   60Co	  source.	  
Eliminating free electron absorption via photobleaching Only	   a	   small	   fraction	   of	   mobile	   electrons	   generated	   upon	   gamma	   radiolysis	   of	   aqueous	   glycerol	  solution	   is	  utilized	  for	  heme-­‐iron	  reduction.	  The	   large	  excess	  of	  unused	  electrons	  result	   in	  a	  deep	  violet	   color	   of	   the	   solution	  which	   hinders	   optical	   characterization	   of	   the	   sample.	   The	   problem	   is	  overcome	  by	  photobleaching	  the	  samples	  in	  a	  shallow,	  wide-­‐mouthed	  liquid	  nitrogen	  dewar	  placed	  in	  the	  path	  of	  a	  focused	  light	  beam	  from	  a	  100W/	  12V	  tungsten	  lamp	  fitted	  with	  a	  450	  nm	  filter	  for	  4	  hours.	  
Data acquisition Changes	  in	  the	  optical	  spectra	  corresponding	  to	  each	  of	  the	  three	  temperature	  sensitive	  processes	  studied	  here	  were	   recorded	   in	   the	   same	   setup	  described	   in	  Chapter	  2	  under	   “Thermal	   annealing	  instrumentation”.	  However,	  this	  time	  the	  thermocouple	  was	  not	  in	  direct	  contact	  with	  the	  protein	  solution	   but	  was	   rather	   fixed	   to	   the	   sample	   holder	   at	   its	   base,	  making	   physical	   contact	  with	   the	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sample	  cuvette	  when	  present.	  Spectra	  were	  recorded	  between	  350	  and	  600	  nm	  at	  a	  scan	  rate	  of	  300	  nm/min	  and	  a	  time	  interval	  of	  1	  min	  between	  100	  K	  and	  200	  K.	  
Modeling the conformational heterogeneity in proteins The	   temperature	   range	   of	   100-­‐200	   K	   falls	   below	   and	   around	   the	   glass	   transition	   temperature	  (~170	  K)	  of	  aqueous-­‐glycerol	  solutions	  used	  here	  (Gonzalez	  et	  al.	  2011).	  In	  this	  temperature	  range	  all	   large-­‐scale	  protein	  motion	  is	  frozen	  and	  therefore,	  conformational	  heterogeneity	  of	  the	  sample	  becomes	  consequential.	  𝑑𝑁𝑑𝑇 = −𝑘𝑁   [14]  where,  𝑘 = 𝐴 !!! 𝑒𝑥𝑝 !!!"    [15]  For  a  linear  temperature  ramp     𝑇 = 𝑇! +𝑚𝑡   [16]  where,  m  is  the  linear  temperature  ramp  rate     N  at  any  given  temperature  can  be  given  by  the  integral  form  of  (2.1)  as,  
𝑁 =   𝑁!𝑒𝑥𝑝 − 𝑘𝑑𝑡′!!      Substituting  ‘t’  for  ‘T’  using  [16]  we  get,     
𝑁 =   𝑁!𝑒𝑥𝑝 − 𝑘𝑚 𝑑𝑇′!!!   
  
Differentiating  w.r.t  ‘T’  to  get  an  expression  for  the  rate  of  change  of  ‘N’  with  temperature  




𝑑𝑁𝑑𝑇 =   𝑁!𝑒𝑥𝑝 − 𝑘𝑚 𝑑𝑇′!!! . −𝑘𝑚   
  
𝑑𝑁𝑑𝑇 =   −𝑁! 𝑘𝑚 𝑒𝑥𝑝 − 𝑘𝑚 𝑑𝑇′!!!   
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𝑑𝑁𝑑𝑇 =   −𝑁! 𝑘𝑚 exp   −𝜃    [17]  where,  𝜃 =    !!!! !!! ! 𝐸! !!" −    !!!! ! 𝐸! !!!!      E3(x)  is  the  exponential  integral  which  can  be  calculated  as,    
𝐸! 𝑥 =    𝑒!!"𝑡!!! 𝑑𝑡     For  a  distributed  energy  barrier  [17]  transforms  into  𝑑𝑁𝑑𝑇 =   −𝑁! 𝑘𝑚 𝑘𝑒𝑥𝑝 −𝜃!! 𝑔 𝐻 𝑑𝐻   [18]  where,     
𝑔 𝐻 =    12𝜋𝜎! 𝑒𝑥𝑝 − 𝐻 − 𝐻! !2𝜎!      and,  k  is  given  by  [15].       The	  schematic	  in	  Figure	  10	  depicts	  organization	  of	  the	  energy	  landscape	  of	  proteins	  and	  the	  origins	  of	  distributed	  barriers.	  If	  A	  and	  B	  are	  two	  normally	  distributed	  energy	  minima	  with	  characteristic	  parameters	  of	  (HA,	  σA)	  	  and	  (HB,	  σB)	  on	  the	  energy	  landscape	  of	  a	  protein,	  separated	  by	  ΔH	  (=	  HA	  –	  HB),	  heretofore	  referred	  to	  as	  H,	  in	  terms	  of	  their	  mean	  enthalpies,	  any	  transition	  between	  A	  and	  B	  could	  also	  be	  represented	  as	  a	  normal	  distribution	  with	  mean	  enthalpy	  of	  H.	  As	   shown	   in	   the	   previous	   chapter,	   a	   linear	   temperature-­‐time	   dependence	   results	   in	   a	   sigmoidal	  shape	  of	  the	  ‘N’	  versus	  ‘T’	  curve	  for	  a	  process	  characterized	  by	  a	  single	  activation	  energy	  barrier.	  A	  distributed	   energy	   barrier	   affects	   the	   curve	   by	   causing	   broadening	   of	   the	   transition	   along	   the	  temperature	   axis.	   	   Figure	   11	   presents	   a	   simulated	   ‘N’	   versus	   ‘T’	   curve	   for	   such	   a	   process	   with	  characteristic	  parameters,	  HP	  and	  σ	  of	  9.5	  and	  0.5	  kcal/mol	  respectively.	  Here,	  HP	  determines	   the	  temperature	   for	   half-­‐transition,	   T1/2	   and	   σ	   effects	   the	   overall	   spread	   of	   the	   transition	   on	   the	  temperature	   domain.	   Figure	   11	   depicts	   this	   point	   aptly.	   Figure	   12A	   contains	   three	   energy	  distributions	  having	  the	  same	  peak	  enthalpy,	  HP	  of	  9.5	  kcal/mol	  but	  varying	  standard	  variances,	  σ	  of	  0.5,	  1.0	  and	  2.0	  kcal/mol.	  Figure	  12B	  shows	  the	  simulated	  concentration	  profiles	  for	  these	  three	  distributions.	  All	  three	  curves	  exhibit	  a	  T1/2	  of	  175	  K	  but	  different	  breadth	  of	  transition	  with	  curves	  corresponding	  to	  broader	  energy	  distributions	  showing	  a	  shallower	  transition.	  Another	  variable	   that	  effects	   the	  shape	  and	  position	  of	  concentration	  profiles	  on	   the	   temperature	  axis	   is	   temperature	  ramp	  rate,	  or	   ‘m’.	  Figure	  13	  shows	  simulated	  plots	   for	   the	  rate	  of	  decrease	  of	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concentration	  of	  starting	  species,	  ‘N’	  as	  a	  function	  of	  temperature	  and	  the	  concentration	  profile	  that	  would	   one	   would	   obtain	   studying	   such	   a	   transition	   via	   TDS.	   	   The	   plot	   contains	   three	   different	  temperature	   ramping	   rates	   and	   peak	   enthalpies	   in	   five	   different	   combinations.	   The	   standard	  variance	  in	  peak	  enthalpy	  was	  kept	  constant	  at	  0.1	  kcal/mol.	  Like	  HP,	  ‘m’	  affects	  T1/2.	  The	  blue	  lines	  represent	   simulated	   curves	   for	   transitions	   having	   identical	   activation	   barriers	   but	   variable	  temperature	  ramp	  rates.	  Higher	  values	  of	  ‘m’	  correspond	  to	  higher	  values	  of	  T1/2.	  The	  same	  trend	  is	  seen	  upon	  keeping	  ‘m’	  constant	  and	  varying	  ‘Hp’	  (curves	  #2,	  3	  and	  5).	  Thus,	  ‘m’	  and	  ‘HP’	  decide	  the	  position	  of	  the	  concentration	  profile	  whereas	  ‘σ’	  governs	  its	  shape.	  
Fitting routine For	   the	   data	   described	   below	   curve	   fitting	   was	   performed	   using	   the	   unconstrained	   nonlinear	  minimization	  routine	  ‘fminsearch'	  in	  MATLAB	  2012b.	  An	  objective	  function	  was	  setup	  to	  calculate	  the	   root	   mean	   square	   difference	   between	   simulated	   and	   experimental	   ’N’	   versus	   ’T’	   curves	   at	  temperatures	  where	  experimental	  data	  was	  available.	  Input	  parameters	  to	  the	  fitting	  routine	  were	  scaled	  to	  fall	  between	  0	  and	  1.	  Different	  initial	  guesses	  were	  tested	  to	  make	  sure	  there	  was	  no	  bias	  in	  the	  fit	  parameters	  obtained	  on	  the	  values	  of	  initial	  guess	  input.	  
RESULTS AND DISCUSSION 
Non-equilibrium relaxation of spin state The	   heme-­‐iron	   of	   cytochromes	   P450	   in	   its	   resting	   state	   exists	   in	   equilibrium	   between	   penta-­‐coordinated,	   high-­‐spin	   and	   hexa-­‐coordinated,	   low-­‐spin	   states.	   Substrate-­‐free	   P450s	   are	  predominantly	  low-­‐spin	  due	  to	  a	  water	  molecule	  coordinated	  as	  the	  sixth	  ligand	  trans	  to	  the	  distal	  cysteine.	   Substrate	   binding	   destabilizes	  water	   ligation	   and	   converts	   the	   heme	   iron	   into	   a	   penta-­‐coordinated,	  high-­‐spin	   ferric	   state.	  This	   is	  accompanied	  by	  a	  positive	  shift	   in	   redox	  potential	   that	  allows	   the	  substrate-­‐bound	  enzyme	  to	  be	  reduced	  by	  NADPH	  from	   its	  redox	  partner,	   cytochrome	  P450	  reductase.	  The	  spin-­‐state	  transition	  is	  essentially	  the	  ‘on’	  switch	  for	  P450	  chemistry	  keeping	  the	   enzyme	   from	   consuming	   redox	   equivalents	   in	   futile	   cycles	   and	   preventing	   the	   formation	   of	  superoxide	  and	  peroxide	  via	  the	  autoxidation	  and	  peroxide	  shunts	  respectively.	  The	   high-­‐spin,	   low-­‐spin	   equilibrium	   can	   be	   studied	   by	   exploiting	   the	   fact	   that	  water,	   although	   a	  weak	  ligand,	  favors	  the	  ferric	  state	  over	  ferrous	  state.	  Reducing	  a	  low-­‐spin	  ferric	  P450	  results	  in	  a	  low-­‐spin	  ferrous	  enzyme	  which	  then	  relaxes	  to	  a	  high-­‐spin	  state,	  a	  transition	  that	  can	  be	  monitored	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spectrophotometrically	   owing	   to	   different	   optical	   absorption	   spectra	   of	   each	   of	   these	   species.	  (Figure	  14	  Top	  panel)	  To	  study	  the	  relaxation	  of	  a	  low-­‐spin	  to	  high	  spin,	  a	  low-­‐spin	  ferric	  enzyme	  preparation	  of	  CYP119	  was	  cryoradiolytically	  reduced	  in	  a	  65%	  glycerol	  solvent	  to	  convert	  it	  into	  its	  low-­‐spin	  ferrous	  state.	  The	  low-­‐spin	  ferrous	  heme	  has	  a	  characteristic	  absorption	  spectra	  with	  maxima	  at	  441	  nm	  and	  561	  nm	   (Denisov	   et	   al.	   2001).	   As	   the	   temperature	   is	   gradually	   increased	   from	   100	   K	   to	   200	   K,	  conformational	  motion	  becomes	  less	  restricted	  which	  allows	  for	  the	  relaxation	  of	  low-­‐spin	  ferrous	  heme	   to	   its	   high-­‐spin	   state.	   Spectrally,	   this	   is	   observed	   as	   the	   appearance	   of	   an	   absorption	  maximum	   at	   410	   nm.	   After	   191	   K,	   carbon	   monoxide	   (CO)	   produced	   as	   a	   result	   of	   radiolysis	   of	  glycerol,	  finds	  its	  way	  into	  the	  active	  site	  where	  it	  reacts	  with	  the	  ferrous	  heme	  to	  form	  the	  ferrous-­‐CO	  complex	  evidenced	  by	  the	  appearance	  of	  the	  450	  nm	  band.	  Figure	  14	  provides	  a	  schematic	  of	  the	  process	  and	  corresponding	  changes	  in	  the	  optical	  absorption	  spectral	  landscape.	  	  In	  order	  to	  trace	  the	  conversion	  of	  low-­‐spin	  ferrous	  to	  high-­‐spin	  ferrous	  from	  the	  complex	  data	  set	  as	  in	  Figure	  14,	  optical	  spectra	  gathered	  between	  110	  K	  and	  195	  K	  (Spectra	  #5-­‐63)	  were	  subjected	  to	  a	  singular	  value	  decomposition	  (svd)	  analysis.	  The	  second	  eigen	  concentration	  vector	   from	  the	  svd	  of	  spectral	  range	  of	  400-­‐500	  nm	  and	  550-­‐570	  nm	  was	  plotted	  against	  temperature	  (Figure	  15A).	  The	  values	  of	  concentration	  obtained	  were	  normalized	  between	  0	  and	  1	  before	   they	  were	   fit	   to	  a	  distributed	  energy	  barrier	  model	  as	  previously	  described.	  	  Best	   fit	   was	   obtained	   with	   a	   combination	   of	   a	   single	   activation	   energy	   barrier	   of	   9.89	   kcal/mol	  (obtained	  as	  a	  distributed	  barrier	  of	  HP,1	  =	  9.89	  kcal/mol	  and	  σ1	  =	  0.005	  kcal/mol)	  and	  a	  distributed	  barrier	  of	  HP,2	  =	  8.28	  kcal/mol	  and	  σ2	  =	  0.684	  kcal/mol.	  The	  relative	  contributions	  of	  HP,1	  and	  HP,2	  were	  0.6	  and	  0.4.	  (Figure	  15B)	  This	  may	  correspond	  to	  states	  of	  the	  enzyme	  with	  water	  or	  glycerol	  present	  in	  the	  active	  site.	  
Di-atomic ligand binding 
Wild-type CYP101 The	  next	  important	  step	  after	  reduction	  of	  ferric-­‐heme	  in	  P450	  catalysis	  is	  the	  binding	  of	  molecular	  oxygen.	  Ferrous	  heme	  in	  P450s,	  like	  in	  other	  heme	  proteins	  such	  as	  myoglobin	  and	  hemoglobin,	  has	  the	   ability	   to	   bind	   a	   molecule	   of	   oxygen	   to	   form	   a	   superoxo	   species	   termed	   as	   the	   oxy-­‐ferrous	  complex.	  This	  stage	  onwards	  the	  enzyme	  can	  either	  proceed	  to	  catalytic	  arm	  of	  the	  P450	  reaction	  wheel	  or	  dissociate	  the	  bound	  oxygen	  as	  a	  superoxide	  anion	  and	  return	  to	  the	  ferric	  resting	  state.	  The	  latter	  process,	  referred	  to	  as	  the	  autoxidation	  shunt,	  constitutes	  the	  first	  uncoupling	  pathway	  in	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P450s.	  The	  quasi-­‐stable	  nature	  of	  oxy-­‐ferrous	  intermediate	  makes	  it	  difficult	  to	  study.	  However,	  to	  study	   the	   binding	   event	   use	   of	   diatomic	   ligands	   such	   as	   CN–,	   NO	   and	   CO	   has	   proven	   to	   be	  more	  beneficial.	  	  In	   the	   current	   study,	   we	   have	   used	   CO	   as	   an	   O2	  mimic.	   The	   Fe-­‐CO	   complex	   has	   a	   characteristic	  absorption	  peak	  at	  448	  nm	  (binding	  of	  CO	  –split	  Soret).	  Moreover,	   the	  Fe-­‐CO	  bond	   is	  photo-­‐labile.	  Monitoring	   rebinding	   of	   CO	   upon	   photolysis	   of	   a	   ferrous-­‐CO	   complex	   provides	   a	   good	  means	   to	  study	  diatomic	  ligand	  binding.	  We	  prepared	  the	  ferrous-­‐CO	  complexes	  of	  substrate	  free	  CYP119	  and	  camphor-­‐bound	  CYP101,	  WT	  and	  T252A	  mutant	  by	  bubbling	  pure,	  compressed	  CO	  through	  a	  preparation	  of	  reduced	  enzyme	  in	  an	   aqueous-­‐glycerol	   solvent.	   The	   resulting	   Fe-­‐CO	   complexes	  were	   then	   photolyzed	   by	   subjecting	  them	  to	  a	  focused	  beam	  of	  light	  from	  a	  tungsten	  lamp	  for	  4	  hours	  at	  77	  K.	  CO-­‐rebinding	  was	  studied	  via	  temperature	  derivative	  spectroscopy,	  monitoring	  the	  increase	  in	  absorbance	  at	  448	  nm	  as	  the	  temperature	  increased	  linearly	  from	  100	  K	  to	  200	  K.	  Photolysis	   of	   ferrous-­‐CO	   complex	   of	  wild-­‐type	   CYP101,	   in	   H2O	   gave	   approximately	   60%	   yield	   of	  photolysis.	  To	  obtain	   the	  energetics	  of	  rebinding	  of	   the	   flashed	  CO-­‐molecule	   to	   the	  heme	   iron	  the	  second	   eigen	   concentration	   vector	   from	   the	   singular	   value	   decomposition	   (svd)	   analysis	   of	   the	  entire	   spectral	   was	   normalized	   and	   fitted	   to	   the	   distributed	   energy	   barrier	   model,	   as	   described	  earlier.	   Using	   a	   pre-­‐exponential	   factor	   of	   109	   and	   a	   ramping	   rate	   of	   1.2	   deg/min,	   which	   is	   the	  average	  ramping	  rate	  of	  the	  transition,	  the	  best	  fit	  to	  the	  experimental	  data	  corresponded	  to	  a	  peak	  enthalpy	  of	  7.42	  kcal/mol	  and	  a	  standard	  variance	  in	  peak	  enthalpy	  of	  0.93	  kcal/mol	  (Figure	  17The	  same	   experiment	   was	   done	   in	   deuterated	   solvent.	   This	   yielded	   a	   peak	   enthalpy	   and	   standard	  variance	   of	   enthalpy	   of	   7.28	   and	   0.95	   kcal/mol	   respectively	   (Figure	   18).	   Since	   the	   geminate	  rebinding	   of	   CO	   is	   not	   expected	   to	   be	   isotope	   sensitive	   we	   expect	   similar	   energy	   distribution	  profiles.	  Observations	  from	  TDS	  annealing	  experiments	  done	  in	  protiated	  and	  deuterated	  solvents	  confirm	  the	  fact.	  
T252A mutant of CYP101 In	  addition	  to	  wild-­‐type	  CYP101	  CO-­‐rebinding	  behavior	  of	   the	  T252A	  mutant	  of	  CYP101	  was	  also	  investigated.	   The	   plot	   of	   fraction	   of	   P450	   that	   was	   still	   without	   CO	   upon	   annealing	   versus	  temperature	  in	  protiated	  aqueous-­‐glycerol	  solvent	  showed	  multiple	  barriers	  as	  opposed	  to	  a	  single	  distributed	  barrier	  seen	  in	  wild-­‐type	  CYP101.	  Similar	  behavior	  was	  observed	  in	  deuterated	  solvent	  (Figure	  19).	  A	  small	  non-­‐overlapping	  region	  on	   the	  concentration	  profiles	  observed	  between	  H2O	  and	  D2O	   is	   an	   artifact	   of	   normalization.	   The	   threonine	   to	   alanine	  mutation	   in	   CYP101	   creates	   an	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extra	  cavity	  in	  the	  active	  site	  of	  CYP101	  where	  the	  CO	  molecule	  may	  migrate	  upon	  flash	  photolysis.	  Figure	  20	  elucidates	  the	  point.	  
Wild-type CYP119 CO-­‐flash	  photolysis	  of	  CYP119	  gave	  a	  15%	  yield	  of	  photolysis.	  Fitting	  the	  geminate	  rebinding	  of	  CO	  as	   a	   function	   of	   temperature	  to	   a	   distributed	   energy	   barrier	  model	   gave	   a	   peak	   enthalpy	   of	   6.52	  kcal/mol	  and	  a	  standard	  variance	  of	  distribution	  of	  0.535	  kcal/mol	  (Figure	  21).	  
Peroxo-annealing Another	  process	  that	  can	  be	  studied	  using	  temperature	  derivative	  spectroscopy	  and	  where	  it	  really	  shows	   its	  utility	   in	  answering	   important	  mechanistic	  questions	   is	  peroxo	  annealing.	   In	   this	  study,	  we	  used	  TDS	  to	  study	  the	  fate	  of	  cryoreduced	  oxy-­‐complexes	  of	  cytochrome	  P450s	  in	  protiated	  and	  deuterated	   aqueous-­‐glycerol	   solvents.	   This	   comparison	   allows	   for	   calculating	   kinetic	   solvent	  isotope	   effects	   (KSIE)	   in	   the	   decay	   of	   the	   peroxo-­‐complex	   which	   in	   turn	   provides	   a	   basis	   to	  distinguish	  between	  mechanisms	  that	  differ	  in	  the	  involvement	  of	  protons	  such	  as	  in	  CYP19A1	  and	  CYP17A1.	   TDS	   distinguishes	   itself	   from	   other	   techniques	   of	   measuring	   KSIEs	   by	   being	   more	  sensitive	   and	   providing	   a	   complete	   temperature	   profile	   of	   KSIE.	   Rates	   of	   chemical	   reaction	   are	  temperature	  dependent	  and	  so	  are	  their	  ratios.	  This	  is	  well	  understood	  but	  not	  applied	  much	  since	  measuring	   rates	   at	   different	   temperatures	   and	   in	   different	   solvent	   conditions	   is	   time,	   labor	   and	  material	   intensive.	   However,	   in	   order	   to	   draw	   a	   faithful	   comparison	   based	   on	   KSIEs	   we	   need	   a	  complete	  temperature	  profile	  of	  rates	  in	  different	  solvent	  systems.	  In	   this	   part	   of	   chapter	   3,	   I	   describe	   the	   results	   obtained	   from	   applying	   temperature	   derivative	  spectroscopy	  to	  monitor	  the	  decay	  of	  reduced	  oxy-­‐ferrous	  complexes	  of	  D251N	  mutant	  of	  CYP101	  and	   human	   CYP19A1.One	   electron	   reduction	   of	   the	   oxy-­‐ferrous	   complex	   in	   P450s	   produces	   the	  ‘peroxo-­‐anion’,	  which	  upon	  protonation	  at	  the	  distal	  oxygen	  atom	  of	  the	  bound	  dioxygen	  molecule	  yields	  the	  ‘hydroperoxo-­‐anion’.	  The	  peroxo-­‐anion,	  and	  sometimes	  the	  hydroperoxo	  anion	  as	  well,	  is	  referred	  to	  as	  ‘Compound	  0’	  in	  P450	  literature.	  A	  second	  protonation	  at	  the	  distal	  oxygen	  facilitates	  O-­‐O	   scission	   giving	   rise	   to	   the	   reactive	   oxo-­‐ferryl	   π-­‐cation	   radical	   known	   as	   ‘Compound	   1’.	   The	  protons	   needed	   to	   ensure	   the	   productive	   progression	   of	   the	   peroxo	   anion	   to	   Compound	   1	   are	  supplied	  by	  a	  hydrogen	  bonding	  network	  comprised	  of	  an	  acid-­‐alcohol	  pair,	  Asp-­‐251	  and	  Thr-­‐252	  in	  CYP101	  and	  Asp-­‐309	  and	  Thr-­‐310	  in	  CYP19A1,	  and	  water	  molecules	  present	  at	  the	  active	  site.	  The	  role	  of	  the	  acid-­‐alcohol	  pair	  was	  first	  discovered	  by	  mutagenesis	  studies	  in	  CYP101.	  A	  mutation	  of	  Asp	  to	  Asn	  in	  CYP101	  has	  been	  shown	  to	  hinder	  the	  first	  protonation	  leading	  to	  an	  accumulation	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of	   the	  peroxo-­‐anion	  as	  opposed	   to	   the	  hydroperoxo	  anion	  as	  seen	   in	  wild-­‐type	  CYP101	  and	  most	  other	   P450s.	   It	   is	   also	   known,	   via	   EPR	   annealing	   experiments	   that	   the	   peroxo	   anion	   in	   D251N	  CYP101	  transforms	  to	  the	  hydroperoxo	  anion	  and	  then	  the	  product	  complex	  (Davydov	  et	  al.	  2001).	  Furthermore,	   under	   steady-­‐state	   turnover	   conditions,	   D251N	   shows	   an	   enhanced	   kinetic	   solvent	  isotope	  effect	  as	  compared	  to	  the	  wild-­‐type	  enzyme	  (Vidakovic	  et	  al.	  1998).	  Prior	  knowledge	  of	  the	  fate	   of	   peroxo	   anion	   upon	   thermal	   annealing	   and	   the	   steady	   state	   kinetic	   behavior	   of	   CYP101/	  D251N	   in	  protiated	  and	  deuterated	   solvents	  makes	   it	   the	  perfect	  model	   candidate	   for	   testing	   the	  idea	  of	  measuring	  KSIE	  during	  peroxo	  annealing	  via	  TDS.	  Success	  in	  doing	  so	  would	  give	  us	  a	  means	  to	  distinguish	  between	  the	  ‘Cpd	  0’	  and	  ‘Cpd	  1’	  mechanisms	  of	  aromatization	  by	  CYP19A1	  (Page	  6).	  Should	  Cpd1	  be	  used	   as	   the	   reactive	   intermediate	   for	  C-­‐C	   scission,	   Cpd	  0	  or	  peroxo-­‐anion	  would	  have	   to	   be	   protonated	   twice	   at	   the	   distal	   oxygen	   to	   facilitate	   O-­‐O	   heterolysis	   that	   results	   in	   the	  formation	  of	  Cpd1.	  This	  would	  manifest	  as	  a	  difference	   in	  rates	  of	  decomposition	  of	  reduced	  oxy-­‐ferrous	   complex	  of	   CYP19A1	   in	  protiated	   and	  deuterated	   solvents.	  On	   the	  other	  hand,	   the	  use	  of	  Cpd0	  as	  the	  reactive	  intermediate	  by	  CYP19A1	  would	  not	  necessitate	  such	  protonation	  and	  would	  therefore,	  show	  no	  H/D	  sensitivity	  under	  similar	  circumstances.	  
D251N mutant of CYP101 The	  magnitude	  of	  optical	  absorption	  signal	  corresponding	   to	  peroxo-­‐annealing	  of	  CYP101	  D251N	  was	   less	   than	   that	   compared	   to	   the	   other	   two	   examples	   of	   application	   of	   TDS	   presented	   in	   this	  chapter.	  A	  slightly	  different	  approach	  than	  used	  previously	  was	  used	   to	  extract	   the	  concentration	  profile	  of	  reduced	  oxy-­‐ferrous	  complex	  of	  CYP101	  D251N	  and	  CYP19A1	  for	  this	  section.	  Difference	  spectra	   from	   the	  TDS	  experiment	  was	  subjected	   to	   svd	  analysis	  and	  reconstructed	  using	   the	   first	  four	   eigen	   vectors.	   Difference	   in	   the	   absorption	   values	   at	   446	   nm	   and	   419	   nm	   corresponds	   to	  conversion	   of	   peroxo-­‐P450	   to	   its	   low-­‐spin	   form	   and	   was	   plotted	   against	   temperature.	  The	  concentration	   values	   were	   normalized	   between	   0	   and	   1	   and	   fit	   to	   a	   distributed	   energy	   barrier	  model	  using	  the	  same	  fitting	  routine	  described	  on	  page	  41.	  Fitting	  was	  performed	  using	  the	  single	  distribution	  model	  and	  best	   fit	  was	  obtained	  with	  a	  single	  distributed	  energy	  barrier	  with	  HP	  =	  8.66	  kcal/mol	  and	  σ	  =	  0.515	  kcal/mol	  and	  HP	  =	  9.31	  kcal/mol	  and	   σ	   =	   0.39	   kcal/mol	   in	   protiated	   and	   deuterated	   solvents	   respectively.	   The	   0.65	   kcal/mol	  increment	  in	  the	  peak	  enthalpies	  in	  D2O	  is	  seen	  by	  a	  positive	  shift	  in	  the	  half	  transition	  temperature	  by	  ~10	  K.	  Figure	  25A	  is	  a	  plot	  of	  the	  rate	  constants	  corresponding	  to	  these	  two	  activation	  energies	  and	  shows	  a	  clear	  temperature	  dependence	  of	  the	  KSIE	  on	  temperature	  (Figure	  25B).	  Based	  on	  this	  analysis,	  the	  KSIE	  on	  peroxo	  annealing	  for	  D251N	  mutant	  of	  CYP101	  at	  298	  K	  is	  3.98.	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CYP19A1 A	  treatment	  similar	  to	  that	  described	  above	  was	  applied	  to	  monitor	  the	  decay	  reduced	  19-­‐oxo-­‐AD	  bound	   oxyCYP19A1	   upon	   thermal	   annealing	   via	   TDS.	   Poor	   signal-­‐to-­‐noise	   interfered	   with	   the	  ability	  to	  obtain	  perfect	  fits	  to	  the	  experimental	  data	  using	  the	  fitting	  routine	  described	  earlier.	  Best	  fit	  was	  obtained	  with	  HP	  =	  9.9	  kcal/mol	  and	  σ	  =	  0.005	  kcal/mol	  and	  HP	  =	  10.26	  kcal/mol	  and	  σ	  =	  0.003	   kcal/mol	   in	   protiated	   and	   deuterated	   solvents	   respectively.	   Despite	   poor	   fitting	   a	   positive	  shift	  in	  the	  temperature	  of	  half	  transition	  in	  D2O	  clearly	  indicates	  the	  presence	  of	  a	  kinetic	  solvent	  isotope	   effect	   of	   greater	   than	   1	   for	   this	   process	   (Figure	   26).	   This	   in	   turn	   supports	   the	   use	   of	  ‘Compound	  1’	  for	  aromatization	  by	  CYP19A1.	  	  
CONCLUSION It	   is	  now	  well	  known	  that	  proteins	  are	  not	  biomolecules	  with	  a	   fixed	  three-­‐dimensional	  structure	  but	   an	   ensemble	   of	   structures	   all	   vibrating	   around	   a	   central	   structure,	   sampling	   innumerable	  related	   structures	   in	   the	   process.	   Enzymes	   and	   also	   substrates	   control	   the	   rate	   and	   route	   of	  catalysis	   by	   altering	   the	   conformational	   landscape	   of	   both	   the	   ground	   and	   excited	   states	   by	  preferentially	  sampling	  some	  energy	  minima	  over	  others.	  A	  randomly	  selected	  pair	  of	  substates	  in	  this	  vast	  conformational	  landscape	  may	  be	  separated	  by	  a	  small-­‐scale	  motion	  such	  as	  a	  single	  bond	  rotation	   or	   vibration	   or	   by	   a	  much	   larger	   scale	  motion	   involving	  multiple	   atoms	   of	   a	   secondary	  structure	  element.	  If	  these	  two	  states	  are	  experimentally	  distinguishable	  one	  may	  be	  able	  to	  see	  the	  conformational	  relaxation	  that	  the	  enzyme	  undergoes	  while	  going	  from	  state	  A	  to	  B.	  This	  has	  been	  done	  by	  matching	  the	  magnitude	  order	  of	  timescale	  in	  which	  these	  transitions	  may	  occur	  by	  faster	  data	  acquisition	  or	  by	  artificially	  slowing	  down	  the	  process	  by	  studying	   it	  at	  a	  significantly	   lower	  temperature.	   	   If	   these	   conditions	   are	   met,	   one	   observes	   distributed	   kinetics	   for	   the	   A	   ⇒	   B	  conversion.	  The	  distribution	  in	  rates	  reflects	  the	  distribution	  in	  energy	  of	  activation	  for	  the	  process	  and	  therefore,	  the	  ruggedness	  of	  the	  conformational	  landscape.	  Temperature	  derivative	  spectroscopy	  is	  a	  general	  experimental	  method	  to	  measure	  processes	  with	  distributed	   kinetics	   in	   combination	  with	   different	   spectroscopic	   techniques	   such	   as	   fluorescence	  spectroscopy,	   FTIR	   and	   Raman	   spectroscopy.	   In	   cytochrome	   P450s,	   the	   various	   iron-­‐heme	  intermediates	  have	  characteristic	  UV-­‐Vis	  absorption	  spectra	  and	  high	  molar	  absorption	  coefficients	  making	   optical	   absorption	   spectroscopy	   a	   perfect	   technique	   to	   mirror	   changes	   occurring	   upon	  thermal	  annealing	  of	  a	  particular	  intermediate	  in	  a	  TDS	  experiment.	  By	  tracking	  the	  conversion	  of	  one	   intermediate	   into	  another	  TDS	  can	  provide	  precise	  quantitative	  data	  on	  the	   fate	  of	   individual	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intermediates.	  As	  shown	  in	  this	  chapter,	  various	  processes	  such	  as	  spin-­‐state	  conversion,	  di-­‐atomic	  ligand	  binding	  and	  peroxo-­‐annealing	  may	  be	  studied	  using	  this	  approach.	  Furthermore,	  by	  performing	  these	  experiments	  under	  different	  solvent	  conditions	  one	  can	  calculate	  precisely	   the	   kinetic	   solvent	   isotope	   effect	   specially	   in	   cases	   where	   it	   answers	   important	  mechanistic	   questions	   as	   in	   the	   case	   of	   CYP19A1.	   The	   application	   of	   TDS	   highlights	   a	   less	  appreciated	   feature	   of	   KSIEs	   which	   is,	   KSIEs	   being	   ratios	   of	   rates	   are	   temperature	   dependent.	  Usually,	   the	   rates	   of	   a	   reaction	   are	   compared	   at	   a	   particular	   temperature	   to	   obtain	   KSIE	   and	  conclusions	  are	  drawn	  from	  its	  numerical	  value.	  As	  is	  shown	  in	  Figure	  25	  KSIE	  bears	  a	  temperature	  dependence.	  A	   true	  comparison	  of	   the	  behavior	  of	  a	   reaction	   in	  protiated	  and	  deuterated	  solvent	  systems	   can	  only	  be	  obtained	   from	   the	   full	   temperature	  profile	  of	  KSIE	   such	  as	   that	  provided	  by	  TDS.	  The	  presence	  of	  narrow	  distributions	  in	  the	  case	  of	  CYP19A1	  and	  slightly	  broader	  distributions	  in	  the	   case	   of	   CYP101	   suggest	   control	   over	   conformational	   heterogeneity	   as	   a	   means	   to	   acquire	  specificity	  by	  an	  enzyme	  system.	  The	  presence	  of	  a	  KSIE	  in	  peroxo	  annealing	  in	  19-­‐oxo-­‐AD	  bound	  CYP19A1	  suggests	  the	  involvement	  of	  Cpd1	  in	  the	  C-­‐C	  lyase	  reaction	  of	  CYP19A1.	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  Figure	  11:	  A	  model	  N	  versus	  T	  curve	  for	  a	  transition	  characterized	  by	  a	  distributed	  energy	  barrier	  of	  peak	  enthalpy,	  HP	  =	  9.5	  kcal/mol	  and	  a	  standard	  variance,	  σ	  of	  0.5	  kcal/mol.	  	   	  
σ	  =	  0.5	  kcal/mol	  
Temperature	  (K)	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  Figure	  12:	  Simulated	  ‘N’	  versus	  ‘T’	  profiles	  for	  three	  energy	  distributions	  having	  a	  peak	  enthalpy,	  HP	  of	  9.5	  kcal	  /mol	  and	  varying	  standard	  variances	  of	  0.5,	  1.0	  and	  2.0	  kcal/mol	  showing	  the	  effect	  of	  the	  breadth	  of	  distribution	  on	  the	  breadth	  of	  transition	  observed	  via	  TDS.	  
m = 1.0 K/min
A!
B!
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  Figure	  13:	  Simulated	   ‘N’	  versus	   ‘T’	  curves	  showing	  the	  effect	  of	  peak	  enthalpy,	   ‘HP’	  and	   ‘m’	  on	  the	  observed	  concentration	  profiles	  in	  a	  TDS	  experiment.	  	   	  
1 2 3 4 5 
















Temperature (K)  
	   52	  
	  















low-spin ferric low-spin ferrous high-spin ferrous ferrous-CO




















IV.#ls Fe+3    :   417 nm
ls Fe+2    :   441, 561 nm
hs Fe+2    :   410 nm





	   53	  













for,  A = 109
       m = 1.2 K/min 
HP, 1 = 8.28   kcal/ mol
σ1    = 0.684 kcal/mol
HP, 2 = 9.89 kcal/ mol
σ2    = 0.005 kcal/mol
α = 0.372
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  Figure	   17:	   A)	   Spectral	   changes	   associate	   with	   CO-­‐rebinding	   in	   CYP101	   in	   H2O	   as	   studied	   by	  Temperature	   Derivative	   Spectroscopy	   (TDS).	   B)	   Normalized	   eigen	   vectors	   from	   singular	   value	  decomposition	  of	   the	  optical	   absorption	  data	   set.	   C)	   svd	   reconstructed	  difference	   spectra.	  D)	  CO-­‐rebinding	  as	  monitored	  by	  the	  difference	  in	  absorption	  at	  448	  nm	  and	  408	  nm	  versus	  temperature.	  The	   blue	   dots	   represent	   actual	   data	   points	   whereas	   the	   red	   line	   shows	   the	   fit	   obtained	   using	   a	  distributed	  energy	  barrier	  model.	  
for,!
m = 1.2 K/min !
A  = 109!
!
HP = 7.42 kcal/ mol!
σ   = 0.934 kcal/mol!
Temperature (K)!Wavelength (nm)!
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  Figure	   18:	   A)	   Spectral	   changes	   associate	   with	   CO-­‐rebinding	   in	   CYP101	   in	   D2O	   as	   studied	   by	  Temperature	   Derivative	   Spectroscopy	   (TDS).	   B)	   Normalized	   eigen	   vectors	   from	   singular	   value	  decomposition	  of	   the	  optical	   absorption	  data	   set.	   C)	   svd	   reconstructed	  difference	   spectra.	  D)	  CO-­‐rebinding	  as	  monitored	  by	  the	  difference	  in	  absorption	  at	  448	  nm	  and	  408	  nm	  versus	  temperature.	  The	   blue	   dots	   represent	   actual	   data	   points	   whereas	   the	   red	   line	   shows	   the	   fit	   obtained	   using	   a	  distributed	  energy	  barrier	  model.	   	  
for,!
m = 1.2 K/min!
A  = 109!
!
HP = 7.28 kcal/ mol!
σ   = 0.949 kcal/mol!
Temperature (K)!Wavelength (nm)!
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  Figure	   20:	   Comparison	   of	   the	   active	   sites	   of	   wild-­‐type	   CYP101	   and	   its	   T252A	   mutant.	   An	   extra	  cavity	   is	   created	   upon	   mutation	   of	   Threonine-­‐252	   to	   Alanine	   that	   explains	   the	   peculiar	   CO-­‐rebinding	  behavior	  of	  CYP101	  T252A	  as	  compared	  to	  the	  wild-­‐type	  enzyme.	   	  
T252A mutant of CYP101!
Wild-type CYP101!
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  Figure	   21:	   A)	   Optical	   absorption	   spectrum	   of	   wild-­‐type	   CYP119	   in	   protiated	   aqueous-­‐glycerol	  solvent	  before	  and	  after	  photolysis.	  B)	  CO	  rebinding	  in	  CYP119	  (blue	  –experimental	  data	  and	  red	  –fit	  based	  on	  a	  distributed	  energy	  barrier	  model).	  
Temperature (K)
for,
m = 1.2 K/min
A  = 109
HP = 6.52 kcal/ mol
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  Figure	  22:	  A)	  Proxy	  annealing	  of	  CYP101	  D251N	  in	  protiated	  aqueous	  glycerol	  solution	  as	  studied	  by	  Temperature	  Derivative	  Spectroscopy	   (TDS).	  B)	  Normalized	  eigen	  vectors	   from	  singular	  value	  decomposition	  of	  the	  optical	  absorption	  data	  set.	  C)	  svd	  reconstructed	  difference	  spectra.	  D)	  Decay	  of	   the	   reduced	   ox-­‐ferrous	   complex	   as	  monitored	   by	   the	   change	   in	   absorbance	   corresponding	   to	  conversion	  of	  the	  proxy	  species	  to	  low-­‐spin	  ferric	  P450.	  The	  blue	  dots	  represent	  actual	  data	  points	  whereas	  the	  red	  line	  shows	  the	  fit	  obtained	  using	  a	  distributed	  energy	  barrier	  model.	  
for,
m = 1.2 K/min
A  = 109
HP = 8.66 kcal/ mol
σ   = 0.515 kcal/mol
Temperature (K)Wavelength (nm)
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  Figure	  23:	  Proxy	  annealing	  of	  CYP101	  D251N	  in	  deuterated	  aqueous	  glycerol	  solution	  as	  studied	  by	  Temperature	   Derivative	   Spectroscopy	   (TDS).	   B)	   Normalized	   eigen	   vectors	   from	   singular	   value	  decomposition	  of	  the	  optical	  absorption	  data	  set.	  C)	  svd	  reconstructed	  difference	  spectra.	  D)	  Decay	  of	   the	   reduced	   ox-­‐ferrous	   complex	   as	  monitored	   by	   the	   change	   in	   absorbance	   corresponding	   to	  conversion	  of	  the	  proxy	  species	  to	  low-­‐spin	  ferric	  P450.	  The	  blue	  dots	  represent	  actual	  data	  points	  whereas	  the	  red	  line	  shows	  the	  fit	  obtained	  using	  a	  distributed	  energy	  barrier	  model.	  
for,
m = 1.2 K/min
A  = 109
HP = 9.31 kcal/ mol
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  Figure	   26:	   Optical	   annealing	   reduced	   oxy-­‐ferrous	   complex	   of	   19-­‐oxo-­‐AD	   bound	   CYP19A1	   in	  protiated	   and	   deuterated	   aqueous	   glycerol	   solvent	   systems.
A = 109
HP = 10.26 kcal/mol
σ = 0.003 kcal/mol         
A = 109
HP = 9.9 kcal/mol
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Chapter 4: Probing the Iron-Oxygen Intermediates of 
Human Aromatase Using Electron Paramagnetic 
Resonance (EPR) Spectroscopy and Electron Neutron 
Double Resonance (ENDOR) Spectroscopy 
INTRODUCTION Electron	  paramagnetic	  resonance	  (EPR)	   is	   the	  phenomenon	  of	  resonant	  absorption	  of	  microwave	  radiation	   by	   a	   paramagnetic	   species	   when	   subjected	   to	   an	   external	   magnetic	   7ield.	   EPR	  spectroscopy	   relies	   on	   the	   splitting	   of	   the	   otherwise	   degenerate	   energy	   levels	   of	   electrons	   upon	  application	  of	  an	  external	  magnetic	  0ield.	  Every	  electron	  has	  a	  spin	  quantum	  number	  and	  associated	  magnetic	   components	   of	   value	   +½	   or	   -­‐½.	   In	   the	   presence	   of	   an	   external	   magnetic	   ,ield,	   the	  electron’s	   magnetic	   moment	   (ms)	   aligns	   itself	   in	   either	   parallel	   or	   anti-­‐parallel	   orientation	   with	  respect	   to	   the	   *ield.	   The	   speci*ic	   energy,	   E	   of	   an	   electron	   in	   each	   of	   these	   states	   is	   directly	  proportional	  to	  ms	  and	  the	  strength	  of	  the	  applied	  magnetic	  0ield,	  B0.	  An	  unpaired	  electron	  can	  move	  between	  these	  two	  energy	  levels	  by	  either	  absorbing	  or	  emitting	  a	  photon	  of	  energy	  hν.	  According	  to	   Maxwell-­‐Boltzmann	   distribution	   more	   molecules	   have	   electrons	   populating	   the	   lower	   energy	  level	  than	  the	  higher	  energy	  level	  so,	  there	  is	  a	  net	  absorption	  of	  energy.	  The	  resonance	  condition	  at	  which	  ΔE	  equals	  hν	  (obtained	  by	  varying	  B0	  at	  a	   $ixed	  ν	  usually)	  results	   in	  a	  positive	  signal	   in	   the	  ‘absorption	  versus	  B0’	  plot	  as	  the	  magnetic	  /ield	  is	  varied	  keeping	  the	  frequency	  of	  incident	  photons	  !ixed.	   ‘g’	   factor	   relates	   the	   resonant	   frequency	   of	   incident	   photons	   and	   the	   magnetic	   6ield,	   B0.	  Interaction	  of	  the	  electron	  spin	  with	  local	  magnetic	  moments	  of	  nuclear	  spin	  (spin-­‐orbit	  coupling)	  causes	   a	   deviation	   in	   g-­‐value	   from	   that	   of	   a	   free	   electron.	   The	   magnitude	   of	   the	   change	   gives	  information	  about	  the	  nature	  of	   the	  atomic	  or	  molecular	  orbital	  containing	  the	  unpaired	  electron.	  Splitting	  of	  EPR	  spectral	  lines,	  referred	  to	  as	  hyper7ine	  coupling,	  and	  line	  width	  provide	  information	  about	   neighboring	   nuclei	   and	   their	   degree	   of	   interaction	   with	   the	   paramagnetic	   center	   under	  investigation	  (Lancaster	  1967;	  Pilbrow	  &	  Hanson	  1993).	  ENDOR	  spectroscopy	  provides	  the	  NMR	  spectrum	  of	  nuclei	   that	   interact	  with	  the	  electron	  spin	  of	  the	   paramagnetic	   center.	   When	   placed	   in	   a	   magnetic	   field,	   NMR	   active	   nuclei	   absorb	  electromagnetic	  radiation	  at	  a	  frequency	  characteristic	  of	  that	  isotope.	  In	  ENDOR,	  a	  radio-­‐frequency	  !ield	   is	   applied	   simultaneously	   with	   the	   microwave	   !ield	   and	   NMR	   transitions	   are	   detected	   as	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change	  in	  the	  EPR	  signal	  intensity	  of	  the	  paramagnetic	  center	  rather	  than	  directly.	  The	  term	  “double	  resonance”	  comes	  from	  the	  fact	  that	  we	  have	  “EPR-­‐detected”	  NMR	  in	  this	  case	  (Hoffman	  1991).	  ENDOR	   increases	   the	   resolution	   of	   the	   EPR	   spectra	   of	   a	   paramagnetic	   species	   under	   study	   by	  adding	  an	  extra	  layer	  of	  NMR	  data	  to	  the	  existing	  EPR	  spectra.	  ENDOR	  signals	  arise	  from	  interaction	  of	   the	  paramagnetic	  species	  with	  nearby	  magnetic	  nuclei	  belonging	   to	   the	  molecule	  on	  which	   the	  unpaired	  electron	  is	  localized	  or	  the	  surrounding	  molecules.	  The	  strength	  of	  hyper7ine	  coupling	  and	  nuclear	  quadruple	  interaction	  are	  related	  to	  the	  electron	  spin	  and	  the	  charge	  density	  distribution	  of	  the	  molecule	  respectively	  and	  therefore	  and	  thus	  help	  discern	  the	  structure	  and	  organization	  of	  the	  paramagnetic	  center	  (Kulik	  &	  Lubitz	  2009;	  Kispert	  &	  Piekara-­‐Sady	  2006).	  Electron	  paramagnetic	  resonance,	  in	  conjunction	  with	  electron	  neutron	  double	  resonance	  (ENDOR)	  spectroscopy	  has	   proved	   to	   be	   an	   important	   tool	   for	   the	   elucidation	   of	   structural	   and	   electronic	  details	  of	  many	  a	  metal	  coordinated	  biological	  complexes	  (Van	  Doorslaer	  &	  Vinck	  2007).	  Among	  the	  transition	  metals	  found	  in	  proteins,	  iron	  has	  the	  richest	  variety	  of	  EPR	  spectra	  and	  therefore,	  EPR	  and	  ENDOR	  spectroscopy	  has	  been	  applied	  heavily	   to	  study	  hemeproteins	   including	  cytochromes	  P450	  as	  described	  below.	  	  
EPR of reduced oxy-ferrous complexes Davydov	   et	   al.	   reported	   the	   first	   EPR	   and	   ENDOR	   spectra	   of	   P450	   peroxo	   intermediate	   states	  prepared	  by	  cryoradiolysis	  using	  60Co	  γ-­‐irradiation	  (Davydov	  et	  al.	  1991).	  Using	  wild-­‐type	  CYP101	  and	   its	   mutants	   D251N	   and	   T252A	   Davydov	   et	   al.	   were	   able	   to	   identify	   and	   characterize	   the	  unprotonated	  and	  protonated	  peroxo	  species	  in	  this	  bacterial	  P450	  (Davydov	  et	  al.	  2001).	  The	  EPR	  spectra	  of	  the	  (hydro)peroxo	  complexes	  of	  CYP101	  were	  found	  to	  be	  similar	  to	  those	  reported	  for	  the	   same	   complexes	   in	   hemoglobin,	   myoglobin	   and	   horse	   radish	   peroxidase,	   and	   fall	   within	   a	  narrow	  span	  of	  g-­‐values	  [2.3–2.25,	  2.2–2.14,	  1.94–1.97]	  (Davydov	  1980;	  Kappl	  et	  al.	  1985;	  Leibl	  et	  al.	  1986;	  Symons	  &	  Petersen	  1978).	  This	  study	  also	  helped	  develop	  an	  understanding	  of	  the	  role	  of	  the	  T252-­‐D251N	  acid-­‐alcohol	  pair	  of	  CYP101	   in	  proton	  delivery.	   It	  was	  noted	   that	   in	  WT	  and	  T252A	  mutant	  CYP101	   the	  hydroperoxo	  anion,	  [5b]	  of	  Figure	  2	  is	  observed	  as	  the	  primary	  product	  of	  cryoradiolysis	  whereas,	  D251N	  yields	  the	   peroxo	   anion,	   [5a]	   of	   Figure	   2.	   Additionally,	   it	   was	   observed	   that	   cryoreduced	  oxyCYP101/T252A	  did	  not	  yield	  product	   like	   the	  wild-­‐type	  enzyme.	  Since	   the	  hydroperoxo	  anion	  lies	  at	  the	  lies	  at	  the	  intersection	  of	  the	  productive	  arm	  of	  the	  P450	  catalytic	  wheel	  and	  the	  peroxide	  shunt,	  whereby	  the	  Fe-­‐O	  bond	  is	  cleaved	  and	  the	  bound	  O-­‐O	  moiety	  is	  lost	  as	  H2O2	  it	  was	  concluded	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the	  that	  threonine-­‐252	  in	  CYP101	  participates	  in	  delivery	  of	  the	  second	  proton	  to	  the	  distal	  oxygen	  of	   the	   hydroperoxo	   anion	   that	   ultimately	   leads	   to	   the	   formation	   of	   Cpd	   1.	   Cryoradiolysis	   of	  oxyCYP101	  D251N	  yields	   the	   peroxo	   anion	   at	   77K	  which	   gives	   product	   upon	   annealing	   that	   this	  residue	  is	  important	  for	  the	  first	  protonation	  step	  (Davydov	  et	  al.,	  2001).	  Via	  the	  application	  of	  1H	  ENDOR	  spectroscopy	  on	  oxy-­‐complexes	  of	  wild-­‐type	  and	  mutant	  CYP101	  upon	  cryoradiolysis	  and	  subsequent	  thermal	  annealing	  the	  same	  study	  afforded	  identification	  and	  delineation	   of	   exchangeable	   protons	   into	   covalently	   bonded	   or	   hydrogen	   bonded	   and	   provided	  strong	   evidence	   for	   the	   involvement	   of	   a	   high-­‐valent	   oxo-­‐ferryl	   intermediate,	   namely	   Cpd	   1	   for	  product	  formation.	  Recognizing	   the	  power	  and	  utility	  of	  EPR	  and	  ENDOR	  spectroscopy	   in	  realizing	  cytochrome	  P450	  mechanism,	   this	   chapter	   describes	   my	   effort	   and	   its	   fruits	   toward	   the	   spectroscopic	  characterization	  of	  cryoreduced	  oxy-­‐complexes	  of	  CYP19A1	  in	  the	  presence	  of	  AD-­‐	  and	  19-­‐oxo-­‐AD,	  substrates	   for	   the	   hydroxylation	   and	   aromatization	   steps	   of	   CYP19A1	   respectively.	   The	   rationale	  being	  that	  stepwise	  thermal	  annealing	  of	  these	  complexes	  will	  allow	  us	  to	  examine	  the	  conversion	  of	   the	   heme-­‐peroxo	   anion	   to	   product	   asking	   the	   question	   –	   is	   the	   protonated	   hydroperoxo	   state	  generated	   prior	   to	   formation	   of	   the	   aromatic	   product?	   For	   Step	   III	   of	   CYP19A1	   catalysis,	   the	  hydroperoxo	  intermediate	  is	  not	  expected	  to	  form	  if	  CYP19A1	  utilizes	  the	  Cpd	  0	  mechanism,	  while	  the	  formation	  of	  the	  hydroperoxo	  intermediate	  would	  be	  essential	  for	  generation	  of	  the	  oxo-­‐ferryl	  species	  in	  the	  potential	  Cpd	  1	  mechanism.	  This	   work	   was	   done	   in	   collaboration	   with	   Roman	   Davydov	   of	   Prof.	   Brian	   Hoffman’s	   group	   at	  Northwestern	  University.	  
MATERIALS AND METHODS 
Expression, purification and Nanodisc incorporation of CYP19A1 The	  expression,	  purification	  and	  incorporation	  of	  CYP19A1	  into	  POPC	  Nanodiscs	  was	  performed	  as	  previously	  described	  in	  pages	  7	  and	  10.	  
Preparation of EPR samples A	   100	   µl	   solution	   containing	   500	   µM	   CYP19	   in	   Nanodiscs,	   700	   µM	   Androstenedione,	   125	   µM	  methylviologen	  and	  15%	  glycerol	  in	  100	  mM	  phosphate	  buffer,	  pH	  7.4	  was	  deoxygenated	  in	  a	  1-­‐ml	  glass	  vial	  fitted	  with	  a	  rubber	  septa	  by	  passing	  a	  gentle	  stream	  of	  Argon	  over	  it,	  under	  rotation,	  for	  4	  minutes	  and	   reduced	  using	  2.5	  Molar	  equivalents	  of	   sodium	  dithionite.	   In	  an	  EPR	   tube,	  150	  µl	  of	  
	   68	  
solution	  containing	  100	  mM	  phosphate	  buffer	  pH	  7.4,	  75%	  glycerol,	  700	  µM	  Androstenedione	  was	  taken	  and	  cooled	  to	  a	  temperature	  of	  -­‐30	  °C	  in	  a	  dry-­‐ice	  ethanol	  bath.	  The	  reduced	  protein	  solution	  was	  rapidly	  injected	  into	  the	  EPR	  tube	  containing	  pre-­‐chilled	  oxygenated	  buffer	  using	  a	  500	  µl	  gas-­‐tight	   Hamilton	   syringe	   fitted	   with	   an	   8”-­‐long	   22-­‐gauge	   needle.	   The	   solution	   was	   mixed	   for	   30	  seconds	  and	  transferred	  to	  another	  dry-­‐ice	  ethanol	  bath	  maintained	  at	  -­‐60	  °C.	  Once	  cooled	  the	  tube	  was	   transferred	   to	   liquid	   nitrogen,	   immersing	   it	   slowly	   to	   prevent	   cracking.	   D2O	   samples	   were	  prepared	  in	  a	  similar	  fashion	  except	  all	  the	  buffers	  used	  were	  prepared	  in	  D2O	  and	  the	  protein	  used	  was	   exchanged	   into	   a	   D2O	   (Cambridge	   Isotope	   Laboratory	   Inc.)	   buffer	   via	   repeated	   rounds	   of	  concentration	  and	  dilution	  in	  a	  10,000	  MWCO	  500	  µl	  Amicon	  centrifugal	  filter.	  An	  alternate	  route	  of	  oxygenation	  was	  followed	  for	  producing	  oxy-­‐complexes	  of	  19-­‐oxo	  AD	  bound	  CYP19A1.	  A	  250	  µl	  solution	  containing	  200	  µM	  CYP19A1,	  5	  µM	  methylviologen,	  500	  µM	  19-­‐oxo	  AD	  (from	  a	  25	  mM	  stock	   solution,	   so	  methanol	   added	   is	   ≤	   2%	  of	   total	   volume	  of	   solution)	   and	  30%	  glycerol	   in	   100	  mM	  phosphate	   buffer	   pH	  7.4	  was	   deoxygenated	   in	   a	   1-­‐ml	   glass	   vial	   fitted	  with	   a	  rubber	  septa	  by	  passing	  a	  gentle	  stream	  of	  Argon	  over	  it,	  under	  rotation,	  for	  1	  minute	  and	  reduced	  with	  2.5	  molar	  excess	  of	   sodium	  dithionite	   solution	   inside	  an	  anaerobic	   chamber	   (Dithionite	  was	  added	  from	  a	  stock	  solution	  of	  concentration	  ≥	  15	  mM	  in	  anaerobic	  100	  mM	  phosphate	  buffer	  pH	  7.4	  to	  keep	  the	  volume	  added	  to	  the	  minimum).	  The	  reduced	  protein	  solution	  was	  let	  to	  sit	   in	  the	  vial	  for	  10	  minutes,	  after	  which	  it	  was	  transferred	  to	  a	  EPR	  tube	  using	  a	  500	  µl	  gas-­‐tight	  Hamilton	  syringe	   fitted	  with	   a	  8”-­‐long	  22-­‐gauge	  needle.	  The	   top	  of	   the	  EPR	   tube	  was	   sealed	  with	   a	   rubber	  septa,	  enclosed	   in	  a	  glass	  cylinder	  and	  brought	  outside	  where	   it	  was	  cooled	  to	   -­‐14	  °C	   in	  a	  dry-­‐ice	  ethanol	   bath.	   Oxy-­‐ferrous	   complexes	  were	   formed	   by	   bubbling	   16O2	   for	   4-­‐5	   seconds	   followed	   by	  rapid	   cooling	   in	   a	   -­‐60	   °C	  dry-­‐ice	   ethanol	   bath.	   The	   samples	  were	   then	   flash	   frozen	   and	   stored	   in	  liquid	  N2.	  D2O	  samples	  were	  prepared	  similarly.	  Reduced	  oxy-­‐ferrous	  complexes	  were	  obtained	  upon	  γ-­‐cryoradiolysis	  of	  oxy-­‐ferrous	  samples	  at	  77K	  using	  a	  total	  dose	  of	  3.5	  MRad	  from	  a	  60Co	  source.	  
EPR CHARACTERIZATION OF REDUCED IRON-OXYGEN INTERMEDIATES OF CYP19A1 X-­‐band	  EPR	  spectra	  were	  recorded	  on	  a	  modified	  Varian	  E-­‐4	  spectrometer	  at	  77	  K.	  Q-­‐band	  (35	  GHz)	  EPR	  and	  ENDOR	  spectra	  were	  recorded	  on	  a	  modified	  Varian	  E-­‐110	  spectrometer	  equipped	  with	  a	  helium	  immersion	  dewar	  at	  Northwestern	  University	  by	  Roman	  Davydov.	  	  To	  follow	  the	  progression	  of	  cryotrapped	  reduced	  oxyferrous	  complexes	  of	  CYP19A1	  upon	  thermal	  annealing,	  cryoreduced	  samples	  were	  annealed	  to	  temperatures	  by	  transferring	  the	  EPR	  tubes	  from	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liquid	  nitrogen	  to	  a	  bath	  at	  fixed	  temperature	  for	  1	  minute,	  after	  which	  the	  sample	  was	  transferred	  back	  to	  liquid	  nitrogen.	  
RESULTS AND DISCUSSION 
EPR of reduced AD-bound-oxyCYP19A1 It	  was	  shown	  earlier	  that	  in	  AD-­‐bound	  CYP19A1	  the	  first	  intermediate	  that	  accumulates	  during	  low	  temperature	   oxygenation	   and	   subsequent	   cryoreduction	   of	   the	   thus	   formed	   oxy-­‐complex	   is	   an	  unprotonated	   peroxo-­‐ferric	   heme	   (Gantt	   et	   al.	   2009).	   This	   suggested	   that	   the	   proton	   delivery	  pathway	  is	  more	  hindered	  in	  CYP19A1	  in	  the	  presence	  of	  AD	  than	  in	  most	  other	  P450s	  and	  perhaps	  the	   same	   intermediate	   acting	   as	   a	   nucleophile	   could	   conduct	   the	   aromatization	   reaction	   via	   an	  attack	  on	  the	  electrophilic	  carbonyl	  of	  19-­‐oxo-­‐AD	  when	  present.	  	  This	  work	  conclusively	  showed	  the	  presence	  of	  peroxo-­‐anion	  however,	  lacked	  proper	  resolution	  to	  trace	   the	   evolution	   of	   this	   intermediate	   to	   the	   product	   complex.	   In	   collaboration	   with	   Roman	  Davydov	   of	   the	   Hoffman	   group	   at	   Northwestern	   University,	   this	   experiment	   was	   repeated	   (see	  Figure	  27)	  and	  the	  following	  observations	  were	  made:	  
• The	  primary	  intermediate	  obtained	  upon	  cryoreduction	  of	  AD-­‐bound	  oxy-­‐CYP19A1	  gave	  a	  g1	  of	  2.263	   at	   160	   K	   consistent	   with	   the	   presence	   of	   an	   unprotonated	   peroxo	   anion	   as	   reported	  earlier	  (Gantt	  et	  al.	  2009).	  
• Upon	  annealing	  to	  180	  K	  a	  new	  intermediate	  with	  g	  =	  [2.41,	  2.45]	  was	  obtained.	  Furthermore,	  this	  species	  showed	  a	  kinetic	  solvent	  isotope	  effect	  (KSIE)	  of	  greater	  than	  3.5.	  This	  suggests	  the	  presence	  of	  a	  protonation	  step	  in	  the	  decay	  of	  this	  species.	  
• Upon	  further	  annealing	  to	  210	  K,	  an	  initial	  product	  complex	  at	  g	  =	  2.40	  is	  observed.	  Figure	  28	  provides	  a	  schematic	  representation	  of	  the	  sequence	  of	  events	  described	  above.	  The	   acid-­‐alcohol	   pair	   along	   with	   water	   molecules	   in	   the	   active	   site	   of	   P450s	   form	   an	   elaborate	  hydrogen-­‐bonding	   network	   that	   supplies	   the	   two	   protons	   necessary	   for	   formation	   of	   the	  hydroperoxo-­‐anion	   and	   subsequently,	   Compound	   1.	   The	   observation	   of	   an	   unprotonated	   peroxo	  intermediate	   in	   CYP19A1	   suggests	   that	   the	   proton	   delivery	   pathway	   in	   CYP19A1	   is	   somewhat	  impeded.	   A	   comparison	   between	   the	   structures	   of	   CYP19A1	   and	   CYP101	   provides	   a	   potential	  explanation.	  Upon	  oxygen	  binding	  to	  ferrous	  CYP101,	  Asp251	  produces	  a	  conformational	  change	  in	  the	  I-­‐helix	  that	  helps	  order	  two	  water	  molecules	  and	  Thr252	  at	  the	  active	  site	  for	  efficient	  dioxygen	  activation	   (Nagano	  &	  Poulos	  2005).	  Asp309	   in	  CYP19A1	   is	  positioned	  slightly	  differently	   than	   its	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CYP101	  analogue.	  In	  CYP19A1,	  Asp309	  is	  engaged	  in	  H-­‐bonding	  interaction	  with	  the	  3-­‐keto	  group	  of	  the	  substrate	  molecule	  and	  is	  not	  available	  as	  freely	  as	  in	  CYP101	  (Ghosh	  et	  al.	  2009).	  	  Density	  functional	  theory	  calculations	  suggest	  a	  7	  kcal/mol	  difference	  in	  the	  energy	  barrier	  for	  H1β	  abstraction	  when	  the	  A-­‐ring	  of	  the	  steroid	  is	  2,3	  enolized	  as	  opposed	  to	  when	  its	  not	  (Hackett	  et	  al.	  2005).	  Asp-­‐309’s	  direct	  role	  in	  catalysis	  via	  enolization	  may	  mean	  that	  its	  active	  site	  orientation	  is	  not	  optimal	  for	  proton	  delivery	  and	  explains	  the	  experimental	  observations	  discussed	  above.	  
EPR and ENDOR of reduced 19-oxo-AD-bound-oxyCYP19A1 If	   the	   peroxo-­‐anion	   hypothesis	   is	   true	   one	   would	   expect	   to	   see	   peroxo-­‐anion	   in	   the	   19-­‐oxo-­‐AD	  bound	   reduced	   oxy-­‐complex	   as	   well.	   In	   contrast	   to	   AD-­‐bound	   enzyme,	   EPR	   characterization	   of	  cryoreduced	  19-­‐oxo-­‐AD	  bound	  oxy-­‐CYP19A1	  shows	  the	  accumulation	  of	  the	  hydroperoxo	  anion	  as	  the	  primary	  species	  with	  g-­‐values	  of	  2.28	  and	  2.33.	  (Figure	  29).	  The	  1H	  ENDOR	  spectra	  of	  g	  =	  2.3	  shows	  H/D	  variability	  and	  provides	  further	  evidence	  that	  the	  species	  at	  g	  =	  2.3	  corresponds	  to	  the	  hydroperoxo	  anion	  (Figure	  30).	  Upon	  annealing,	   the	   species	   at	   g	  =	  2.28	  diminishes	   and	  a	  new	   species	   at	   g	  =	   [2.43,	   2.5]	   emerges.	  ENDOR	  spectra	  of	  cryoreduced	  19-­‐oxo-­‐AD	  bound	  oxyCYP19A1	  shows	  the	  presence	  of	  exchangeable	  protons	   suggesting	   that	   this	   species	   is	   the	   resting	   ferric	   aquo-­‐heme.	  The	   species	  with	   g	  =	  2.33	   is	  hypothesized	   to	   be	   a	   minor	   conformation	   of	   the	   hydroperoxo	   anion.	   However,	   the	   annealing	  behavior	   of	   this	   g	   =	   2.33	   species	   is	   different	   to	   the	   main	   g	   =	   2.28	   peak	   and	   warrants	   further	  investigation.	   Beyond	   215	   K	   a	   species	   with	   g	   =	   [2.43,	   2.25]	   is	   obtained.	   This	   presumably	  corresponds	   to	   the	   ferriheme	   complex	   but	   remains	   to	   be	   verified	   independently	   (Davydov	   et	   al.	  2001).	  
CONCLUSION Because	  of	  the	  challenges	  associated	  with	  producing	  reduced	  oxy-­‐samples	  with	  signal-­‐noise	  ratios	  conducive	  to	  annealing	  type	  experiments,	   further	  experiments	  planned	  in	  this	  direction	  could	  not	  be	   completed	   before	   preparation	   of	   this	   thesis.	   However,	   in	   repeated	   attempts	   to	   trap	   and	  characterize	   the	   annealing	   behavior	   of	   the	   reduced	   19-­‐oxo-­‐AD	   bound	   oxyCYP19A1	   via	   EPR,	  including	  the	  data	  presented	  here,	  it	  was	  conclusively	  shown	  that	  the	  primary	  species	  obtained	  in	  this	  case	  was	  the	  protonated	  peroxo	  anion.	  This	  observation	  contradicts	   the	  Cpd0	  mechanism	  for	  the	   aromatization	   step	  of	  CYP19A1	  wherein	   the	  peroxo	  anion	  acting	   as	   a	  nucleophile	   attacks	   the	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carbonyl	  carbon	  at	  C19	  position	  of	  the	  19-­‐oxo-­‐AD	  intermediate	  and	  orchestrates	  the	  C-­‐C	  lyase	  and	  aromatization	  reaction	  and	  tips	  the	  scales	  in	  the	  favor	  of	  Cpd1	  mediated	  catalysis	  (page	  6).	  In	  our	  experiments	  with	  reduced	  AD-­‐bound	  oxyCYP19A1,	  we	  confirmed	  the	  presence	  of	  the	  peroxo	  anion	  as	  the	  primary	  intermediate	  and	  discovered	  a	  previously	  undiscovered	  intermediate	  with	  g	  =	  [2.41	  2.45].	  We	  hypothesize	   that	   this	  new	   intermediate	   is	   the	  product	   complex	   still	  bound	   to	   the	  heme-­‐iron	  of	  water-­‐ligated	  complex	  in	  some	  non-­‐equilibrium	  conformation.	  In	   conclusion,	   our	   experiments	   suggest	   that	   in	   CYP19A1	   the	   C-­‐C	   scission	   and	   aromatization	   is	  mediated	   by	   the	   archetypical	   Cpd1	   mediated	   H-­‐rebound	   mechanism	   as	   opposed	   to	   a	   Cpd0	  mediated.	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  Figure	  27:	  EPR	  annealing	  of	  cryoreduced	  AD-­‐bound	  oxy-­‐CYP19A1	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  Figure	  29:	  EPR	  annealing	  of	  cryoreduced	  19-­‐oxo-­‐AD	  bound	  CYP19A1	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  Figure	   31:	   ENDOR	   spectra	   of	   the	   cryoreduced	   19-­‐oxo-­‐AD	   bound	   oxyCYP19	   annealed	   at	   204K	  showing	   the	  presence	  of	  exchangeable	  protons	  suggesting	   that	   the	  species	  observed	  at	  204K	  [g	  =	  2.43,	  2.5]	  is	  the	  resting	  ferric	  aquo-­‐heme.	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Chapter 5: RR Characterization of Ferric, Oxy-ferrous and 
Reduced Oxy-ferrous Complexes of Substrate-bound 
CYP19A1 
INTRODUCTION Raman	   spectroscopy	   is	   a	   type	   of	   vibrational	   spectroscopy	   that	   reports	   the	   transition	   between	  different	   vibrational	   levels	   in	   a	   molecule	   upon	   excitation	   by	   incident	   light	   from	   a	   laser	   beam.	  Photons	   from	   the	   exciting	   light	   excite	   the	  molecule	   in	   its	   ground	   state	   to	   a	   virtual	   excited	   state.	  When	   the	  molecule	   relaxes,	   it	   emits	   a	   photon	   and	   returns	   to	   a	   different	   vibrational	   level	   of	   the	  ground	   state.	   The	   reemitted	   photon	   lies	   at	   a	   frequency	   either	   higher	   or	   lower	   than	   that	   of	   the	  exciting	  beam,	  this	  is	  referred	  to	  as	  the	  ‘Raman	  effect’.	  In	  resonance	  Raman,	  the	  wavelength	  of	  the	  exciting	   laser	   line	   is	   tuned	   to	   coincide	   with	   an	   allowed	   electronic	   transition.	   This	   allows	   the	  vibrational	  modes	  corresponding	  to	  that	  particular	  transition	  to	  be	  intensified	  compared	  to	  the	  off-­‐resonance	   values	   making	   the	   rR	   technique	   more	   sensitive	   to	   its	   off-­‐resonance	   (normal	   Raman)	  version.	  This	  aspect	  becomes	  especially	  useful	  for	  biomolecules	  with	  chromophores	  in	  embedded	  in	  them,	  such	  as	  cytochromes	  P450.	  A	  heme	  prosthetic	  group	  forms	  the	  heart	  of	  the	  enzymes’	  catalytic	  activity.	  Tuning	  the	  laser	  to	  the	  charge	  transfer	  transition	  of	  the	  heme	  group	  enhances	  iron-­‐ligand	  stretching	  modes	  and	  some	  modes	  associated	  with	  the	  ligand	  alone.	  rR	  is	  a	  powerful	  tool	  to	  study	  the	   heme	   environment	   in	   a	   P450.	   Porphyrin	   skeletal	   vibrations	   provide	   information	   about	   the	  coordination	  geometry	  and	  spin-­‐state	  of	   the	  heme	   iron	  (Spiro	  &	  Czernuszewicz	  1995).	  Vibrations	  associated	  with	  CO	  in	  the	  ferrous-­‐CO	  adduct	  help	  characterize	  the	  heme	  distal	  site	  and	  property	  of	  an	  axial	  ligand	  (Spiro	  &	  Wasbotten	  2005)	  whereas	  the	  Fe-­‐S	  stretch	  serves	  as	  a	  structural	  marker	  for	  the	  heme	  proximal	  site.	  Recently,	   RR	   has	   been	   used	   to	   substrate	   induced	   structural	   changes	   in	   the	   active	   site	   of	   human	  CYP3A4	   (Mak	   et	   al.	   2011)	   and	   human	   CYP17	   (Mak	   et	   al.	   2014);	   characterize	   the	   oxy-­‐ferrous	  complexes	  of	  CYP17	  especially	  in	  terms	  of	  their	  H-­‐bonding	  geometry	  (M.	  Gregory	  et	  al.	  2013)	  and	  characterize	   the	   peroxo	   and	   hydroperoxo	   states	   of	   CYP101	   (Denisov	   et	   al.	   2008).	   These	   studies	  underscore	  the	  applicability	  and	  value	  of	  rR	  in	  studying	  various	  arms	  of	  the	  P450	  catalytic	  wheel,	  particularly	  the	  reactive	  and	  perhaps	  more	  interesting	  oxy-­‐ferrous	  and	  peroxo	  states.	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This	   chapter	   outlines	   the	   application	   of	   rR	   for	   structural	   characterization	   of	   human	   CYP19A1	   in	  Nanodiscs	   in	   the	  presence	  of	  AD,	  19-­‐OH	  AD	  and	  19-­‐oxo	  AD	   in	   its	   ferric	  and	  oxy-­‐ferrous	   states	   to	  identify	   features	   that	   could	   in	   turn	   help	   us	   identify	   the	   reactive	   intermediate	   involved	   in	   the	  hydroxylation	  and	  C-­‐C	  lyase	  chemistries.	  AD	  and	  19-­‐OH	  AD	  undergo	  hydroxylation	  whereas	  19-­‐oxo	  AD	  undergoes	  C-­‐C	   scission	   and	  aromatization,	   two	  very	  different	   chemical	   reactions	  occurring	   at	  the	  same	  active	  site.	  Structural	  differences	  between	  AD-­‐	  and	  19-­‐oxo	  AD-­‐bound	  CYP19A1	  or	  the	  lack	  thereof	  may	  shed	  some	  light	  on	  how	  these	  seemingly	  diverse	  chemical	  transformations	  occur	  at	  the	  same	  active	  site	  and	  lift	  the	  cloud	  of	  mystery	  surrounding	  the	  identity	  of	  heme-­‐oxygen	  intermediate	  responsible	  for	  catalysis	  in	  both	  these	  cases.	  The	  resonance	  Raman	  characterization	  of	  CYP19A1	  in	  its	  various	  substrate	  bound	  states	  has	  been	  performed	   before.	   Tosha	   et	   al.	   (Tosha	   et	   al.	   2006)	   measured	   the	   rR	   spectra	   of	   substrate-­‐bound	  CYP19A1	  and	  discovered	  substrate	  induced	  changes	  in	  the	  heme	  environment	  in	  both	  the	  distal	  and	  proximal	  side.	  They	  also	  found	  evidence	  of	  reduced	  electron	  donation	  from	  the	  axial	  thiolate	  to	  the	  heme	   iron	   in	   the	  presence	  of	  19-­‐oxo-­‐AD	  and	   favored	   the	  Cpd0	  mechanism	   for	  C-­‐C	   lyase	   (page	  6)	  arguing	   that	   the	   reduced	   axial	   electron	   donation	   may	   stabilize	   the	   ferric	   peroxo	   anion	   and	  suppresses	  the	  formation	  of	  Cpd1	  in	  the	  presence	  of	  this	  substrate.	  However,	  these	  measurements	  were	   done	   using	   detergent	   solubilized	   CYP19A1	   and	   were	   subject	   to	   limitations	   of	   non-­‐specific	  protein	  aggregation	  and	  non-­‐native	  protein	  conformational	  state	  of	   the	  membrane	  protein.	  There	  was	   a	   also	   substantial	   amount	   of	   P420	   in	   the	   enzyme	   preparation	   leading	   to	   erroneous	  observations	  as	  pointed	  out	  later.	  The	  rR	  experiments	  described	  in	  this	  chapter	  were	  done	  with	  CYP19A1	  incorporated	  in	  MSP1D1-­‐POPC	  Nanodiscs.	  By	  providing	  a	  native	  membrane-­‐like	  environment	  to	  the	  membrane-­‐bound	  P450	  Nanodiscs	  help	  preserve	  the	  enzyme’s	  structural	  and	  functional	  characteristics	  and	  provide	  a	  better	  representation	  of	   spin-­‐state	  populations,	   substrate	  binding	   and	   stability	   of	   dioxygen	  adducts	   and	  peroxo	  complexes.	  	  This	  work	  was	  done	   in	   collaboration	  with	  Piotr	  Mak	  of	  Prof.	   James	  Kincaid’s	   group	  at	  Marquette	  University.	  I	  prepared	  the	  oxy-­‐complexes	  and	  reduced	  oxy-­‐complexes	  in	  different	  substrate	  bound	  and	   solvent	   states	   whereas,	   Piotr	   Mak	   conducted	   the	   rR	   experiments	   and	   analyzed	   data.	   Data	  interpretation	  and	  manuscript	  synthesis	  was	  done	  collectively.	  
	   80	  
PREPARATION OF OXY-FERROUS AND REDUCED OXY-FERROUS COMPLEXES FOR 
RR SPECTROSCOPY 
CYP19A1 substrates Androstenedione	   (AD)	   and	   19-­‐oxo-­‐AD	   (19oxoAD)	   were	   purchased	   from	   Sigma-­‐Aldrich	   and	  Steraloids,	  respectively,	  and	  were	  used	  as	  a	  25	  mM	  stock	  solution	  in	  methanol.	  
Protein expression, purification and incorporation into Nanodiscs The	  expression,	  purification	  and	  incorporation	  of	  CYP19A1	  into	  POPC	  Nanodiscs	  was	  performed	  as	  previously	  described	  in	  pages	  7	  and	  10.	  
Preparation of oxy-samples for rR measurements 70	  µL	  of	  250	  µM	  ferric	  CYP19A1,	  6.25	  µM	  methylviologen	  (Sigma-­‐Aldrich),	  500	  µM	  substrate,	  30	  %	  (v/v)	   glycerol	   (or	   glycerol-­‐d3	  where	   appropriate)	   in	  0.1	  M	  potassium	  phosphate,	   pH	  7.4	  was	  de-­‐aerated	   under	   a	   continuous	   flow	   of	   Argon	   for	   5	   minutes	   in	   a	   small	   glass	   vial.	   The	   protein	   was	  reduced	   with	   a	   2.5	   fold	   molar	   excess	   of	   sodium	   dithionite	   (Riedel-­‐de	   Haën	   AG,	   Germany)	   and	  transferred	  to	  5	  mm	  O.D.	  NMR	  tubes	  (WG-­‐5	  Economy,	  Wilmad)	  under	  anaerobic	  conditions.	  After	  incubation	  at	  room	  temperature	  for	  10	  minutes	  the	  reduced	  sample	  was	  cooled	  down	  in	  a	  dry	  ice-­‐ethanol	  bath	  to	  -­‐13	  °C	  for	  1	  minute.	   	  Oxy-­‐ferrous	  complexes	  were	  formed	  by	  bubbling	  16O2	  or	  18O2	  gas	   for	  3-­‐5	  seconds,	   followed	  by	  rapid	  cooling	   in	  a	   -­‐60	  °C	  dry	   ice-­‐ethanol	  bath.	  The	  samples	  were	  then	  flash	  frozen	  and	  stored	  in	  liquid	  N2	  until	  measurement.	  
rR measurement 
Ferric complexes The	  samples	  of	  ferric	  CYP17	  samples	  were	  measured	  using	  the	  406.7	  and	  356.7	  nm	  excitation	  lines	  from	   a	   Kr+	   laser	   (Coherent	   Innova	   Sabre	   Ion	   Laser).	   The	   rR	   spectra	  were	   collected	   in	   the	   back-­‐scattering	   geometry	   using	   a	   Spex	   1269	   spectrometer	   equipped	  with	   Spec-­‐10	   LN-­‐cooled	   detector	  (Princeton	  Instruments,	  NJ).	  The	  laser	  power	  was	  adjusted	  to	  ~10	  mW	  and	  all	  measurements	  were	  done	   at	   room	   temperature.	   Spectra	   were	   calibrated	   with	   fenchone	   (Sigma-­‐Aldrich,	   WI)	   and	  processed	  with	  Grams/32	  AI	  software	  (Galactic	  Industries,	  Salem,	  NH).	  
Oxy-ferrous complexes The	   resonance	   Raman	   spectra	   of	   oxy	   complexes	   of	   ND:CYP19	  were	   acquired	   using	   a	   Spex	   1269	  spectrometer	   equipped	  with	   a	   Spec-­‐10	   LN-­‐cooled	   detector	   (Princeton	   Instruments,	  NJ).	   The	   data	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were	  measured	  with	  413.1	  nm	  excitation	  line	  from	  a	  Kr+	  laser	  (Coherent	  Innova	  Sabre	  Ion	  Laser).	  The	   rR	   spectra	  were	   collected	   using	   back	   scattering	   (180°)	   geometry	  with	   the	   laser	   beam	   being	  focused	  by	  a	  cylindrical	  lens	  to	  form	  a	  line	  image	  on	  the	  sample.	  The	  laser	  power	  was	  adjusted	  to	  1	  mW	  or	  less.	  All	  measurements	  were	  done	  at	  77	  K	  and	  total	  collection	  time	  was	  3-­‐4	  hours	  in	  the	  high	  frequency	  region	  and	  4-­‐5	  hours	  in	  the	  low	  frequency	  region.	  The	  slit	  width	  was	  set	  at	  150	  μm	  and	  the	  1200	  g/mm	  grating	  was	  used.	  The	  NMR	  tubes	  were	  positioned	  into	  a	  double-­‐walled	  quartz	  low	  temperature	   cell	   filled	  with	   liquid	   nitrogen.	   The	   sample	   tubes	  were	   spun	   to	   avoid	   local	   heating.	  Spectra	   were	   calibrated	   with	   fenchone	   (Sigma-­‐Aldrich,	   WI)	   and	   processed	   with	   Grams/32	   AI	  software	  (Galactic	  Industries,	  Salem,	  NH).	  
RESULTS AND DISCUSSION 
AD-, 19-OH-AD and 19-oxo-AD bound ferric CYP19A1 Although	   the	   structure	   of	   AD-­‐bound	   CYP19A1	   was	   a	   significant	   advancement	   in	   the	   field	   of	  aromatase	   research	   it	   did	   not	   offer	   any	   clues	   as	   to	   the	  whether	   the	   substrate	   itself	   can	   alter	   the	  enzyme’s	   active	   site	   and	   therefore	   affect	   its	   own	   catalysis	   as	   seen	   in	   CYP17	   (Mak	   et	   al.	   2014).	  Moreover,	  no	  structural	  information	  was	  available	  for	  19-­‐oxo-­‐AD	  bound	  CYP19A1,	  the	  substrate	  for	  the	  lyase	  step	  of	  CYP19A1.	  To	  address	  these	  deficiencies	  resonance	  Raman	  was	  used	  to	  probe	  the	  active	   site	  of	  CYP19A1	  and	   study	   its	   interaction	  with	   its	   three	   substrates,	  AD,	  19-­‐OH-­‐AD	  and	  19-­‐oxo-­‐AD.	  By	  monitoring	   the	  oxidation	  and	  spin	   state	  marker	  bands	  and	  Fe-­‐S	   stretches	   in	  different	  substrate	  binding	  configurations	  one	  can	  study	  changes	  occurring	   in	  both	  the	  distal	  and	  proximal	  side	  of	  heme	  iron	  upon	  substrate	  binding.	  
Figure	  32	  shows	  the	  high-­‐frequency	  rR	  spectra	  of	  ferric	  CYP19A1	  in	  substrate-­‐free	  and	  substrate-­‐bound	   states.	   The	   high	   frequency	   region	   contains	   core	   size	   and	   spin-­‐state	  markers	   and	   provides	  information	   about	   the	   oxidation	   state	   and	   the	   spin-­‐state	   of	   the	   heme	   iron.	   For	   substrate-­‐free	  CYP19A1,	   the	   oxidation	   state	  marker	   band	  ν4	   and	   the	   spin	   state	  marker	   bands	  ν3,	  ν2	   and	  ν10	  are	  observed	  at	  1374	  cm-­‐1,	  1501	  cm-­‐1,	  1583	  cm-­‐1	  and	  1638	  cm-­‐1	  respectively.	  This	  is	  characteristic	  of	  a	  low-­‐spin,	  hexa-­‐coordinated	  ferric	  heme	  and	  indicates	  that	  substrate-­‐free	  CYP19A1	  is	  pure	  low-­‐spin	  (Champion	   et	   al.	   1978).	   Substrate	   binding	   results	   in	   a	   change	   in	   coordination	   geometry	   (6-­‐coordinated	   to	   5-­‐coordinated)	   and	   spin	   state	   (low-­‐spin	   to	   high-­‐spin)	   of	   the	   heme-­‐iron.	   Full	   spin	  state	   conversion	   from	   low-­‐spin	   in	   substrate-­‐free	   P450s	   to	   high-­‐spin	   in	   substrate-­‐bound	   P450	   is	  seen	  as	  a	  14-­‐17	  cm-­‐1	  downshift	  of	  all	  three	  spin	  state	  marker	  bands	  (Mak,	  Im,	  et	  al.	  2008;	  Mak	  et	  al.	  2011;	   Mak	   et	   al.	   2014;	   Mak,	   Kaluka,	   et	   al.	   2008).	   High-­‐frequency	   rR	   spectra	   of	   substrate-­‐bound	  
	   82	  
CYP19A1	   shows	  peaks	   at	   1485	   cm-­‐1	  (ν3,	  HS),	   1501	   cm-­‐1	  	  (ν3,	  LS);	   1568	   cm-­‐1	  (ν2,	  HS),	   1583	   cm-­‐1	  	  (ν2,	  LS);	  and	  1621	  cm-­‐1	  (ν10,	  HS),	  1638	  cm-­‐1	  	  (ν10,	  LS)	  for	  all	  three	  substrates.	  The	  ratios	  of	  intensities	  of	  ν3,LS	  and	  
ν3,HS,	  proposed	  to	  represent	  percent	  spin-­‐state	  conversion	  in	  P450s	  by	  Mak	  et	  al.	  (Mak	  et	  al.	  2013),	  correspond	   well	   with	   spin	   state	   conversion	   observed	   using	   optical	   spectroscopy	   in	   the	   case	   of	  CYP19A1	  as	  well	  (Table	  1).	  
Figure	   33	   shows	   the	   low-­‐frequency	   rR	   spectra	   of	   CYP19A1.	   Low-­‐frequency	  modes	   in	   P450s	   are	  sensitive	   to	   changes	   in	   the	   heme-­‐macrocycle	   or	   peripheral	   substituents	   produced	   as	   a	   result	   of	  changes	  in	  the	  active	  site	  such	  as	  those	  produced	  upon	  substrate	  binding	  (Hu	  et	  al.	  1996;	  Mak	  et	  al.	  2004;	  Mak,	  Kaluka,	  et	  al.	  2008).	  	  
The	  ν7	  and	  ν8	  modes	  are	  observed	  at	  675	  cm-­‐1	  and	  345	  cm-­‐1.	  	  Low-­‐frequency	  rR	  spectra	  of	  substrate-­‐free	   CYP19A1	   shows	   propionate	   bending	  modes	   at	   369	   cm-­‐1	   and	   376	   cm-­‐1,	   as	   well	   as	   two	   vinyl	  bending	  modes	  at	  407	  cm-­‐1	  and	  430	  cm-­‐1.	  AD	  binding	  has	  no	  effect	  on	  propionate	  bending	  modes	  but	  causes	  a	  8	  cm-­‐1	  downshift	  of	  the	  higher	  frequency	  vinyl	  bending	  mode.	  AD	  binding	  also	  causes	  an	  activation	  of	  the	  ν7	  mode.	  Similar	  behavior	  is	  seen	  upon	  binding	  of	  19-­‐OH-­‐AD	  and	  19-­‐oxo-­‐AD.	  	  
19-­‐OH	  AD	  binding	  causes	  a	  decrease	   in	  the	   intensity	  of	   the	  propionate	  bending	  mode	  at	  369	  cm-­‐1	  but	  no	  change	  in	  the	  intensity	  of	  the	  band	  at	  376	  cm-­‐1.	  19-­‐oxo	  AD	  binding	  causes	  an	  increase	  in	  the	  intensity	   of	   the	   376	   cm-­‐1	   band.	   It	   has	   been	   shown	   that	   the	   frequency	   of	   the	   propionate-­‐bending	  mode	   is	   sensitive	   to	   hydrogen-­‐bonding	   with	   the	   protein	   environment	   and	   that	   disruption	   of	   H-­‐bonding	  causes	  a	  decrease	  in	  propionate	  bending	  frequency	  by	  ~	  10	  cm-­‐1	  (Hu	  et	  al.	  1996;	  Peterson	  et	  al.	  1998).	  Binding	  of	  substrates	  in	  CYP19A1	  causes	  no	  change	  in	  the	  frequency	  of	  the	  propionate	  bending	  modes	  implying	  that	  none	  of	  the	  substrates	  significantly	  affect	  the	  hydrogen	  bonding	  to	  the	  propionate	  groups.	  The	  two	  modes	  at	  369	  cm-­‐1	  and	  376	  cm-­‐1	  may	  be	  assigned	  to	  the	  non-­‐H-­‐bonded	  and	  H-­‐bonded	  fractions	  of	  the	  substrate	  bound	  enzyme.	  
Fe-S stretches for AD and 19-oxo-AD bound CYP19A1 Electron	  donation	  from	  the	  axial	  thiolate	  is	  an	  important	  parameter	  in	  determining	  the	  stability	  of	  Compound	   I	   (Dawson	  1988).	  Tosha	  et	  al.	  observed	  differences	   in	   the	  Fe-­‐S	  stretch	   frequencies	   for	  AD,	  19-­‐OH	  AD	  and	  19-­‐oxo-­‐AD-­‐bound	  ferric	  CYP19A1	  suggesting	  that	  substrate	  binding	  in	  CYP19A1	  effects	  both	   the	  heme-­‐distal	  and	  proximal	   sites	   (Tosha	  et	  al.	  2006).	  Their	  observations	  suggested	  that	   in	   CYP19A1	   substrates	   could	  modulate	   the	   electronic	   property	   of	   the	   axial	   thiolate	   and	   that	  owing	  to	  the	  poor	  electron	  donation	  from	  the	  axial	  thiolate	  in	  the	  presence	  of	  19-­‐oxo-­‐AD	  the	  ferric	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peroxo	  species	  would	  be	  stabilized.	  This	  line	  of	  reasoning	  favors	  the	  ‘Compound	  0’	  mechanism	  for	  lyase	  step	  of	  CYP19A1.	  	  We	  too	  measured	  the	  Fe-­‐S	  stretch	   frequency	   for	  AD-­‐bound	  and	  19-­‐oxo-­‐AD-­‐bound	  ferric	  CYP19A1	  but	  found	  no	  difference	  in	  the	  ν(Fe-­‐S)	  for	  these	  two	  substrates	  (Figure	  35)	  thus	  refuting	  the	  above	  stated	   hypothesis	   of	   reduced	   electron	   donation	   from	   the	   axial-­‐thiolate	   in	   19-­‐oxo-­‐AD	   bound	  CYP19A1	  being	  responsible	  for	  an	  enhanced	  stability	  of	  the	  peroxo	  anion	  that	  then	  may	  be	  able	  to	  conduct	  the	  C-­‐C	  scission	  owing	  to	  its	  nucleophilic	  character.	  More	   informative	  and	  valuable	   than	  structural	   characterization	  of	   the	   ferric	   states	  of	  CYP19A1	   is	  the	   vibrational	   spectra	   of	   the	   dioxygen	   adducts	   of	   CYP19A1	   bound	   with	   different	   substrates,	  especially	   in	   the	   light	   of	   differential	   H-­‐bonding	   arrangements	   with	   the	   bound	   O-­‐O	   fragment.	   H-­‐bonding	  interactions	  to	  the	  O-­‐O	  moiety	  of	  the	  peroxo	  anion	  may	  give	  us	  a	  clue	  about	  the	  enzyme’s	  preference	   for	   the	   peroxo-­‐anion	   or	   Cpd	   1	   for	   the	   lyase	   step,	   as	   recently	   shown	   in	   CYP17A1	   (M.	  Gregory	  et	  al.	  2013).	  
AD- and 19-oxo-AD bound oxy-ferrous complexes of CYP19A1 O-­‐O	  stretch	  frequencies	  and	  their	  behavior	  upon	  isotopic	  substitution	  provide	  valuable	  information	  about	  the	  active	  site	  structure	  of	  the	  oxy-­‐ferrous	  (Fe-­‐O-­‐O)	  complex	  and	  its	  propensity	  to	  transform	  into	   the	   peroxo	   anion	   or	   the	   hydroperoxo	   anion	   upon	   ensuing	   reduction.	   Here	   the	   rR	   spectra	   is	  used	   to	   characterize	   the	   active	   site	   structure	   of	   oxy-­‐ferrous	   complexes	   of	   CYP19A1	  bound	   to	  AD	  and	   19-­‐oxo-­‐AD	   to	   see	   if	   differences	   in	   organization	   of	   the	   active	   site	   can	   shed	   light	   on	   the	  differences	   in	   the	   choice	   of	   reactive	   intermediate	   mediating	   hydroxylation	   and	   C-­‐C	   scission	   by	  CYP19A1.	  This	   feasibility	   of	   this	   approach	   was	   recently	   demonstrated	   in	   CYP17A1	   wherein	   the	   dioxygen	  adducts	  of	  CYP17A1	  in	  the	  presence	  of	  17-­‐OH-­‐progesterone	  (17-­‐OH-­‐Prog)	  or	  17-­‐OH-­‐pregnenolone	  (17-­‐OH-­‐Preg)	  were	  studied	  using	  rR	  (M.	  Gregory	  et	  al.	  2013).	  17-­‐OH-­‐Prog	  and	  17-­‐OH-­‐Preg	  undergo	  hydroxylation	  and	  C-­‐C	   scission	   respectively.	  There	   is	   a	   growing	  body	  of	   evidence	   suggesting	   that	  the	  conversion	  of	  17-­‐OH-­‐Preg	   to	  dihydroepiandrosterone	   (DHEA)	  goes	  via	  a	  peroxo-­‐intermediate	  (Akhtar	  et	  al.	  2011;	  Akhtar	  et	  al.	  1994;	  Lee-­‐Robichaud	  et	  al.	  1998).	  Gregory	  et	  al.	   showed	  that	  rR	  spectra	   of	   the	   oxy-­‐ferrous	   complexes	   of	   CYP17A1	   in	   17-­‐OH-­‐Prog	   and	   17-­‐OH-­‐Preg	   bound	   states	  showed	   differences	   in	   H-­‐bonding	   to	   the	   Fe-­‐O-­‐O	  moiety.	   DFT	   calculations	   in	   histidine-­‐ligated	   oxy	  complexes	  predict	   that	  H-­‐bonding	  to	  the	  proximal	  oxygen	  atom	  weakens	  the	  O-­‐O	  and	  Fe-­‐O	  bonds	  whereas	   that	   to	   the	   terminal	  oxygen	  atom	  weakens	   the	  O-­‐O	  bond	  but	   strengthens	   the	  Fe-­‐O	  bond	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(Spiro	   et	   al.	   2013).	   In	   other	   words,	   H-­‐bonding	   to	   the	   terminal	   oxygen	   of	   Fe-­‐O-­‐O	   promotes	   O-­‐O	  cleavage	  resulting	  in	  the	  formation	  of	  Cpd1	  whereas,	  that	  to	  the	  proximal	  oxygen	  atom	  prolongs	  the	  lifetime	  of	   the	  peroxo	  anion	  which	  may	   then	  act	   as	   the	   catalytic	   intermediate	  via	   its	  nucleophilic	  character.	   Such	   differential	   H-­‐bonding	   interactions	   and	   the	   resulting	   difference	   in	   the	   choice	   of	  reactive	  intermediate	  employed	  by	  the	  enzyme	  for	  catalysis	  has	  been	  seen	  previously	  in	  nitric	  oxide	  synthase	   (Li	   et	   al.	   2007).	   rR	   characterization	   of	   CYP17A1	   showed	  H-­‐bonding	   to	   terminal	   oxygen	  atom	   in	   the	   case	   of	   17-­‐OH-­‐Prog	   and	   that	   to	   the	   proximal	  O-­‐atom	   in	   the	   case	   of	   17-­‐OH-­‐Preg	   also	  pointing	  towards	  the	  peroxo-­‐anion	  mediated	  mechanism	  for	  C-­‐C	  lyase	  in	  CYP17A1.	  Figure	   36	   shows	   the	   high-­‐frequency	   rR	   spectra	   of	   AD-­‐bound	   oxyCYP19	   with	   the	   ν(O-­‐O)	   band	  present	  at	  1130	  cm-­‐1	  and	  exhibiting	  an	  expected	  64	  cm-­‐1	  downshift	  upon	  16O2/18O2	  substitution.	  A	  2	  cm	   -­‐1	  upshift,	   typically	  associated	  with	  H-­‐bonding	  with	  amino	  acid	  or	  water	  molecules	  present	   in	  the	   heme	   pocket	   is	   observed	   upon	   H/D	   substitution.	   Figure	   37	   shows	   the	   high	   frequency	   of	   rR	  spectra	  of	  19-­‐oxo-­‐AD	  bound	  oxyCYP19.	  The	  ν(O-­‐O)	  band	  is	  observed	  at	  1132	  cm	  -­‐1.	  Substitution	  of	  16O2	  to	  18O2	  and	  1H1	  to	  2H1	  show	  a	  downshift	  of	  64	  cm-­‐1	  and	  upshift	  of	  0.5	  cm-­‐1	  respectively.	  The	  low	  frequency	   spectra	   of	   AD-­‐	   and	   19-­‐oxo-­‐AD	   bound	   CYP19A1	   (Insets	   in	   Figure	   36	   and	   Figure	   37	  respectively)	   show	   a	   ν(Fe-­‐O)	   stretch	   at	   538	   cm-­‐1	   and	   534	   cm-­‐1	   respectively.	   On	   the	   whole,	   the	  observed	   frequencies	   and	   isotopic	   shifts	   obtained	   for	   19-­‐oxo-­‐AD-­‐bound	   oxy	   CYP19A1	   are	   quite	  similar	   to	   the	   data	   acquired	   for	   the	   AD-­‐bound	   enzyme,	   with	   only	   the	   absolute	   values	   for	   the	  ν(Fe−O)	   modes	   differing,	   but	   even	   then	   with	   identical	   29	   cm-­‐1	   downshift	   upon	   16O2/18O2	  substitution.	  Figure	  38	  summarizes	  the	  stretch	  frequencies	  and	  isotopic	  shifts	  observed	  for	  O-­‐O	  and	  Fe-­‐O	  for	  AD-­‐	  and	  19-­‐oxo-­‐AD-­‐bound	  oxyCYP19A1	  as	  described	  above.	  The	   spectral	   pattern	   of	  ν(O-­‐O)	   in	   the	   range	   of	   1130-­‐1140	   cm-­‐1	   and	   a	   1-­‐2	   cm-­‐1	   upshift	   upon	  H/D	  substitution	  is	  characteristic	  of	  a	  Fe-­‐O-­‐O	  weakly	  stabilized	  by	  H-­‐bonding	  interactions	  from	  nearby	  amino	   acid	   residues	   or	  water	  molecules	   present	   in	   the	   heme	  pocket.	   The	   resonance	  Raman	  data	  acquired	  here	  suggests	  that	  neither	  of	  the	  substrates	  exhibits	  an	  unusual	  H-­‐bonding	  arrangement	  to	  the	  Fe-­‐O-­‐O	  fragment	  as	  seen	  in	  CYP17A1.	  Both	  AD	  and	  19-­‐oxo-­‐AD	  bound	  oxyCYP19A1	  show	  signs	  of	   H-­‐bonding	   to	   the	   distal	   oxygen	   atom	   which	   suggests	   the	   involvement	   of	   Cpd	   1	   in	   both	   the	  hydroxylation	  and	  aromatization	  steps	  of	  CYP19A1.	  Similarity	  in	  the	  rR	  signatures	  of	  oxyCYP19A1	  bound	   to	   AD,	   substrate	   for	   the	   hydroxylase	   step	   and	   19-­‐oxo-­‐AD,	   substrate	   for	   the	   lyase	   step	   of	  aromatase	  suggests	  that	  the	  same	  iron-­‐oxygen	  intermediate	  is	  involved	  in	  carrying	  out	  both	  these	  distinct	   chemical	   modifications.	   It	   is	   widely	   accepted	   that	   hydroxylation	   in	   P450s,	   including	  CYP19A1	  happens	  via	  H-­‐rebound	  mechanism	  mediated	  by	   the	  archetypical	  Cpd	  1	   (Groves	  1985).	  	  Therefore,	  our	  data	  suggests	  that	  Cpd	  1	  is	  also	  responsible	  for	  the	  lyase	  reactivity	  of	  CYP19A1.	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Difference	   in	   characteristics	   of	   the	   rR	   spectra	   of	   oxyCYP17A1	   and	   oxyCYP19A1	   upon	   H/D	  substitution	  when	  bound	  to	  corresponding	  substrates	  undergoing	  carbon-­‐carbon	  scission	  suggest	  that	  the	  choice	  of	  iron-­‐oxygen	  intermediate	  utilized	  by	  the	  P450	  to	  carry	  out	  catalysis	  may	  partially	  depend	  on	  the	  substrate	  molecule	  itself.	  The	  substrate	  molecule	  may,	  by	  controlling	  the	  H-­‐bonding	  status	   of	   the	   bound	  O-­‐O	  moiety,	   actively	   decide	   if	   the	   peroxo-­‐anion	   or	   Cpd	   1	  would	   be	   used	   for	  catalysis.	   	   This	  novel	   phenomenon,	  well	   demonstrated	  by	   comparing	  CYP19A1	  and	  CYP17A1	  has	  been	   coined	   as	   ‘substrate-­‐assisted	   catalysis’	   and	   would	   be	   subject	   to	   future	   research	   by	   the	  laboratories	  of	  Drs.	  Sligar	  and	  Kincaid.	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  Figure	   32:	   The	   high	   frequency	   RR	   spectra	   of	   CYP19	   without	   substrate	   (SF)	   and	   with	  androstenedione	  (AD),	  19-­‐OH-­‐androstenedione	  (19-­‐OH-­‐AD)	  and	  19-­‐oxo	  androstenedione	  (19-­‐oxo-­‐AD).	  Spectra	  are	  normalized	  to	  the	  ν4	  mode.	  Protein	  concentration	  is	  120	  µM	  and	  the	  substrates	  is	  700	  μM.	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CYP19A1	   %	  High-­‐spin	   %	  Low-­‐spin	  Substrate-­‐free	   6	   94	  +	  Androstenedione	   86	   14	  +	  19-­‐OH	  androstenedione	   53	   47	  +	  19-­‐oxo	  androstenedione	   60	   40	  	  Table	  1:	   Percentage	  high-­‐	   and	   low-­‐spin	   in	  CYP19A1	   in	   substrate-­‐free	   and	   substrate-­‐bound	   forms	  based	  on	  resonance	  Raman	  (Mak	  et	  al.	  2013).	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  Figure	  33:	  The	  low	  frequency	  RR	  spectra	  of	  CYP19	  without	  substrate	  (SF),	  with	  an	  androstenedione	  (AD)	   19-­‐OH-­‐androstenedione	   (19-­‐OH	  AD)	   and	   19-­‐oxo	   androstenedione	   (19-­‐oxo	  AD).	   Spectra	   are	  normalized	  to	  the	  ν7	  mode.	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  Figure	  34:	  As	  in	  Figure	  33	  but	  expanded	  for	  better	  view	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  Figure	  35:	  The	  low	  frequency	  spectra	  of	  ferric	  ND:CYP19	  with	  AD	  (A)	  and	  19-­‐oxo-­‐AD	  (B)	  substrates.	  Excitation	  line	  was	  356.7	  nm,	  the	  spectra	  were	  normalized	  to	  the	  ν7	  mode	  at	  676	  cm-­‐1.	  The	  lower	  intensity	   of	   the	   ν(Fe-­‐S)	   mode	   in	   the	   spectrum	   of	   19-­‐oxo-­‐AD	   reflects	   the	   lower	   high	   spin	   state	  population	  in	  this	  sample,	  as	  compared	  to	  the	  AD-­‐bound	  sample.	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  Figure	  36:	  The	  high	  frequency	  region	  of	  AD-­‐bound	  oxy	  complexes	  of	  ND:CYP19	  and	  their	  difference	  traces.	  Inset	  Difference	  traces	  in	  the	  low-­‐frequency	  region.	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  Figure	   37:	   The	   high	   frequency	   spectral	   region	   of	   	   19-­‐oxo-­‐AD-­‐bound	   oxy	   complexes	   of	  ND:CYP19	  and	  the	  difference	  traces.	  Inset	  Difference	  traces	  in	  the	  low-­‐frequency	  region.	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  Figure	  38:	  ν(O-­‐O)	  and	  ν(Fe-­‐O)	  stretch	  frequencies	  and	  isotopic	  shifts	  for	  AD-­‐	  and	  19-­‐oxo-­‐AD-­‐bound	  oxyCYP19A1	  complexes.	  
Resonant frequency & 
16O - 18O shiftν(O-O) = 1130 ; 64 cm-1ν(Fe-O) = 538 ; 29 cm-1
ν(O-O) = 1132 ; 64 cm-1ν(Fe-O) = 534 ; 29 cm-1
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Chapter 6: Kinetic Solvent Isotope Effect in Steady State 
Kinetics of NADPH Consumption and Product Formation 
by CYP19A1 
INTRODUCTION The	   effect	   of	   deuterium	   substitution	   on	   turnover	   rates	   can	   be	   used	   as	   indicator	   to	   ascertain	   the	  involvement	  of	  protons	  in	  O-­‐O	  heterolysis	  in	  P450s.	  This	  was	  first	  shown	  by	  Vidakovic	  et	  al.	  in	  wild-­‐type	   and	  D251N	  mutant	   of	   CYP101	   (Vidakovic	   et	   al.	   1998),	   and	   recently	   by	   (M.	   C.	   Gregory	   et	   al.	  2013)	  in	  human	  CYP17A1.	  (M.	  C.	  Gregory	  et	  al.	  2013)	  used	  kinetic	  solvent	  isotope	  effect	  (KSIE)	  to	  draw	   a	   distinction	   between	   the	   reaction	   mechanisms	   for	   hydroxylase	   and	   lyase	   chemistries	   of	  human	  CYP17A1.	  CYP17A1	  is	  a	  membrane-­‐bound	  steroidogenic	  P450.	  It	  acts	  upstream	  to	  CYP19A1	  in	   the	   human	   steroidogenesis	   pathway	   and	   is	   responsible	   for	   the	   biosynthesis	   of	   pregnenolone,	  progesterone,	   17-­‐α-­‐hydroxy	   pregnenolone,	   17-­‐α-­‐hydroxy	   progesterone,	   dihydroepiandrosterone	  and	   androstenedione.	   Just	   like	   CYP19A1,	   it	   is	   unclear	   whether	   Compound	   0	   or	   Compound	   1	   is	  responsible	  for	  the	  lyase	  chemistry	  of	  CYP17A1.	  	  Two	   distinct	   protonation	   events	   facilitate	   O-­‐O	   heterolysis	   to	   generate	   Compound	   1	   from	   the	  peroxoanion	   intermediate	   in	   P450s.	   The	   two	   proposed	   hypothesis,	   namely	   ‘Compound	   0’	   and	  ‘Compound	   1’	   mechanisms	   for	   C-­‐C	   scission	   in	   CYP19A1	   differ	   in	   the	   identity	   of	   reaction	  intermediate	  that	  orchestrates	  catalysis	  and	  therefore,	  differ	  in	  the	  involvement	  of	  protons.	  Kinetic	  solvent	   isotope	   effect	   is	   a	   great	   way	   to	   distinguish	   between	   ‘Compound	   0’	   and	   ‘Compound	   1’	  mechanisms.	   The	   hydroxylase	   and	   lyase	   chemistries	   of	   CYP17A1	   exhibit	   KSIEs	   of	   1.3	   and	   0.39	  respectively.	  This	  suggests	  the	  involvement	  of	  iron-­‐bound	  ferric	  peroxoanion	  for	  C17-­‐C20	  scission	  instead	  of	  the	  archetypical	  Compound	  1	  (M.	  C.	  Gregory	  et	  al.	  2013).	  The	  same	  approach	  was	  applied	  to	  CYP19A1	  and	  the	  results	  are	  discussed	  below.	  
MATERIALS AND METHODS 
CYP19A1 expression, purification and Nanodisc incorporation The	  expression,	  purification	  and	  incorporation	  of	  CYP19A1	  into	  POPC	  Nanodiscs	  was	  performed	  as	  previously	  described	  on	  sections	  pages	  7	  and	  10.	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CPR expression and purification Cytochrome	   P450	   reductase	   from	   rat	   was	   expressed	   in	   the	   pOR262	   vector	   and	   purified	   as	  described	  previously	  in	  (Vermilion	  &	  Coon	  1978).	  The	  rat	  CPR/pOR262	  plasmid	  was	  obtained	  as	  a	  gift	  from	  Dr.	  Todd	  D.	  Porter	  (University	  of	  Kentucky,	  Lexington,	  KY).	  
Formation of CPR–CYP19A1 complex Incorporation	  of	  CPR	  into	  preformed	  and	  purified	  human	  CYP19A1	  Nanodiscs	  was	  made	  by	  direct	  addition	   of	   oligomeric	   CPR	   at	   a	   molar	   ratio	   of	   1:4	   CYP19A1	   (200	   pmol)	   to	   CPR	   (800	   pmol),	   as	  described	  previously	  (Grinkova	  et	  al.	  2010).	  Briefly,	  1	  ml	  of	  CYP19A1	  and	  CPR	  solution	  in	  100	  mM	  potassium	  phosphate	  buffer,	  pH	  7.4,	  containing	  50	  mM	  NaCl	  and	  50	  μM	  substrate	  (AD,	  19-­‐OH-­‐AD,	  or	  19-­‐oxo-­‐AD)	  was	  brought	   to	  37	  °C	   in	  a	  stirred	  quartz	  cuvette	  with	  a	  path	   length	  of	  0.4	  cm.	  The	  sample	  was	  incubated	  for	  3	  minutes	  to	  facilitate	  formation	  of	  functional	  CYP19A1–CPR	  complex.	  A	  ratio	  of	  1:4	  of	  P450:CPR	  was	  chosen	  based	  on	  previously	  established	  optimal	  ratio	  of	  reductase	  to	  P450	   for	   in	  vitro	  turnover	   experiments	  using	   the	  Nanodisc	   system	   (Grinkova	   et	   al.	   2010).	   In	   this	  approach	  the	  reductase,	  in	  a	  dynamic	  equilibrium	  with	  reductase	  molecules	  in	  solution,	  inserts	  into	  the	  P450	  containing	  Nanodisc	  through	  its	  membrane	  anchoring	  tail	  thereby	  allowing	  the	  formation	  of	  an	  efficient	  electron	  transfer	  complex.	  	  	  	  
NADPH consumption 300	   μM	   of	   NADPH	   was	   added	   to	   the	   reaction	   mixture	   to	   initiate	   turnover.	   The	   consumption	   of	  NADPH	  was	  monitored	  by	  recording	  the	  decrease	  in	  absorbance	  at	  340	  nm	  for	  10	  min.	  The	  reaction	  was	  then	  stopped	  by	  adding	  50	  μl	  of	  9	  M	  sulfuric	  acid	  to	  reduce	  the	  pH	  of	  the	  reaction	  below	  4.0.	  The	  sample	  was	  removed	  from	  the	  cuvette,	  flash	  frozen	  in	  liquid	  nitrogen,	  and	  stored	  at	  -­‐80	  °C	  until	  further	  analysis.	  All	  optical	  measurements	  were	  performed	  on	  Hitachi	  U-­‐3300	  spectrophotometer	  supplied	  with	  temperature	  controller	  and	  a	  built-­‐in	  magnetic	  stirrer.	  The	  rate	  of	  NADPH	  oxidation	  was	   determined	   from	   the	   slope	   of	   absorption	   at	   340	  nm	  during	   the	   first	   three	  minutes	   using	   an	  extinction	  coefficient	  of	  6.22	  cm-­‐1mM-­‐1.	  	  
Product formation The	  conversion	  of	  AD,	  19-­‐OH	  and	  19-­‐oxo-­‐AD	  to	  estrone	  was	  analyzed	  by	  HPLC	  (Waters).	  Briefly,	  1	  μl	  of	  18	  mM	  progesterone	  solution	  in	  methanol	  (for	  use	  as	  an	  internal	  standard)	  was	  added	  to	  1	  ml	  each	  of	   the	   reaction	   sample	   and	   vortexed	   for	   30	   seconds.	   2	  ml	   of	   chloroform	  was	   added	   to	   each	  aliquot	   and	   vortexed	   for	   30	   seconds.	   The	   organic	   phase	   was	   removed	   and	   dried	   under	   the	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continuous	  stream	  of	  nitrogen.	  The	  dried	  sample	  was	  then	  dissolved	  in	  100	  μl	  of	  methanol.	  30	  μl	  of	  this	  solution	  was	  injected	  onto	  a	  150	  x	  2.1	  mm,	  3	  µm	  C18-­‐HPLC	  column	  (ACE-­‐111-­‐1502).	  45%	  each	  of	  methanol	  and	  acetonitrile	   in	  water	  was	  used	  as	   the	  mobile	  phase	  at	  a	   flow	  rate	  of	  0.2	  ml/min.	  The	  19-­‐hydroxylated	  and	  19-­‐oxo	  product	  of	  AD	  were	  separated	  on	  the	  linear	  gradient	  of	  methanol	  and	  acetonitrile	   from	  20%	  to	  80%	  in	  30	  min,	  and	  detected	  at	  240	  nm.	  The	   formation	  of	  estrogen	  was	  detected	  at	  280	  nm.	  Peak	  integration	  was	  performed	  with	  GRAM/32	  software	  (Thermo	  Fischer	  Scientific).	  In	   order	   to	   determine	   the	   reaction	   time	   for	   the	   substrates	   AD,	   19-­‐OH-­‐AD	   and	   19-­‐oxo-­‐AD,	   time-­‐depended	  substrate	  conversion	  was	  performed	  first	  and	  the	  10	  min	  incubation	  time	  chosen	  for	  the	  catalytic	  activity,	  during	  which	  the	  catalytic	  activity	  was	  still	  in	  linear	  phase	  (Figure	  39).	  	  	  All	  measurements	  were	  made	  in	  deuterated	  buffers	  of	  same	  ionic	  strength	  and	  pD	  7.0.	  Deuterated	  samples	  were	  prepared	  by	  exhaustive	  exchange	  of	  the	  proteins	  in	  D2O.	  
RESULTS AND DISCUSSION 
Product formation rates and effect of H/D substitution Upon	  evaluating	  the	  rates	  of	  product	  formation	  for	  the	  three	  steps	  of	  CYP19	  catalysis	  in	  protiated	  and	  deuterated	  buffers	  the	  following	  observations	  were	  made	  (Figure	  40):	  
• Using	  AD	  as	  a	  substrate,	  two	  products	  were	  obtained,	  19-­‐OH-­‐AD	  and	  19-­‐oxo-­‐AD.	  The	  individual	  rates	   of	   formation	   of	   these	   two	   products	   was	   1.63	   ±	   0.04	   min-­‐1	   and	   4.06	   ±	   0.30	   min-­‐1	   ,	  respectively,	  (total	  rate	  of	  5.70	  ±	  0.34	  min-­‐1)	  in	  H2O.	  The	  same	  rates	  slowed	  to	  0.62	  ±	  0.07	  min-­‐1	  and	  1.52	  ±	  0.15	  min-­‐1,	  respectively	  (a	  total	  of	  2.14	  ±	  0.22	  min-­‐1)	  when	  H2O	  was	  substituted	  for	  D2O.	  This	  corresponds	  to	  a	  KSIE	  (kH/kD)	  of	  2.7	  for	  the	  first	  step	  of	  CYP19	  catalysis.	  	  
• Using	  19-­‐OH-­‐AD	  as	   the	   starting	   substrate,	   two	  products	  were	  obtained	   again,	   19-­‐oxo-­‐AD	  and	  estrone.	  The	  rates	  of	  product	  formation	  of	  these	  two	  products	  were	  2.3	  ±	  0.2	  min-­‐1	  and	  1.8	  ±	  0.3	  min-­‐1	   in	   H2O	   and	   2.39	   ±	   0.2	   min-­‐1	   and	   0.91	   ±	   0.3	   min-­‐1	   in	   D2O.	   The	   total	   rates	   of	   19-­‐OH-­‐AD	  turnover	   by	   CYP19	   of	   4.1	   ±	   0.5	   min-­‐1	   and	   3.3	   ±	   0.23	   min-­‐1	   in	   H2O	   and	   D2O	   respectively	  correspond	  to	  a	  KSIE	  of	  1.2.	  
• When	  19-­‐oxo-­‐AD	   is	  used	  as	  a	  substrate	  estrone	  was	  obtained	  as	   the	  sole	  product.	  The	  rate	  of	  estrone	   formation	   in	   H2O	   and	   D2O	   was	   calculated	   to	   be	   7.1	   ±	   0.8	   min-­‐1	   and	   2.8	   ±	   0.8	   min-­‐1	  respectively.	  This	  corresponds	  to	  a	  KSIE	  of	  2.53.	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The	   value	   of	   KSIE	   for	   steps	   I	   and	   II	   are	   consistent	   with	   those	   reported	   for	   other	   P450	   systems	  catalyzing	   hydroxylation	   chemistry	   via	   a	   Cpd1	   mediated	   hydrogen	   abstraction	   and	   radical	  recombination	  (Vidakovic	  et	  al.	  1998;	  Batabyal	  et	  al.	  2013;	  Liu	  &	  Ortiz	  de	  Montellano	  2000).	  A	  KSIE	  of	  2.53	  for	  step	  III	  suggests	  the	  involvement	  of	  same	  intermediate,	  Compound	  1	  in	  the	  lyase	  step	  of	  CYP19A1.	  	  The	  conversion	  of	  19-­‐hydroxy	  androstenedione	  gives	  a	  KSIE	  of	  1.2	   in	  contrast	   to	  2.7	  and	  2.53	  for	  androstenedione	   and	  19-­‐oxo-­‐androstenedione	   turnover.	  This	   is	   an	   interesting	  observation	   and	   is	  discussed	  below:	  Catalysis	  by	  CYP19A1	  is	  distributive	  as	  evidenced	  by	  formation	  of	  19-­‐OH	  AD	  and	  19-­‐oxo	  AD	  from	  AD	   and	   19-­‐oxo	   AD	   and	   estrone	   from	   19-­‐OH	   AD.	   Using	   AD	   as	   the	   starting	   substrate	   we	   observe	  formation	  of	  19-­‐OH	  AD	  and	  19-­‐oxo	  AD	  under	   steady	   state	   conditions.	  Rates	  of	   formation	  of	  both	  these	   products	   show	   slowing	   down	   upon	   H2O	   to	   D2O	   substitution.	   Both,	   rates	   of	   formation	   of	  individual	   products	   and	   total	   product,	   display	   an	   isotope	   effect	   of	   ≥	   2.6.	   Using	   19-­‐OH	   AD	   as	   the	  starting	  substrate	  we	  observe	  19-­‐oxo	  AD	  and	  estrone	  under	  steady	  state	  turnover	  conditions.	  This	  case	  is	  a	  little	  peculiar	  though.	  Formation	  of	  estrone	  shows	  a	  KSIE	  of	  2	  (1.8	  min-­‐1	  in	  H2O	  versus	  0.91	  min-­‐1	  in	  D2O),	  however,	  the	  formation	  of	  19-­‐oxo	  AD	  shows	  no	  solvent	  isotope	  effect	  bringing	  down	  the	  net	  KSIE	  of	   product	   formation	  down	   to	  1.2	   (Table	  2).	   Conversion	  of	   19-­‐OH	  AD	   to	  19-­‐oxo	  AD	  goes	  through	  a	  hydroxylation	  at	  the	  C19	  to	  produce	  a	  gem-­‐diol	  that	  then	  undergoes	  dehydration	  to	  yield	  the	  19-­‐oxo	  AD	  intermediate	  (Figure	  41).	  It	  is	  plausible	  that	  the	  rate	  of	  dehydration	  of	  the	  gem-­‐diol	   intermediate	   is	   partially	   rate	   limiting.	   This	   would	   explain	   the	   diminished	   magnitude	   of	  observed	  KSIE	  for	  step	  II	  as	  compared	  to	  steps	  I	  and	  III.	  
Rates of NADPH consumption and the effect of deuterium substitution on them The	   overall	   rate	   of	  NADPH	  oxidation	   in	   the	   presence	   of	   different	   substrates	  was	   also	   studied.	   In	  protiated	  solvent	  system,	  NADPH	  consumption	  rates	  in	  the	  presence	  of	  AD,	  19-­‐OH	  AD	  and	  19-­‐oxo	  AD	  were	   found	   to	   be	   37	   ±	   4.5	  min-­‐1,	   37	   ±	   4	  min-­‐1	  and	  35	   ±	   1	  min-­‐1.	   Upon	  H/D	   substitution,	   they	  decreased	   to	   14	   ±	   1.5	   min-­‐1,	   8.00	   ±	   1.3	   min-­‐1	   and	   6	   ±	   1.2	   min-­‐1	   respectively.	   A	   corresponding	  increase	   in	   the	  coupling	  efficiency	   from	  15,	  11	  and	  20%	  to	  16,	  41	  and	  47%	  respectively	  was	  also	  observed	   (Figure	   42).	   A	   higher	   level	   of	   coupling	   in	   deuterated	   solvents	   is	   due	   to	   slowing	   of	   the	  proton	  dependent	  uncoupling	  pathways,	  predominantly	  the	  peroxide	  and	  oxidase	  shunt	  pathways.	  	  The	   higher	   coupling	   efficiency	   observed	   in	   the	   presence	   of	   19-­‐OH-­‐AD	   and	   19-­‐oxo-­‐AD	   may	   be	  attributed	   to	   the	  polar	  nature	  of	   these	  substrates	   thereby	  making	  possible	  presence	  of	  additional	  water	  molecules	   and/or	   enhanced	   stabilization	   of	   the	   existing	   hydrogen-­‐bonding	   network	   at	   the	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active	   site	   of	   the	   enzyme.	   Slowing	  down	  of	   the	  NADPH	  oxidation	   rates	  upon	   solvent	   substitution	  when	  AD,	  19-­‐OH-­‐AD	  or	  19-­‐oxo-­‐AD	  are	  used	  as	  starting	  substrates	   indicates	  that	   in	  all	   three	  steps	  protonation	  is	  rate	  limiting.	  	  Taken	   together,	   the	   NADPH	   oxidation	   and	   product	   formation	   rates	   suggest	   that	   the	   same	  intermediate,	  Cpd	  1	  is	  responsible	  for	  both	  the	  hydroxylation	  and	  lyase	  chemistries	  of	  CYP19A1.	  
CONCLUSION We	  observe	  a	  normal	  slowing	  of	  Steps	  1	  and	  2	  of	  CYP19A1	  catalysis	  (kH/kD	  of	  2.7	  and	  1.2)	  consistent	  with	   the	   need	   for	   two	   protonation	   steps	   in	   concomitant	   formation	   of	   the	   hydroperoxo-­‐ferric	  complex	   and	   Cpd	   1	   in	  D2O.	   	   These	   observations	   are	   also	   consistent	  with	   the	   previous	   reports	   of	  solvent	  isotope	  effects	  in	  P450cam	  and	  other	  P450s	  (Raag	  et	  al.	  1991;	  Batabyal	  et	  al.	  2013;	  Groves	  2006;	  Shimada	  et	   al.	   1997).	  The	  presence	  of	  kinetic	   solvent	   isotope	  effect	  of	   a	   similar	  magnitude	  when	  19-­‐oxo-­‐AD,	   the	  substrate	   for	   lyase	  step	  of	  CYP19A1	   is	  present,	   suggests	   the	   involvement	  of	  the	   same	   intermediate	   viz.	   Cpd	   1	   for	   the	   aromatization	   step	   of	   CYP19A1	   as	   well.	   In	   addition,	  CYP19A1	  also	  showed	  the	  highest	  coupling	  for	  the	  lyase	  substrate,	  19-­‐oxo-­‐AD,	  compared	  with	  the	  hydroxylase	  substrates,	  AD	  and	  19-­‐OH-­‐AD,	  in	  both	  protiated	  and	  deuterated	  solvent	  system.	  	  Taken	  together,	  our	  results	  suggest	  that	  the	  involvement	  of	  the	  same	  high-­‐valent	  iron-­‐oxo	  species,	  Cpd	  1,	  as	  the	  reactive	  intermediate	  during	  the	  conversion	  of	  AD,	  19-­‐OH-­‐AD	  and	  19-­‐oxo-­‐AD.	  This	  is	  based	  on	  the	  significant	  KSIE	  observed	  during	  the	  first	  two	  steps	  of	  hydroxylation	  as	  well	  as	  the	  last	  step	  of	   lyase	   reaction.	  Our	   conclusions	   are	   also	   are	   in	   line	  with	   the	   suggestion,	   albeit	   indirect,	   of	  Cpd1	  mediated	  C-­‐C	  scission	  by	  CYP19A1	  provided	  by	  the	  rR,	  characterization	  of	  the	  oxy-­‐complexes	  of	   AD-­‐	   and	   19-­‐oxo-­‐AD	   bound	   CYP19A1	   in	   Nanodiscs.	   This	   suggestion	   of	   involvement	   of	   Cpd	   1	  during	  C10-­‐C19	  lyase	  reaction	  by	  CYP19A1	  is	  in	  contrast	  to	  recent	  observation	  of	  an	  inverse	  KSIE	  in	  human	  CYP17A1	   involved	   in	  androgen	   formation	  where	   the	  reactive	  peroxoanion	   intermediate	   is	  involved	  in	  the	  catalytic	  step	  (M.	  C.	  Gregory	  et	  al.	  2013).	  	  In	   conclusion,	   our	   results	   highlight	   the	   involvement	   of	   Cpd	   1	   during	   the	   first	   two	   steps	   of	  aromatization	   by	   CYP19A1,	   a	   general	  mechanism	   known	   to	   be	   involved	   in	   other	   P450s.	  We	   also	  implicate	   the	   involvement	   of	   Cpd	   1	   as	   a	   reactive	   intermediate	   during	   the	   controversial	   C10-­‐C19	  lyase	  reaction	  by	  human	  aromatase.	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  Figure	   39:	   Time	   dependent	   total	   conversion	   of	   AD	   (A),	   19-­‐OH-­‐AD	   (B)	   and	   19-­‐oxo-­‐AD	   (C)	   by	  CYP19A1.	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  Figure	  40:	  Total	  product	  formation	  rate	  for	  AD	  (A),	  19-­‐hydroxy-­‐AD	  (B)	  and	  19-­‐oxo-­‐AD	  (C)	  catalysis	  by	   CYP19A1	   in	   protiated	   (black	   bars)	   and	   deuterated	   (open	   bars)	   solvent	   systems.	   Error	   bars	  represent	  standard	  deviation	  of	  3-­‐5	  independent	  measurements.	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  Figure	  42:	  NADPH	  oxidation	  rates	  (solid	  bars)	  and	  corresponding	  coupling	  efficiencies	  (open	  bars)	  for	  steps	  I,	  II	  and	  III	  of	  CYP19A1	  catalysis	  in	  H2O	  (A)	  and	  D2O	  (B).	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Substrate  
 
           


















AD 1.63 4.06  
2.49 2.6 2.7 5.69 2.7 0.62 1.52 
 
2.45 2.14 
19-OH AD  
2.30 1.80 0.78 1.0 2.0 4.10 1.2 
 
2.39 0.91 0.38 3.30 
19-oxo-AD   
7.10 - 2.5 7.10 2.5 
  
2.80 - 2.80 H2O/	  D2O	  	  Table	  2:	  Individual	  and	  net	  product	  formation	  rates	  starting	  with	  different	  androgenic	  substrates	  of	  CYP19A1	   and	   corresponding	   kinetic	   solvent	   isotope	   effects	   upon	   H/D	   substitution.
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